0001654954-22-015035.txt : 20221110 0001654954-22-015035.hdr.sgml : 20221110 20221110172105 ACCESSION NUMBER: 0001654954-22-015035 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221110 DATE AS OF CHANGE: 20221110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Dermata Therapeutics, Inc. CENTRAL INDEX KEY: 0001853816 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40739 FILM NUMBER: 221378662 BUSINESS ADDRESS: STREET 1: 3525 DEL MAR HEIGHTS RD., #322 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858)-223-0882 MAIL ADDRESS: STREET 1: 3525 DEL MAR HEIGHTS RD., #322 CITY: SAN DIEGO STATE: CA ZIP: 92130 10-Q 1 drma_10q.htm FORM 10-Q drma_10q.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OFTHE SECURITIES EXCHANGE ACT OF 1934

 

For the Quarterly Period Ended September 30, 2022

 

Commission File Number: 001-40739

 

DERMATA THERAPEUTICS, INC.

(Exact name of registrant as specified in the charter)

 

Delaware

86-3218736

(State or other jurisdiction of

(I.R.S. Employer

incorporation or organization)

Identification Number)

 

3525 Del Mar Heights Rd., #322, San Diego, CA 92130

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: 858-800-2543

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.0001 Par Value

 

DRMA

 

The Nasdaq Capital Market

Common Stock Purchase Warrants

 

DRMAW

 

The Nasdaq Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No.

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No.

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated Filer

☒

Smaller reporting company

☒

 

 

Emerging growth company

☒

 

If an emerging growth company, indicate by check mark if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ☒

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No.

 

There were 12,102,214 shares of common stock, par value $0.0001 of Dermata Therapeutics, Inc. issued and outstanding as of November 10, 2022.

 

 

 

 

DERMATA THERAPEUTICS, INC.

(FORMERLY DERMATA THERAPEUTICS, LLC)

Form 10-Q

Table of Contents

 

INDEX

 

 

 

 

Page No.

Part I

Financial Information

 

 

 

 

 

 

Item 1:

Financial Statements (unaudited)

 

3

 

 

 

 

 

Balance Sheets

 

3

 

Statements of Operations

 

4

 

Statements of Stockholders’ Equity

 

5

 

Statements of Cash Flows

 

8

 

Notes to Financial Statements

 

9

Item 2:

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

27

Item 3:

Quantitative and Qualitative Disclosures about Market Risk

 

36

Item 4:

Controls and Procedures

 

36

 

 

 

 

Part II

Other Information

 

 

 

 

 

 

Item 1:

Legal Proceedings

 

38

Item 1A:

Risk Factors

 

38

Item 2:

Unregistered Sales of Equity Securities and Use of Proceeds

 

38

Item 3:

Defaults Upon Senior Securities

 

38

Item 4:

Mine Safety Disclosures

 

38

Item 5:

Other Information

 

38

Item 6:

Exhibits

 

39

 

 

 

 

Signatures

 

40

 

 
2

Table of Contents

 

Part I

 

Item 1: Financial Statements

 

DERMATA THERAPEUTICS, INC.

(FORMERLY DERMATA THERAPEUTICS, LLC)

Balance Sheets

 

 

 

September 30,

2022

 

 

December 31,

2021

 

 

 

(unaudited)

 

 

 

 

Assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$8,066,822

 

 

$10,798,806

 

Prepaid expenses and other current assets

 

 

908,067

 

 

 

825,134

 

Total assets

 

$8,974,889

 

 

$11,623,940

 

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity:

 

 

 

 

 

 

 

 

Liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$483,741

 

 

$515,245

 

Accrued and other current liabilities

 

 

1,020,581

 

 

 

1,001,591

 

Total liabilities

 

 

1,504,322

 

 

 

1,516,836

 

Commitments and Contingencies (see Note 10)

 

 

 

 

 

 

 

 

Stockholders’ Equity:

 

 

 

 

 

 

 

 

Common Stock, par value $0.0001, 250,000,000 shares authorized and 12,102,214 shares issued and outstanding as of September 30, 2022; and 90,000,000 shares authorized and 8,328,629 shares issued and outstanding as of December 31, 2021, respectively

 

 

1,210

 

 

 

833

 

Additional paid-in capital

 

 

51,392,942

 

 

 

46,088,546

 

Accumulated deficit

 

 

(43,923,585 )

 

 

(35,982,275 )

Total stockholders’ equity

 

 

7,470,567

 

 

 

10,107,104

 

Total liabilities and stockholders’ equity

 

$8,974,889

 

 

$11,623,940

 

 

The accompanying notes are an integral part of these financial statements.

 

 
3

Table of Contents

 

DERMATA THERAPEUTICS, INC.

(FORMERLY DERMATA THERAPEUTICS, LLC)

Statements of Operations

(unaudited)

 

 

 

For the three months ended

September 30,

 

 

For the nine months ended

September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$1,553,295

 

 

$799,779

 

 

$4,761,686

 

 

$2,347,564

 

General and administrative

 

 

892,777

 

 

 

912,490

 

 

 

3,201,111

 

 

 

2,956,444

 

Total operating expenses

 

 

2,446,072

 

 

 

1,712,269

 

 

 

7,962,797

 

 

 

5,304,008

 

Loss from operations

 

 

(2,446,072 )

 

 

(1,712,269 )

 

 

(7,962,797 )

 

 

(5,304,008 )

Other income and expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest (income) expense, net

 

 

(21,486 )

 

 

651

 

 

 

(21,486)

 

 

45,613

 

Net loss

 

$(2,424,586 )

 

$(1,712,920 )

 

$(7,941,311 )

 

$(5,349,621 )

Deemed dividend upon the redemption of 5,221,156 shares of Series 1c preferred stock (see Note 6)

 

$-

 

 

$269,038

 

 

$-

 

 

$269,038

 

Deemed dividend upon the amendment of terms of the Series 1d convertible preferred stock (see Note 6)

 

$-

 

 

$2,293,199

 

 

$-

 

 

$2,293,199

 

Net loss attributable to common stockholders

 

$(2,424,586 )

 

$(4,275,157 )

 

$(7,941,311 )

 

$(7,911,858 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share of common stock, basic and diluted

 

$(0.20 )

 

$(0.86 )

 

$(0.75 )

 

$(2.69 )

Weighted-average basic and diluted common units/shares

 

 

12,276,394

 

 

 

4,980,306

 

 

 

10,622,277

 

 

 

2,945,351

 

 

The accompanying notes are an integral part of these financial statements.

 

 
4

Table of Contents

 

DERMATA THERAPEUTICS, INC.

(FORMERLY DERMATA THERAPEUTICS, LLC)

Statements of Stockholder’s Equity

Unaudited

 

 

 

 

 

 

 

 Additional

 

 

 

 

Total

 

 

 

 Common Stock

 

 

 Paid-in

 

 

 Accumulated

 

 

 Stockholders’

 

 

 

 Shares

 

 

Par Value 

 

 

Capital

 

 

 Deficit

 

 

Equity

 

Balance at December 31, 2021

 

 

8,328,629

 

 

$833

 

 

$46,088,546

 

 

$(35,982,275 )

 

$10,107,104

 

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

531,566

 

 

 

-

 

 

 

531,566

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(2,786,151 )

 

 

(2,786,151 )

Balance at March 31, 2022

 

 

8,328,629

 

 

$833

 

 

$46,620,112

 

 

$(38,768,426 )

 

$7,852,519

 

Issuance of common stock and warrants, net of issuance costs

 

 

898,585

 

 

 

90

 

 

 

4,276,275

 

 

 

-

 

 

 

4,276,365

 

Issuance of common stock upon exercise of pre-funded warrants

 

 

875,000

 

 

 

87

 

 

 

-

 

 

 

-

 

 

 

87

 

Issuance of restricted stock unit awards

 

 

-

 

 

 

-

 

 

 

55,625

 

 

 

-

 

 

 

55,625

 

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

205,947

 

 

 

-

 

 

 

205,947

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(2,730,573 )

 

 

(2,730,573 )

Balance at June 30, 2022

 

 

10,102,214

 

 

$1,010

 

 

$51,157,959

 

 

$(41,498,999 )

 

$9,659,970

 

Issuance of common stock upon exercise of pre-funded warrants

 

 

2,000,000

 

 

 

200

 

 

 

-

 

 

 

-

 

 

 

200

 

Issuance of restricted stock unit awards

 

 

-

 

 

 

-

 

 

 

55,625

 

 

 

-

 

 

 

55,625

 

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

179,358

 

 

 

-

 

 

 

179,358

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(2,424,586 )

 

 

(2,424,586 )

Balance at September 30, 2022

 

 

12,102,214

 

 

$1,210

 

 

$51,392,942

 

 

$(43,923,585 )

 

$7,470,567

 

 

The accompanying notes are an integral part of these financial statements.

 

 
5

Table of Contents

 

DERMATA THERAPEUTICS, INC.

(FORMERLY DERMATA THERAPEUTICS, LLC)

Statements of Stockholder’s Equity (Deficit)

Unaudited

  

 

 

Class A Common

 

 

Class B Common

 

 

Series 1 Preferred

 

 

Series 1a Preferred

 

 

Series 1a Warrants

 

 

Series 1b Preferred

 

 

 

Units

 

 

Amount

 

 

Units

 

 

Amount

 

 

Units

 

 

Amount

 

 

Units

 

 

Amount

 

 

Units

 

 

Amount

 

 

Units

 

 

Amount

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2020

 

 

508,777

 

 

$10,430

 

 

 

1,767,477

 

 

$2,342,853

 

 

 

6,906,244

 

 

$6,833,877

 

 

 

5,018,750

 

 

$4,380,081

 

 

 

1,419,228

 

 

$723,431

 

 

 

6,500,000

 

 

$4,119,595

 

Series 1d Preferred Units issued

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

Class B Common Units forfeited

 

 

 -

 

 

 

 -

 

 

 

(22,494 )

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

Conversion of Common Units to Common Stock

 

 

(508,777 )

 

$(10,430 )

 

 

(1,744,983 )

 

$(2,342,853 )

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

Conversion of Preferred Units to Preferred Stock

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

(6,906,244 )

 

$(6,833,877 )

 

 

(5,018,750 )

 

$(4,380,081 )

 

 

 -

 

 

 

 -

 

 

 

(6,500,000 )

 

$(4,119,595 )

Conversion of Warrant Units to Preferred Stock Warrants

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

(1,419,228 )

 

$(723,431 )

 

 

 -

 

 

 

 -

 

Stock-based compensation

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

Net loss

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

Balance at March 31, 2021

 

 

-

 

 

$-

 

 

 

-

 

 

$-

 

 

 

-

 

 

$-

 

 

 

-

 

 

$-

 

 

 

-

 

 

$-

 

 

 

-

 

 

$-

 

Stock-based compensation

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

Net loss

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

Balance at June 30, 2021

 

 

-

 

 

$-

 

 

 

-

 

 

$-

 

 

 

-

 

 

$-

 

 

 

-

 

 

$-

 

 

 

-

 

 

$-

 

 

 

-

 

 

$-

 

Redemption of Series 1c preferred shares

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

Conversion of Preferred Stock to Common Stock

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

Conversion of Preferred Stock Warrants to Common Stock Warrants

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

Conversion of Convertible Debt to Common Stock

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

Issuance of Common Stock and warrants, net issuance costs

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

Stock-based compensation

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

Net loss

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

Balance at September 30, 2021

 

 

-

 

 

$-

 

 

 

-

 

 

$-

 

 

 

-

 

 

$-

 

 

 

-

 

 

$-

 

 

 

-

 

 

$-

 

 

 

-

 

 

$-

 

  

The accompanying notes are an integral part of these financial statements.

 

 
6

Table of Contents

 

DERMATA THERAPEUTICS, INC.

(FORMERLY DERMATA THERAPEUTICS, LLC)

Statements of Stockholder’s and Member’s Equity (Deficit) Continued

Unaudited

 

 

 

Series 1c Preferred

 

 

Series 1d Preferred

 

 

Preferred Stock

 

 

Preferred Stock Warrants

 

 

Common Stock

 

 

Additional

 

 

 

 

 

 

 

 

 

Units

 

 

Amount

 

 

Units

 

 

Amount

 

 

Shares

 

 

 Par Value

 

 

Shares

 

 

 Par Value

 

 

Shares

 

 

 Par Value

 

 

Paid-in

Capital

 

 

Accumulated

Deficit

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2020

 

 

46,553,188

 

 

$6,491,592

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

$(28,079,798)

 

$(3,177,939)

Series 1d Preferred Units issued

 

 

-

 

 

 

-

 

 

 

6,065,989

 

 

$5,034,801

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

$5,034,801

 

Class B Common Units forfeited

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

$-

 

Conversion of Common Units to Common Stock

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,911,009

 

 

$191

 

 

 

2,353,092

 

 

 

-

 

 

$-

 

Conversion of Preferred Units to Preferred Stock

 

 

(46,553,188)

 

$(6,491,592)

 

 

(6,065,989)

 

$(5,034,801)

 

 

71,044,171

 

 

$7,104

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

26,852,842

 

 

 

-

 

 

$-

 

Conversion of Warrant Units to Preferred Stock Warrants

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,419,228

 

 

$142

 

 

 

-

 

 

 

-

 

 

 

723,289

 

 

 

-

 

 

$-

 

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,160,049

 

 

 

-

 

 

$1,160,049

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

$(2,304,908)

 

$(2,304,908)

Balance at March 31, 2021

 

 

-

 

 

$-

 

 

 

-

 

 

$-

 

 

 

71,044,171

 

 

$7,104

 

 

 

1,419,228

 

 

$142

 

 

 

1,911,009

 

 

$191

 

 

 

31,089,272

 

 

$(30,384,706)

 

$712,003

 

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

113,987

 

 

 

-

 

 

$113,987

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

$(1,331,792)

 

$(1,331,792)

Balance at June 30, 2021

 

 

-

 

 

$-

 

 

 

-

 

 

$-

 

 

 

71,044,171

 

 

$7,104

 

 

 

1,419,228

 

 

$142

 

 

 

1,911,009

 

 

$191

 

 

 

31,203,259

 

 

$(31,716,498)

 

$(505,802)

Redemption of Series 1c preferred shares

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(5,221,156)

 

$(522)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(999,478)

 

 

-

 

 

$(1,000,000)

Conversion of Preferred Stock to Common Stock

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(65,823,015)

 

$(6,582)

 

 

-

 

 

 

-

 

 

 

3,813,973

 

 

$381

 

 

 

6,200

 

 

 

-

 

 

$-

 

Conversion of Preferred Stock Warrants to Common Stock Warrants

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(1,419,228)

 

$(142)

 

 

-

 

 

 

-

 

 

 

142

 

 

 

-

 

 

$-

 

Conversion of Convertible Debt to Common Stock

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

32,219

 

 

$3

 

 

 

180,430

 

 

 

-

 

 

$180,434

 

Issuance of Common Stock and warrants, net issuance costs

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

2,571,428

 

 

$257

 

 

 

15,385,932

 

 

 

-

 

 

$15,386,189

 

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

142,655

 

 

 

-

 

 

$142,655

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

$(1,712,920)

 

$(1,712,920)

Balance at September 30, 2021

 

 

-

 

 

$-

 

 

 

-

 

 

$-

 

 

 

-

 

 

$-

 

 

 

-

 

 

$-

 

 

 

8,328,629

 

 

$833

 

 

 

45,919,140

 

 

$(33,429,418)

 

$12,490,555

 

 

The accompanying notes are an integral part of these financial statements.

 

 
7

Table of Contents

 

DERMATA THERAPEUTICS, INC.

(FORMERLY DERMATA THERAPEUTICS, LLC)

Statements of Cash Flows

(unaudited)

 

 

 

For the nine months ended

September 30,

 

 

 

2022

 

 

2021

 

Cash flows from operating activities:

 

 

 

 

 

 

Net loss

 

$(7,941,311 )

 

$(5,349,621 )

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

709,435

 

 

 

1,416,691

 

Amortization of debt discount costs

 

 

-

 

 

 

14,126

 

Increase/(decrease) in cash resulting from changes in:

 

 

 

 

 

 

 

 

Prepaid expenses and other current assets

 

 

(82,933 )

 

 

(1,007,393 )

Accounts payable

 

 

(31,504 )

 

 

665,587

 

Accrued and other current liabilities

 

 

337,677

 

 

 

371,127

 

Net cash used in operating activities:

 

 

(7,008,636 )

 

 

(3,889,483 )

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Proceeds from issuance of common stock and warrants, net of issuance costs

 

 

4,276,365

 

 

 

15,386,189

 

Proceeds from issuances of common stock upon exercises of pre-funded warrants

 

 

287

 

 

 

-

 

Redemption of Series 1c preferred stock

 

 

-

 

 

 

(1,000,000 )

Payments on debt

 

 

-

 

 

 

(556,482 )

Net proceeds from issuance of convertible subordinated promissory notes

 

 

-

 

 

 

1,562,717

 

Proceeds from issuance of Series 1d preferred units

 

 

-

 

 

 

570,000

 

Net cash provided by financing activities:

 

 

4,276,652

 

 

 

15,962,424

 

Net increase (decrease) in cash and cash equivalents

 

 

(2,731,984 )

 

 

12,072,941

 

Cash and cash equivalents at beginning of period

 

 

10,798,806

 

 

 

530,400

 

Cash and cash equivalents at end of period

 

$8,066,822

 

 

$12,603,341

 

 

 

 

 

 

 

 

 

 

Supplemental disclosures:

 

 

 

 

 

 

 

 

Cash paid for interest

 

$-

 

 

$1,420

 

Cash paid for taxes

 

$800

 

 

$1,400

 

Non-cash financing activities:

 

 

 

 

 

 

 

 

Conversion of common and preferred units and warrants to common and preferred stock and warrants

 

$-

 

 

$29,936,660

 

Conversion of convertible subordinated promissory notes to Series 1d preferred units

 

$-

 

 

$4,464,801

 

Deemed dividend upon amendment to the terms of the Series 1d convertible preferred stock

 

$-

 

 

$2,293,199

 

Conversion of convertible subordinated promissory notes and accrued interest to common shares at IPO

 

$-

 

 

$180,434

 

Conversion of preferred stock to common stock at IPO

 

$-

 

 

$6,582

 

 

The accompanying notes are an integral part of these financial statements.

 

 
8

Table of Contents

 

DERMATA THERAPEUTICS, INC.

(FORMERLY DERMATA THERAPEUTICS, LLC)

Notes to Financial Statements

(unaudited)

 

1. Organization and Basis of Presentation

 

Dermata Therapeutics, Inc., (the “Company”), was formed in December 2014 as a Delaware limited liability company (“LLC”) under the name Dermata Therapeutics, LLC. On March 24, 2021, the Company converted from an LLC to a Delaware C-corporation and changed its name to Dermata Therapeutics, Inc. Any references in these Notes to Financial Statements to equity securities as “units” refer to pre-conversion equity securities and any references to “shares” or “stock” in these Notes to Financial Statements refer to post-conversion equity securities. The Company is a clinical-stage biotechnology company focused on the treatment of medical and aesthetic skin conditions and diseases.

 

Initial Public Offering

 

On August 17, 2021, the Company completed its initial public offering (“IPO”), in which it sold 2,571,428 shares of its common stock together with 2,571,428 warrants to purchase one share of common stock with an exercise price of $7.00 per share, at a combined offering price of $7.00. Additionally, the underwriters exercised their option to purchase an additional 385,714 warrants to purchase common stock with an exercise price of $7.00 per share. The Company received net cash proceeds of approximately $15.4 million from the IPO after deducting underwriters’ discounts and offering expenses of approximately $2.6 million.

 

Each of the following occurred in connection with the completion of the IPO in August 2021:

 

 

-

The sale of 2,571,428 shares of common stock along with 2,957,142 warrants to purchase common stock.

 

 

 

 

-

The conversion of 65,823,015 shares of convertible preferred stock into an aggregate of 3,813,973 shares of common stock.

 

 

 

 

-

The conversion of $175,000 principal amount of outstanding convertible promissory notes and accrued interest of $5,434 into 32,219 shares of common stock.

 

 

 

 

-

The conversion of 1,419,228 Series 1a preferred warrants into 69,212 warrants exercisable into common stock.

 

Each purchaser in the IPO received one share of common stock and one warrant to purchase one share of common stock at a combined offering price of $7.00. Each warrant to purchase common stock entitles the holder to purchase one share of common stock, are immediately exercisable, and expire five years from the date of issuance. The Company evaluated the terms of the warrants issued and determined that they should be classified as equity instruments.

 

The Company’s shares of common stock and warrants are listed on the Nasdaq Stock Market LLC under the symbols “DRMA,” and “DRMAW,” respectively, and both began trading in August 2021.

 

After the IPO, there were no shares of preferred stock or preferred stock warrants outstanding. Prior to the IPO, the Company had 1,911,009 shares of common stock outstanding after giving effect for the Company’s reverse stock split in July 2021.

 

Reverse Stock Split

 

On July 1, 2021, the Company effected a reverse split of shares of the Company’s common stock at a ratio of 1-for-20.5 pursuant to an amendment to the Company’s certificate of incorporation approved by the Company’s board of directors and stockholders. The par value was not adjusted as a result of the reverse split. All issued and outstanding common stock shares and per share amounts contained in the financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented, and the conversion ratios for the Company’s outstanding preferred stock was adjusted accordingly. See Note 6 – Equity Securities for additional information.

 

 
9

Table of Contents

 

Liquidity and Going Concern Uncertainty

 

Since its inception, the Company has devoted substantially all of its resources to research and development activities and has not generated any revenue or commercialized any product candidates. As of September 30, 2022, cash and cash equivalents totaled $8.1 million and the Company had an accumulated deficit of $43.9 million. For the nine months ended September 30, 2022 and the year ended December 31, 2021, the Company used cash of $7.0 million and $5.7 million, respectively, in operations. The Company’s cash balances are expected to fund operations into the third quarter of 2023. The Company anticipates that it will continue to incur net losses for the foreseeable future. These factors raise substantial doubt about the Company’s ability to continue as a going concern for the one-year period following the date that these financial statements were issued.

 

Historically, the Company’s principal sources of cash have included proceeds from the issuance of common and preferred equity units and proceeds from the issuance of debt. The Company’s principal uses of cash have included cash used in operations and payments for license rights. The Company expects that the principal uses of cash in the future will be for continuing operations, funding of research and development, conducting preclinical studies and clinical trials, and general working capital requirements. The Company expects that as research and development expenses continue to grow, it will need to raise additional capital to sustain operations and research and development. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

 

Management’s Plan to Continue as a Going Concern

 

To continue as a going concern, the Company will need, among other things, to raise additional capital resources. Until the Company can generate significant cash from operations, management’s plans to obtain such resources for the Company include proceeds from offerings of the Company’s equity securities or debt, or transactions involving product development, technology licensing or collaboration. Management can provide no assurance that any sources of a sufficient amount of financing or collaboration agreements will be available to the Company on favorable terms, if at all. Additionally, the COVID-19 pandemic continues to evolve and has already disrupted global financial markets. The Company’s ability to raise additional capital may be adversely impacted by potential worsening of global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the pandemic. If the disruption persists or deepens, the Company could experience an inability to access additional capital.

 

The Company has raised additional capital through the initial public offering of its common stock and warrants and through a private placement financing; however, management’s current plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern.

 

Basis of Presentation

 

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, the accompanying financial statements reflect all adjustments (consisting of normal recurring adjustments) that are necessary for a fair statement of the financial position, results of operations, cash flows, and stockholders’ equity for the interim periods presented. Interim results are not necessarily indicative of results for a full year. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ materially from those estimates.

 

 
10

Table of Contents

 

2. Summary of Significant Accounting Policies

 

Use of Estimates

 

The Company’s financial statements are prepared in accordance with GAAP. The preparation of the Company’s financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, including those related to accrued research and development expenses, stock-based compensation, and the estimated fair values of equity instruments. Management evaluates its estimates on an ongoing basis. The Company bases its estimates on various assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

 

Segment Information

 

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company’s chief operating decision maker view the Company’s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceuticals. The Company operates in only one segment.

 

Deferred Financing Costs

 

The Company capitalizes certain legal, accounting, and other fees and costs that are directly attributable to in-process equity financings as deferred offering costs until such financings are completed. Upon the completion of an equity financing, these costs are recorded as a reduction of additional paid-in capital of the related offering. Upon the completion of the IPO in August 2021, approximately $2.6 million of offering costs related to the IPO were reclassified to additional paid-in capital. As of December 31, 2021, the Company had deferred financing costs of $0.06 million and as of September 30, 2022, the Company had no deferred financing costs.

 

Cash and Cash Equivalents

 

The Company deposits its cash with reputable financial institutions that are insured by the Federal Deposit Insurance Corporation (“FDIC”). This cash is held in checking, cash sweep, and money market accounts. At times, deposits held may exceed the amount of insurance provided by the FDIC. The Company maintains an insured cash sweep account in which cash from its main operating checking account is invested overnight in highly liquid, short-term investments. The Company considers all highly liquid investments with a maturity date of 90 days or less at the date of purchase to be cash equivalents. The Company has not experienced any losses in its cash and cash equivalents and believes they are not exposed to significant credit risk.

 

Fair Value Measurement

 

The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company believes the carrying amount of cash and cash equivalents, accounts payable, accrued expenses and debt approximate their estimated fair values due to the short-term maturities of these financial instruments.

 

Interest Income

 

Interest income consists of interest income earned on cash equivalents from interest bearing demand accounts.

 

 
11

Table of Contents

 

Patent Costs

 

                Patent costs related to obtaining and maintaining patent protection in both the United States and other countries are expensed as incurred. Patents costs are classified as general and administrative expenses.

 

Research and Development 

 

Research and development costs consist of expenses incurred in connection with the development of the Company’s product candidates. Such expenses include expenses incurred under agreements with contract research organizations, manufacturing and supply scale-up expenses and the cost of acquiring and manufacturing preclinical and clinical trial supply, outsourced laboratory services, including materials and supplies used to support the Company’s research and development activities, and payments made for license fees and milestones that have not been demonstrated to have commercial value. Such costs are expensed in the periods in which they are incurred. Upfront payments and milestone payments for licensed technology are expensed as research and development as incurred or when the milestone is achieved or is determined to be probable of being achieved. Advanced payments for goods or services to be received in the future for research and development activities are recorded as prepaid expenses and expensed as the related goods are received or services are performed.

 

Income Taxes

 

From inception until March 24, 2021, the Company operated as a limited liability company taxed as a partnership. Therefore, any income tax liability or benefit through that date accrued to the Company’s members. Since March 24, 2021, the Company has operated as a C-Corporation and accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

 

The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.

 

The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.

 

Stock-Based Compensation

 

In March 2021, the Company’s board of directors and shareholders approved the 2021 Omnibus Equity Incentive Plan (“the 2021 Plan”). For stock options granted under the 2021 Plan, the Company measures and recognizes compensation expense for all stock-based awards made to employees, directors, and non-employees, based on estimated fair values recognized using the straight-line method over the requisite service period. The fair value of options to purchase common stock granted to employees is estimated on the grant date using the Black-Scholes valuation model. The calculation of stock-based compensation expense requires that the Company make certain assumptions and judgments about variables used in the Black-Scholes model, including the expected term of the stock-based award, expected volatility of the underlying common stock, dividend yield, and the risk-free interest rate. Forfeitures are accounted for in the period they occur. Restricted stock units (“RSUs”) granted under the 2021 Plan are measured at the grant date fair value of the common stock, with corresponding compensation expense recognized ratably over the requisite service period. Refer to Note 7- Equity Incentive Plan for further discussion.

 

 
12

Table of Contents

 

Comprehensive Loss

 

Comprehensive loss includes net loss and other comprehensive income (loss) for the periods presented. The Company did not have other comprehensive income (loss) items such as unrealized gains and losses and so for the three and nine months ended September 30, 2022, and September 30, 2021, comprehensive loss was equal to the net loss.

 

Net Loss Per Common Unit/Share

 

On March 24, 2021, the Company converted from an LLC to a C-corporation. Upon the conversion, each outstanding common unit and preferred unit was converted into one share of common stock and preferred stock, respectively. Common units had similar rights and characteristics of common stock issued upon the conversion. In calculating net loss per share, the Company retrospectively applied the effects of the conversion to the number of common units outstanding prior to the conversion. Net loss per share for periods prior to the conversion to a C-corporation refers to net loss per common unit.

 

Basic net loss per unit/share is calculated by dividing net loss attributable to common unitholders or shareholders by the weighted-average number of units or shares outstanding during the period, contingently issuable restricted stock units for which no future service is required as a condition to the delivery of the underlying common stock, and pre-funded warrants because their exercise requires only nominal consideration for the delivery of shares (collectively, “basic shares”), without consideration of common unit or share equivalents. Diluted net loss per unit or share is calculated by adjusting basic shares outstanding for the dilutive effect of common unit or share equivalents outstanding for the period. For purposes of the diluted net loss per unit or share calculation, preferred units or shares, profit interests, and warrants to purchase preferred units or shares are considered to be common unit or share equivalents but are excluded from the calculation of diluted net loss per common unit or share if their effect would be anti-dilutive.

 

As the Company has reported a net loss for the periods presented, diluted net loss per common unit or share is the same as the basic net loss per common unit or share for the periods presented.

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$(2,424,586 )

 

$(1,712,920 )

 

$(7,941,311 )

 

$(5,349,621 )

Deemed dividend upon redemption of 5,221,156 shares of Series 1c convertible preferred stock

 

$-

 

 

$269,038

 

 

$-

 

 

$269,038

 

Deemed dividend upon amendment of the terms to the

Series 1d convertible preferred stock

 

$-

 

 

$2,293,199

 

 

$-

 

 

$2,293,199

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to common stockholders

 

$(2,424,586 )

 

$(4,275,157 )

 

$(7,941,311 )

 

$(7,911,858 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted net loss per common unit/share

 

$(0.20 )

 

$(0.86 )

 

$(0.75 )

 

$(2.69 )

Weighted-average basic and diluted common units/shares

 

 

12,276,394

 

 

 

4,980,306

 

 

 

10,622,277

 

 

 

2,945,351

 

 

The common unit or share equivalents that are not included in the calculation of diluted net loss per common unit or share but could potentially dilute basic earnings per share in the future are as follows:

 

 

 

As of September 30,

 

 

 

2022

 

 

2021

 

Common stock options

 

 

1,056,326

 

 

 

523,199

 

Common stock warrants

 

 

6,993,813

 

 

 

3,091,657

 

Total potentially dilutive securities

 

 

8,050,139

 

 

 

3,614,856

 

 

 
13

Table of Contents

 

Recent Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard-setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

 

3. Balance Sheet Details

 

The following provides certain balance sheet details:

 

 

 

September 30,

 

 

December 31,

 

 

 

2022

 

 

2021

 

Prepaid expenses and other current assets

 

 

 

 

 

 

Prepaid insurance

 

$806,661

 

 

$769,416

 

Prepaid research and development costs

 

 

52,100

 

 

 

-

 

Prepaid other

 

 

36,413

 

 

 

-

 

Interest receivable

 

 

12,893

 

 

 

-

 

Deferred offering costs

 

 

-

 

 

 

55,718

 

Total prepaid expenses and other current assets

 

$908,067

 

 

$825,134

 

 

 

 

 

 

 

 

 

 

Accrued and other current liabilities

 

 

 

 

 

 

 

 

Accrued research and development costs

 

$633,293

 

 

$235,384

 

Accrued compensation and benefits

 

 

317,089

 

 

 

766,207

 

Accrued legal fees

 

 

13,801

 

 

 

-

 

Accrued board compensation

 

 

55,625

 

 

 

-

 

Accrued other

 

 

773

 

 

 

-

 

Total accrued and other current liabilities

 

$1,020,581

 

 

$1,001,591

 

 

4. Subordinated Convertible Promissory Notes

 

In July and October 2020, the Company issued an aggregate of $3,000,000 of subordinated convertible promissory notes (the “Notes”). Notes in the amount of $1,145,000 were issued to existing investors who are also related parties (See Note 11 - Related Parties), $1,730,000 were issued to existing investors who are not related parties and notes in the amount of $125,000 were issued to new investors. The Notes bore interest at 4% per annum and were to mature on July 17, 2021. The Notes were subordinated to the Company’s long-term debt and were convertible into a qualified Series A financing of at least $10 million at a 20% discount to the lowest price per unit paid by investors for that financing. Under authoritative accounting guidance, this contingent beneficial conversion feature was to be measured and recognized when the contingency is resolved. The Notes were recorded upon issuance net of debt discount costs of $28,301. The Company recognized $14,126 of amortized debt discount costs during the nine months ended September 30, 2021.

 

On January 27, 2021, the Company amended the terms of the Notes to increase the maximum amount of convertible promissory notes to be issued from $3,000,000 to $5,000,000, to allow for the conversion of the convertible promissory notes into shares of common stock upon a Qualified Initial Public Offering with aggregate gross proceeds to the Company of at least $10,000,000 at a 20% discount to the lowest price per share paid by investors for that financing and to extend the maturity date to December 31, 2021. In connection with this amendment, Notes in the amount of $1,255,000 were issued to existing investors who are also related parties (See Note 11 - Related Parties) and $311,000 were issued to existing investors who are not related parties.

 

 
14

Table of Contents

 

In March 2021, the Company further amended the terms of the Notes to allow for the conversion of the Notes into Series 1d Preferred Units at the same price as purchasers of Series 1d Preferred Units. As of March 15, 2021, $4,391,000 of the Notes, along with related interest of $73,801, were converted to 5,379,247 Series 1d Preferred Units. Since the Notes did not convert at a discount, there was no beneficial conversion feature.

 

The Company considers the above modification of the Notes in March 2021 to be a substantial modification requiring extinguishment accounting under Accounting Standards Codification (“ASC”) 470-50-40-10. Based upon an independent valuation of the reacquisition price of the Notes, the difference between the reacquisition price and the net carrying amount of the Notes immediately prior to the modification is not material to the financial statements.

 

In connection with the Company’s IPO in August 2021, the outstanding principal of the Notes and accrued interest totaling $180,434 converted into 32,219 shares of common stock. Upon this conversion, since the conversion contained a 20% discount, the Company measured the beneficial conversion feature and determined that it was not material to the financial statements.

 

As of December 31, 2021, and September 30, 2022, the Company had no promissory notes outstanding.

 

5. Long-Term Debt

 

In February 2017, the Company entered into a Loan and Security Agreement with Silicon Valley Bank (“SVB”) whereas SVB agreed to provide term loans to the Company in two tranches. The first tranche of $2,500,000 was drawn in February 2017 and bore interest at a rate of 1.5% above the prime rate, which was 3.25% as of December 31, 2020, with principal and interest payable monthly through February 9, 2021. The second tranche was not utilized.

 

In connection with the Loan and Security Agreement, SVB also received warrant units to purchase, at any time after February 9, 2017 and prior to February 9, 2027, 187,978 Series 1a Preferred Units or the equivalent Series A Preferred Units had they purchased Series 1a Preferred Units, if Series A Preferred Units are issued, at a price of $1.00 per unit. The estimated fair value of these warrant units of $104,630 (See Note 6 – Equity Securities), as well as costs associated with the term loan, including provision for a final payment of $225,000, were recorded as a discount to outstanding debt and amortized to interest expense utilizing the effective interest method over the underlying term of the loan.

 

In June 2019, the Company and SVB entered into a First Amendment to the Loan and Security Agreement whereby if the Company did not achieve certain capital milestones by December 1, 2019, term loan principal payments would be deferred from December 21, 2019 through May 1, 2020 with the deferred principal payments being payable in equal monthly installments, in addition to those principal payments already scheduled to be paid, starting on June 1, 2020 and extending through the February 9, 2021 maturity date of the term loan. In addition, if those principal payments were deferred for that six-month period, a non-refundable amendment fee of $100,000 would be due and payable on the earliest to occur of the maturity date, the prepayment of the term loan or the occurrence of an event of default. The capital milestones were not achieved by December 1, 2019 and, therefore, the defined principal repayments were deferred.

 

The non-refundable amendment fee of $100,000, as well as $12,280 of costs associated with the amendment, were recorded as a discount to outstanding debt and were amortized to interest expense utilizing the effective interest method over the remaining underlying term of the loan.

 

In January and February 2021, the Company paid the final principal payments of $231,482 under the SVB Loan and Security Agreement. The Company also paid the final payment fee of $225,000 in February 2021 and the amendment fee of $100,000 in March 2021. For the nine months ended September 30, 2021, the Company paid a total of $556,482 to SVB as final payments for its long-term debt.

 

As of December 31, 2021, and September 30, 2022, the Company had no long-term debt outstanding.

 

 
15

Table of Contents

 

6. Equity Securities

 

Common Stock and Preferred Stock

 

On March 24, 2021, the Company entered into a Plan of Conversion (“Conversion”) whereby the Company converted from an LLC under the laws of the State of Delaware to a Delaware C-corporation with the name Dermata Therapeutics, Inc. In connection with the Conversion, each fully paid preferred and common unit in the LLC was converted into a like number of shares of preferred and common stock of the Company with a par value of $0.0001 per share. The Shares issued had the same rights, preferences and privileges that had accrued to the pre-converted Units. Any references in these Notes to Financial Statements to equity securities as “units” refer to pre-conversion equity securities and any references to “shares” or “stock” in these Notes to Financial Statements refer to post-conversion equity securities.

 

On July 1, 2021, the Company effected a reverse split of shares of the Company’s common stock at a ratio of 1-for-20.5 pursuant to an amendment to the Company’s certificate of incorporation approved by the Company’s board of directors and stockholders. The par value was not adjusted as a result of the reverse split. All issued and outstanding common stock share and per share amounts contained in the financial statements have been retroactively adjusted to reflect this reverse split for all periods presented.

 

On August 17, 2021, the Company completed its IPO, in which it sold 2,571,428 shares of its common stock together with 2,571,428 warrants to purchase one share of common stock with an exercise price of $7.00 per share at a combined offering price of $7.00. Additionally, the underwriters exercised their option to purchase an additional 385,714 warrants with an exercise price of $7.00 per warrant. The Company received net cash proceeds of approximately $15.4 million from the IPO after deducting underwriters’ discounts and offering expenses of approximately $2.6 million.

 

Each of the following occurred in connection with the completion of the IPO in August 2021:

 

 

-

The sale of 2,571,428 shares of common stock along with 2,957,142 warrants to purchase common stock.

 

 

 

 

-

The conversion of 65,823,015 shares of convertible preferred stock into an aggregate of 3,813,973 shares of common stock.

 

 

 

 

-

The conversion of $175,000 principal amount of outstanding convertible promissory notes and accrued interest of $5,434 into 32,219 shares of common stock.

 

 

 

 

-

The conversion of 1,419,228 Series 1a preferred warrants into 69,212 warrant shares exercisable into common stock.

 

After the IPO, there were no shares of preferred stock or preferred stock warrants outstanding. Prior to the IPO, the Company had 1,911,009 shares of common stock outstanding after giving effect for the Company’s reverse stock split in July 2021.

 

On April 25, 2022, the Company closed a private placement (“PIPE”), in which it sold 898,585 shares of its common stock together with 2,875,000 pre-funded warrants to purchase one share of common stock with an exercise price of $0.0001 per share (“Pre-funded Warrant”), and 3,773,585 warrants to purchase one share of common stock with an exercise price of $1.325 per share (“PIPE Common Warrant”) at a combined offering price of $1.325. The Company received net cash proceeds of approximately $4.3 million from the PIPE after deducting underwriters’ discounts and offering expenses of approximately $0.7 million. The PIPE Common Warrant related to this private placement will expire on May 12, 2027. During the quarter ended June 30, 2022, 875,000 of the Pre-funded Warrants were exercised. Further, during the quarter ended September 30, 2022, 2,000,000 of the Pre-funded Warrants were exercised. No Pre-Funded Warrants were outstanding as of September 30, 2022.

 

The Company’s total common stock issued and outstanding was 12,102,214 and 8,328,629 shares as of September 30, 2022, and December 31, 2021, respectively.

 

Series 1 Preferred Units

 

From the Company’s formation on December 8, 2014 through 2016, the Company issued 6,906,244 Series 1 Preferred Units for net consideration of $6,833,877. The Company’s Series 1 Preferred Units were converted to preferred stock during the first quarter of 2021. Additionally, in August 2021, the Company converted all preferred stock into common stock. No Series 1 Preferred Units were outstanding as of December 31, 2021 and September 30, 2022.

 

 
16

Table of Contents

 

Series 1a Preferred Units

 

In 2016, the Company issued 5,000,000 Series 1a Preferred Units in exchange for cash of $5,000,000 and net of issuance costs of $19,868. Purchasers of the Series 1a Preferred Units also received 1,250,000 Warrant Units to purchase an additional amount of Series 1a Preferred Units. The estimated fair value of the warrant units was recorded as a separate component of members’ equity (deficit) in the accompanying balance sheet as of December 31, 2020 with an offset to the Series 1a proceeds. In June 2020, 18,750 of the warrants were exercised for consideration of $18,750, which consideration was received in July 2020. The Company’s Series 1a Preferred Units were converted to preferred stock during the first quarter of 2021. Additionally, in August 2021, the Company converted all preferred stock into common stock. No Series 1a Preferred Units were outstanding as of December 31, 2021 and September 30, 2022.

 

Series 1b Preferred Units

 

In 2018, the Company issued 6,500,000 Series 1b Preferred Units in exchange for cash of $6,500,000 and net of issuance costs of $40,405. Purchasers of the Series 1b Preferred Units also received 1,268,279 Class B Common Units. The estimated fair value of the Class B Common units has been recorded as a component of members’ equity (deficit) in the accompanying balance sheet as of December 31, 2020 with an offset to the Series 1b proceeds. The Company’s Series 1b Preferred Units were converted to preferred stock during the first quarter of 2021. Additionally, in August 2021, the Company converted all preferred stock into common stock. No Series 1b Preferred Units were outstanding as of December 31, 2021 and September 30, 2022.

 

Series 1c Preferred Units

 

On June 14, 2019, the Company closed participation in a $5,785,000 Series 1c financing from current and new investors. As of December 31, 2019, cash of $5,535,000, including $150,000 from the conversion of a convertible note issued to a Managing Member of the Company for a loan made to the Company, net of issuance costs of $25,857, had been received. The accrued interest on the convertible note in the amount of $1,487 was also converted into Series 1c Preferred Units. The remaining balance of $250,000 committed to the financing was paid in the amounts of $125,000 in May 2020 and $125,000 in June 2020.

 

In June 2019, 5,221,156 Series 1c Preferred Units were issued in connection with the settlement and license agreement, and in July 2021, the Company redeemed these units/shares in connection with an amendment to the settlement and license agreement. See Note 9 – License Agreements for more information.

 

The Company’s Series 1c Preferred Units were converted to preferred stock during the first quarter of 2021. Additionally, in August 2021, the Company converted all preferred stock into common stock. No Series 1c Preferred Units were outstanding as of December 31, 2021 and September 30, 2022.

 

Series 1d Preferred Units

 

In March 2021, the Company issued 686,742 Series 1d Preferred Units at a cost of $0.83 per unit for total proceeds of $570,000. In addition, as described in Note 4 – Subordinated Convertible Promissory Notes, as of March 15, 2021, $4,391,000 of convertible promissory notes, along with related interest of $73,801, were converted into 5,379,247 Series 1d Preferred Units. The outstanding Series 1d Preferred Units were converted to preferred stock during the first quarter of 2021. Additionally, in August 2021, the Company converted all preferred stock into common stock. No Series 1d Preferred Units were outstanding as of December 31, 2021 and September 30, 2022.

 

 
17

Table of Contents

 

Class A Common Units

 

During 2014 and 2015, the Company issued 508,777 Class A Common Units in exchange for consideration of $10,430. The Class A Common Units outstanding converted to common stock during the first quarter of 2021. No Class A Common Units were outstanding as of December 31, 2021 and September 30, 2022.

 

Class B Common Units

 

The Company had 1,767,477 Class B Common Units outstanding as of December 31, 2020. This includes 133,953 Class B Common Units issued for consideration of $2,853 and 1,268,279 Class B Common Units issued in connection with the issuance of the Series 1b Preferred Units, which were assigned an estimated fair value of $2,340,000. The remaining 365,245 Class B Common Units were issued as a profits interest as that term is defined by Revenue Procedure 93-27, 1993-2 C.B. 343, as clarified by Revenue Procedure 2001-43, 2001-2 C.B. 191, with participation thresholds from $0.001 to $0.36. During the first quarter 2020, the Company issued 2,439 Class B Common Units, all of which represented a profits interest. During the first quarter of 2021, 22,494 Class B Common Units were forfeited as a result of employee resignations. The remaining Class B Common Units outstanding converted to common stock during the first quarter of 2021. No Class B Common Units were outstanding as of December 31, 2021 and September 30, 2022.  

 

Liquidation Preference

 

Prior to the Company’s IPO in August 2021, the Company’s preferred units were subject to liquidation preferences contained herein. So long as there were no Series A Preferred Units outstanding at the time of a liquidity event, any liquidity event proceeds would have been distributed as follows: First, the Series 1d Preferred Units had a two times preference in liquidation over the Series 1c Preferred Units and then participated with the Series 1c, 1b and 1a Preferred Units once the Series 1c Preferred Unit preferences had been satisfied. Second, proceeds to Series 1c Preferred Unit holders sufficient to cover two times their Series 1c investment; third, proceeds to Series 1, Series 1a, Series 1b, Series 1c, and Series 1d Preferred Unit holders sufficient to cover interest at the rate of 8% per annum on the Series 1 Preferred Units, the Series 1a Preferred Units, the Series 1b Preferred Units, the Series 1c Preferred Units, and Series 1d Preferred Units; fourth, proceeds to the Series 1, Series 1a, Series 1b and Series 1c Preferred Unit holders sufficient to cover the unit value of Series 1 Preferred Units, Series 1a Preferred Units, Series 1b Preferred Units, Series 1c Preferred Units, and Series 1d Preferred Units; fifth, to Class A and Class B Common holders proceeds sufficient to cover their pro-rata portion of distributions made to Series 1, Series 1a, Series 1b, Series 1c, and Series 1d Preferred Unit holders, provided that no Class B Common Units would share in any distribution until after the point at which the amount per Class A Common Unit exceeds the amount of such Class B Common Unit’s Participation Threshold; and sixth, a pro-rata distribution of the remaining proceeds to all equity holders. Upon the issuance of Series A Preferred Units, each Series 1 Preferred Unit, each Series 1a Preferred Unit, each Series 1b Preferred Unit, each Series 1c Preferred Unit and each Series 1d Preferred Unit would have automatically converted into the number of Series A Preferred Units equal to the sum of the unit value of the Series 1, Series 1a, Series 1b, Series 1c or Series 1d Preferred Units plus all accumulated preferred return as of the conversion date that would have been due with respect to such Series 1, Series 1a, Series 1b, Series 1c or Series 1d Preferred Units in the case of a liquidity event. As of December 31, 2021 and September 30, 2022, no Series A Preferred Units had been issued, and no preferred stock remained outstanding.

 

Conversion Rights

 

Prior to the Company’s IPO in August 2021, the Company’s preferred units were subject to conversion rights contained herein. Upon the first issuance by the Company of any Series A Preferred Units, each Series 1 Preferred Unit and each Series 1a Preferred Unit and each Series 1b Preferred Unit and each Series 1c Preferred Unit and each Series 1d Preferred Unit would have automatically been converted into the number of Series A Preferred Units equal to the sum of the Unit Value with respect to such Series 1 Preferred Unit or Series 1a Preferred Unit or Series 1b Preferred Unit or Series 1c Preferred Unit or Series 1d Preferred Unit as of the conversion date divided by the product of 0.80 multiplied by the Unit Value of the Series 1 Preferred Units or Series 1a Preferred Units or Series 1b Preferred Units or Series 1c Preferred Units or Series 1d Preferred Unit issued on the conversion date. The Series A Preferred Units issued to the Series 1 Preferred Members and Series 1a Preferred Members and Series 1b Preferred Members and Series 1c Preferred Members and Series 1d Preferred Members upon conversion of such Series 1 Preferred Units and Series 1a Preferred Units and such Series 1b Preferred Units and Series 1c Preferred Units and Series 1d Preferred Units would have had the same rights, privileges and preferences as the other Series A Preferred Units issued by the Company on the conversion date. The Company considered the classification of the Preferred Units and concluded that they were appropriately included as a component of equity since each class of Preferred Units participates in the same form of consideration received upon a change in control. As of December 31, 2021 and September 30, 2022, no preferred units or stock remained outstanding.

 

 
18

Table of Contents

 

Stockholders’ Agreements

 

On March 24, 2021, in connection with the conversion of Dermata Therapeutics, LLC into a Delaware corporation, the Company entered into a Stockholders’ Agreement (as amended, the Stockholders’ Agreement) with all of its then-existing stockholders, including Proehl Investment Ventures, LLC and Hale Biopharma Ventures, LLC. The Stockholders’ Agreement among other things, provided for certain restrictions on transfer of the Company’s shares of capital stock, set forth agreements and understandings with respect to how shares of its capital stock held by the stockholders party thereto will have been voted on, or tendered in connection with, an acquisition of the Company and provided for certain voting rights with respect to the election of directors. In addition, pursuant to the Stockholders’ Agreement, holders of the Company’s Series 1a Preferred Stock were entitled to purchase, at any time prior to March 14, 2026, such number of shares of the Company’s Series 1a Preferred Stock as such Series 1a Stockholder shall request, up to an aggregate number of shares of Series 1a Preferred Stock not to exceed the product of 25% and the aggregate number of shares Series 1a Preferred Stock then held by such Series 1a Stockholder (or the Series 1a Preferred Warrant Rights). The shares of Series 1a Preferred Stock purchased pursuant to any Series 1a Preferred Warrant Right had a per share purchase price of $20.50 (subject to appropriate adjustment in the event of any stock dividend, stock split, combination, or other similar recapitalization). Upon the consummation of the Company’s IPO of common stock, each Series 1a Preferred Stock Warrant became exercisable for the same number of shares of Common Stock with the same per share exercise price of $20.50 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination, or other similar recapitalization). The Stockholders’ Agreement would have automatically terminated upon the earliest of (a) immediately prior to the consummation of the Company’s initial public offering of common stock, and (b) the consummation of a sale of the Company, subject to certain conditions. The Company completed the IPO of common stock in August 2021, thereby terminating the Stockholders’ Agreement.

 

On June 29, 2021, with effectiveness on July 1, 2021, the Company’s board of directors amended its Certificate of Incorporation to adjust the conversion price and certain conversion mechanics of the Company’s issued and outstanding Series 1d Preferred Stock, whereby each share of Series 1d Preferred stock would convert into such number of Common Stock as determined by dividing (i) the product of (a) the Original Issue Price for the Series 1d Preferred Stock, multiplied by (b) 1.2, rounded to the nearest whole cent, by (ii) the 80% of the initial public per share offering price in the IPO. The Series 1d conversion shall not be subject to further adjustment for any stock split.

 

On June 29, 2021, with effectiveness on July 1, 2021, the Company’s board of directors approved an amendment to the 2021 Plan to increase the number of shares of Common Stock available for issuances from 593,340 to 1,648,213 shares. Effective January 1, 2022, an evergreen provision contained in the Company's 2021 Omnibus Equity Incentive Plan, or the 2021 Plan, added one percent of common shares outstanding as of December 31, 2021 to the 2021 Plan. This evergreen provision resulted in an increase of 83,286 shares to the 2021 Plan, increasing shares authorized for issuance under the 2021 Plan to 1,731,499 as of January 1, 2022.

 

On June 29, 2021, the Company’s board of directors approved a 1-for-20.5 reverse split of all outstanding shares of common stock, effected on July 1, 2021 (no fractional shares were issued). Except as otherwise noted, all references to share and per share amounts related to common stock and common units have been restated to reflect the reverse stock split.

 

On July 12, 2021, the Company’s board of directors amended its Certificate of Incorporation to further adjust the conversion price and certain conversion mechanics of the Company’s issued and outstanding Series 1d Preferred Stock. The two amendments to the Series 1d Preferred Stock conversion terms were combined for purposes of accounting for the amendments. In order to determine if these amendments resulted in a modification or extinguishment of the Series 1d Preferred Stock, pursuant to the related authoritative guidance, the Company engaged an independent third-party valuation firm to assist with determining the fair value of the Series 1d Preferred Stock immediately before the change in conversion terms, as well as immediately after the change in conversion terms. This resulted in a substantive increase in fair value, and as such, the Company determined the amendments resulted in extinguishment accounting. Accordingly, the Company applied ASC 260, Earnings per Share, and ASC 470, Debt, by analogy to determine the appropriate measurement and presentation. The Company compared the fair value of the Series 1d Preferred Stock, as amended, to its carrying value and recorded the resulting difference of approximately $2.3 million as a deemed dividend for the Series 1d preferred shareholders. The Company recorded the deemed dividend to additional paid-in capital during the quarter ended September 30, 2021. Because the Company is in an accumulated deficit position, the deemed dividend increased the net loss attributable to the common shareholders for the three and nine months ended September 30, 2021.

 

 
19

Table of Contents

 

On July 30, 2021, the Company entered into a Second Amendment to the License and Settlement Agreement (or, the Second License Amendment), whereby, for the settlement of certain disputes arising under the License Agreement, the Company agreed to exchange the shares of Series 1c Preferred Stock owned by Villani, Inc. (“Villani”) for an increase of milestone payments and royalty rates due to Villani under the License Agreement. On July 30, 2021, Villani surrendered 5,221,156 shares of Series 1c Preferred Stock to the Company and on August 17, 2021, the Company paid to Villani $1.0 million upon the close of the Company’s initial public offering for the redemption of the Series 1c shares. The Company determined that the deemed dividend to Villani for the Series 1c preferred share redemption was the difference between the $1.0 million paid for the shares and the carrying value of the shares of $730,962, resulting in a deemed dividend of $269,038. This deemed dividend of $269,038 was recorded to additional paid-in capital during the quarter ended September 30, 2021. Because the Company is in an accumulated deficit position, the deemed dividend increased the net loss attributable to common shareholders for the three and nine months ended September 30, 2021.

 

On August 14, 2021, the Company’s board of directors approved an amendment to the Company’s Certificate of Incorporation to increase the number of shares of Common Stock authorized to 90,000,000.

 

On July 11, 2022, the Company filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to increase the number of authorized shares of the Company’s common stock from 90,000,000 shares to 250,000,000 shares. The increase in the number of authorized shares was approved by the holders of a majority of the outstanding shares of common stock of the Company at its annual meeting on July 11, 2022.

 

Warrants

 

Warrants issued at IPO

 

On August 17, 2021, the Company completed its IPO, in which it sold 2,571,428 shares of its common stock together with 2,571,428 warrants to purchase one share of common stock with an exercise price of $7.00 per share at a combined offering price of $7.00. The underwriters exercised their option to purchase an additional 385,714 warrants with an exercise price of $7.00, increasing the number of warrants issued at IPO to 2,957,142. Each warrant is immediately exercisable at the option of the holder and expires five years from the date of issuance.

 

The Company evaluated the terms of the warrants issued at the IPO and determined that they should be classified as equity instruments based upon accounting guidance provided in ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging. Since the Company determined that the warrants were equity classified, the Company recorded the proceeds from the IPO, net of issuance costs, within common stock at par value and the balance of proceeds to additional paid in capital. The fair value of each warrant on August 17, 2021 was $0.9995 based on the closing trading price on that day.

 

As of September 30, 2022, the Company had 2,957,142 warrants outstanding resulting from the IPO with an exercise price of $7.00 and which expire August 17, 2026. As of September 30, 2022, the outstanding warrants are exercisable into 2,957,142 shares of common stock whose fair value was $0.52 per share, based on the closing trading price on that day.

 

 
20

Table of Contents

 

Underwriter IPO Warrants

 

Upon the closing of the Company's IPO in August 2021, the Company issued to the underwriters warrants to purchase 128,571 of shares of common stock at an exercise price equal to 115% of the public offering price, or $8.05 per share, exercisable for a period of five years, or until August 2026. As of September 30, 2022, the Company had 128,571 warrants outstanding resulting from the underwriter IPO warrants with an exercise price of $8.05 and which expire August 17, 2026. As of September 30, 2022, the outstanding warrants are exercisable for 128,571 shares of common stock whose fair value was $0.52 per share, based on the closing trading price on that day.

 

Warrants issued with Class B Common Units

 

In March 2021, the Company granted Class B Common Units Profits interests to certain former employees and consultants. In connection with the conversion from an LLC to a C-Corporation, the Company converted 65,303 of vested Units to fully vested Common Stock Warrants with an exercise price of $5.74. These Common Stock Warrants issuances were considered a modification under ASC 718, Stock Compensation, in which the fair value of the Class B Common Units profits interests were measured at the modification date and compared to the fair value of the common stock warrants, with the difference of $279,812 recorded as stock-based compensation expense in the first quarter of 2021.

 

As of September 30, 2022, the Company had 65,303 common warrants outstanding related to the prior Class B Common Units with an exercise price of $5.74 and which expire December 31, 2024. As of September 30, 2022, the outstanding warrants are exercisable into 65,303 shares of common stock whose fair value was $0.52 per share, based on the closing trading price on that day.

 

Warrants issued with Series 1a Preferred Units

 

In connection with the issuance of 5,000,000 Series 1a Preferred Units in November 2016, each Series 1a Preferred Member received Warrant Units to purchase from the Company, at any time after November 15, 2016 and on or prior to November 15, 2021, such number of Series 1a Preferred Units as such Series 1a Preferred Member shall request, up to an aggregate number of Series 1a Preferred Units not to exceed the product of 25% and the aggregate number of Series 1a Preferred Units then held by such Series 1a Preferred Member, which was 1,231,250 units at December 31, 2020. The exercise price for each Warrant Unit was $1.00, subject to adjustment for unit splits and combinations. The warrants had a 5-year term. The Company received total proceeds of $5,000,000 for the Series 1a Preferred Units and warrants which were allocated on a relative fair value basis to the Units and warrants resulting in a relative fair value of $4,381,199 and $618,801, respectively. The estimated fair value of the Series 1a Warrant Units was recorded as a separate component of members’ equity (deficit) in the accompanying financial statements as of December 31, 2020. In June 2020, 18,750 of the warrants were exercised for consideration of $18,750, which consideration was received in July 2020.

 

In connection with the Loan and Security Agreement, SVB also received Warrant Units to purchase, at any time after February 9, 2017 and prior to February 9, 2027, 187,978 Series 1a Preferred Units or the equivalent Series A Preferred Units had they purchased Series 1a Preferred Units, if Series A Preferred Units are issued, at an exercise price of $1.00 per unit. On March 24, 2021, in connection with the conversion from an LLC to a C-Corporation, each warrant to purchase Series 1a Preferred Units in the LLC was automatically converted into a warrant to purchase, upon the same terms and conditions, shares of Series 1a Preferred Stock of the Company.

 

In July 2021, the Company effected a reverse split of shares of the Company’s common stock at a ratio of 1-for-20.5, and the conversion ratio of the preferred stock was adjusted accordingly. In August 2021, in connection with the Company’s IPO, the outstanding Series 1a preferred warrants were converted into 69,212 common warrants.

 

As of September 30, 2022, the Company had 69,212 common warrants outstanding related to the prior Series 1a preferred warrants with an exercise price of $20.50 and which expire November 15, 2026. As of September 30, 2022, the outstanding warrants are exercisable into 69,212 shares of common stock whose fair value was $0.52 per share, based on the closing trading price on that day.

 

 
21

Table of Contents

 

Common and Pre-Funded Warrants issued with PIPE

 

In April 2022, the Company completed the PIPE, in which it sold 898,585 shares of its common stock together with 2,875,000 Pre-funded Warrants to purchase one share of common stock with an exercise price of $0.0001 per share, and 3,773,585 PIPE Common Warrants to purchase one share of common stock with an exercise price of $1.325 per share, at a combined offering price of $1.325. Each PIPE Common Warrant is immediately exercisable at the option of the holder and expires May 13, 2027.

 

During the quarter ended June 30, 2022, 875,000 of the Pre-funded Warrants were exercised. During the quarter ended September 30, 2022, the remaining 2,000,000 Pre-funded Warrants were exercised. No additional Pre-funded Warrants are outstanding as of September 30, 2022.

 

As of September 30, 2022, the Company had 3,773,585 PIPE Common Warrants outstanding with an exercise price of $1.325 and which expire May 13, 2027. As of September 30, 2022, the outstanding PIPE Common Warrants are exercisable into 3,773,585 shares of common stock whose fair value was $0.52 per share, based on the closing trading price on that day.

 

7. Equity Incentive Plan

 

Under the Company’s 2021 Omnibus Equity Incentive Plan (the “2021 Plan”), the Company may grant options to purchase common stock, restricted stock awards, performance stock awards, incentive bonus awards, other cash-based awards or directly issue shares of common stock to employees, directors, and consultants of the Company. Effective January 1, 2022, an evergreen provision contained in the Company’s 2021 Plan increased the total number of shares of common shares issuable under the 2021 Plan in an amount equal to one percent of the Company’s common shares outstanding as of December 31, 2021. This evergreen provision resulted in an additional 83,286 common shares issuable pursuant to the 2021 Plan, increasing the total authorized shares available for issuance under the 2021 Plan to 1,731,499 as of January 1, 2022. Stock awards may be granted at an exercise price per share of not less than 100% of the fair market value at the date of grant. Stock awards granted are exercisable over a maximum term of 10 years from the date of grant and generally vest over a period of four years for employees and one year for directors of the Company’s board and consultants.

 

As of September 30, 2022, there remain an additional 547,447 shares reserved for issuance under the 2021 Plan.

 

Fair Value Measurement

 

The Company uses the Black-Scholes option valuation model, which requires the use of highly subjective assumptions, to determine the fair value of stock-based awards. The fair value of each employee stock option is estimated on the grant date under the fair value method using the Black-Scholes model. The estimated fair value of each stock option is then expensed over the requisite service period, which is generally the vesting period. The assumptions and estimates that the Company uses in the Black-Scholes model are as follows:

 

 

·

Fair Value of Common Stock. The estimated fair value of the common stock underlying the Company’s stock option plan was determined by management by considering various factors as discussed below. All options to purchase shares of the Company’s common stock are intended to be exercisable at a price per share not less than the per-share fair value of the Company’s common stock underlying those options on the date of grant. In the absence of a public trading market for the Company’s common stock, before the initial public offering, on each grant date, the Company developed an estimate of the fair value of its common stock based on the information known to the Company on the date of grant, upon a review of any recent events and their potential impact on the estimated fair value per share of the common stock and in part on input from an independent third-party valuation firm. After the Company’s initial public offering, the fair value of common stock is measured as the Company’s closing price of common stock on the date of grant.

 

 

 

 

·

Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes valuation model on the implied yield available on U.S. Treasury zero-coupon issues with a term equivalent to that of the expected term of the options.

 

 

 

 

·

Expected Term. The expected term represents the period that the Company’s stock-based awards are expected to be outstanding. Because of the limitations on the sale or transfer of the Company’s common stock as a privately held company, the Company does not believe its historical exercise pattern is indicative of the pattern it will experience as a publicly traded company. The Company plans to continue to use the SAB 110 simplified method until it has sufficient trading history as a publicly traded company.

 

 
22

Table of Contents

 

 

·

Volatility. The Company determines the price volatility based on the historical volatilities of industry peers as it has limited trading history for its common stock price. Industry peers consist of several public companies in the biotechnology industry with comparable characteristics, including clinical trials progress and therapeutic indications.

 

 

 

 

·

Dividend Yield. The expected dividend assumption is based on the Company’s current expectations about its anticipated dividend policy. To date, the Company has not declared any dividends to common shareholders, and therefore the Company has used an expected dividend yield of zero.

 

The following table presents the weighted-average assumptions used for the stock option grants:

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Grant date fair value

 

$0.45

 

 

$4.54

 

 

$1.46

 

 

$4.87

 

Risk-free rate

 

 

2.9%

 

 

0.98%

 

 

1.5%

 

 

0.92%

Dividend yield

 

 

0.00%

 

 

0.00%

 

 

0.0%

 

 

0.00%

Expected life in years

 

 

6.1

 

 

 

5.8

 

 

 

5.4

 

 

 

5.7

 

Expected volatility

 

 

132%

 

 

125%

 

 

123%

 

 

122%

 

Stock-based Compensation Expense

 

In general, stock-based compensation is allocated to research and development expense or general and administrative expense according to the classification of cash compensation paid to the employee, director, or consultant to whom the stock award was granted.

 

On March 24, 2021, in connection with the conversion from an LLC to a C-Corporation, the Company converted 277,448 of Class B Common Units profits interests, for which no consideration had been received, into 277,448 options to purchase common stock at an exercise price of $5.74 to $6.314 per share. The fair value of common stock prior to IPO was determined in part based upon input from an independent third-party valuation firm. The Company considered the conversion of these Class B Common Units profits interests as a modification under ASC 718, Stock Compensation, in which the fair value of the Class B Common Units profits interests was measured at the modification date and compared to the fair value of the common stock options, with the difference of $1,339,993 resulting in incremental stock-based compensation expense. Related to the options, the Company recorded $849,564 of stock-based compensation expense recorded in the first quarter of 2021.

 

In December 2021, the Company’s board of directors authorized a stock option grant in lieu of a cash bonus for the Company’s Chairman and Chief Executive Officer. The stock-based compensation expense of $0.4 million related to the stock option grant was booked to the fiscal year ended December 31, 2021; however, the impact to additional paid-in capital was not booked until the first quarter of 2022, when the stock option award was granted.

 

 
23

Table of Contents

 

The following table summarizes the total stock-based compensation expense related to stock options and RSUs included in the Company’s statements of operations:

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Research and development

 

$54,907

 

 

$30,075

 

 

$163,417

 

 

$310,046

 

General and administrative

 

 

180,076

 

 

 

112,580

 

 

 

546,018

 

 

 

1,106,645

 

 

 

$234,983

 

 

$142,655

 

 

$709,435

 

 

$1,416,691

 

 

Stock Option Award Activity

 

A summary of the Company’s Equity Plan stock option activity is as follows:

 

 

 

Number of

Options

Outstanding

 

 

Weighted-

Average

Exercise

Price

 

 

Weighted-

Average

Remaining

Contractual

Term (in

Years)

 

Balance at December 31, 2021

 

 

523,199

 

 

$5.84

 

 

 

8.8

 

Options granted

 

 

533,127

 

 

 

1.75

 

 

 

-

 

Options exercised

 

 

-

 

 

 

-

 

 

 

-

 

Options cancelled

 

 

-

 

 

 

-

 

 

 

-

 

Balance at September 30, 2022

 

 

1,056,326

 

 

$3.77

 

 

 

8.5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options exercisable at September 30, 2022

 

 

586,100

 

 

$4.32

 

 

 

8.6

 

 

The aggregate intrinsic value of options exercisable as of September 30, 2022 is calculated as the difference between the exercise price of the underlying options and the closing market price of the Company’s common stock on that date, which was $0.52 per share. The intrinsic value of options outstanding and exercisable as of September 30, 2022 was $385.

 

As of September 30, 2022, total unrecognized compensation cost related to stock options was approximately $1.1 million and the weighted average period over which this cost is expected to be recognized is 2.5 years.

 

 Restricted Stock Unit Award Activity

 

A summary of the Company’s Equity Plan restricted stock unit, or RSU, award activity is as follows:

 

 

 

Number of

RSU’s outstanding

 

Balance at December 31, 2021

 

 

-

 

RSUs granted

 

 

127,726

 

RSUs settled

 

 

-

 

RSUs cancelled

 

 

-

 

Balance at September 30, 2022

 

 

127,726

 

 

During the three and nine months ended September 30, 2022, the Company issued to certain of the Company’s directors 80,589 and 127,726 RSUs, respectively, as partial compensation for their services during 2022. The Company recognized stock-based compensation expense of approximately $0.1 million during the three and nine months ended September 30, 2022 related to the restricted stock unit awards. There were no RSUs outstanding during 2021 and there is no unrecognized compensation expense related to outstanding RSUs as of September 30, 2022.  

 

 
24

Table of Contents

 

8. 401(k) Plan

 

The Company sponsors a 401(k) savings plan for all eligible employees. The Company may make discretionary matching contributions to the plan to be allocated to employee accounts based upon employee deferrals and compensation. To date, the Company has not made any matching contributions into the savings plan.

 

9. License Agreements

 

On March 31, 2017, the Company entered into a license agreement, as amended (the “License Agreement”) with Villani, Inc. whereby Villani has granted the Company an exclusive, sub-licensable, royalty-bearing license (the “License”) under the Licensed Patents (as defined in the License Agreement), to formulate, develop, seek regulatory approval for, make or sell products that contain Spongilla lacustris (alone or in combination with other active or inactive ingredients) for the treatment of diseases, disorders and conditions of the skin, including but not limited to acne, rosacea, psoriasis, atopic dermatitis, seborrheic dermatitis, actinic keratosis and eczema that were developed using certain licensed know-how (“Licensed Products”). The Company is responsible for the development (including manufacturing, packaging, non-clinical studies, clinical trials and obtaining regulatory approval and commercialization (including marketing, promotion, distribution, etc.)) for all Licensed Products. In partial consideration of the License, the Company forgave its previous outstanding loan to Villani in the amount of $400,000.

 

The original License Agreement was amended in 2019 and, in consideration of the receipt of certain know-how and patents, the Company issued to Villani 5,221,156 Series 1c Preferred Units equal to 5% of the Company’s fully diluted capitalization, valued at $730,962. Pursuant to the amended License Agreement, the Company was required to make future milestone payments to Villani in an aggregate amount of up to $20.25 million upon the achievement of specified development and sales milestones, payable in cash or in equity, at the option of Villani, as well as single-digit royalty payments on net sales.

 

On July 30, 2021, the Company further amended the License Agreement in the Second Amendment to the License and Settlement Agreement (the “Second Amendment”). In consideration of the Second Amendment, Villani exchanged the 5,221,156 Series 1c Preferred Shares issued to Villani in 2019 for an increase in milestone payments and royalty rates payable pursuant to the License Agreement and the Company paid Villani $1 million after the close of the IPO. Pursuant to the Second Amendment, the Company is required to make future milestone payments to Villani in an aggregate amount of up to $40.5 million upon the achievement of specified development and sales milestones, payable in cash or in equity, at the option of Villani, as well as single-digit royalty payments on net sales. The Second Amendment includes customary terms relating to, among others, indemnification, intellectual property protection, confidentiality, remedies, and warranties. See Note 6 – Equity Securities for additional information regarding the Company’s redemption of the Series 1c Preferred Shares from Villani.

 

10. Commitments and Contingencies

 

Clinical Trials

 

During 2021, the Company initiated a clinical trial which completed patient enrollment in June 2022; however, the Company had not completed data analysis for the clinical trial by September 30, 2022. Accordingly, the Company anticipates additional research and development expense of $0.1 to $0.2 million to be incurred during the fourth quarter of fiscal year 2022 related to this ongoing clinical trial.

 

Coronavirus Pandemic

 

On March 11, 2020, the World Health Organization declared the outbreak of a coronavirus (COVID-19) pandemic. Significant uncertainties may arise with respect to potential shutdowns of operations or government orders to cease activities due to emergency declarations, inability to operate, employee shortages, or claims for business interruption insurance, etc. Each of these matters may have a significant impact on the future results of the Company.

 

 
25

Table of Contents

 

Supplier Agreement

 

As a result of Russia’s invasion of Ukraine, the United States, the United Kingdom, and the European Union governments, among others, have developed coordinated sanctions and export-control measure packages against Russian individuals and entities. The Company is currently a party to an exclusive supply agreement for the supply of the Spongilla raw material used in DMT310 and DMT410. The counterparty to this supply agreement is a Russian entity. The imposition of enhanced export controls and economic sanctions on transactions with Russia and Russian entities by the United States, the United Kingdom, and/or the European Union could prevent the Company from performing under this existing contract or any future contract it may enter or may prevent the Company from remitting payment for raw material purchased from the Company’s supplier. The Company has received two shipments of raw material from its supplier during fiscal year 2022 containing additional quantities of Spongilla raw material which will provide the Company with sufficient quantities of Spongilla to initiate and complete two Phase 3 studies in moderate-to-severe acne and support filing a new drug application for DMT310 in acne upon the successful completion of two Phase 3 studies. Depending on the extent and breadth of new sanctions or export controls that may be imposed against Russia, otherwise or as a result of the impact of the war in Ukraine, it is possible that the Company’s ability to obtain additional supply of the Spongilla raw material used in DMT310 and DMT410 could be negatively impacted, which could adversely affect its business, results of operations, and financial condition.

 

Legal Proceedings

 

In the normal course of business, the Company may be involved in legal proceedings or threatened legal proceedings. The Company is not a party to any legal proceedings or aware of any threatened legal proceedings which are expected to have a material adverse effect on its financial condition, results of operations or liquidity.

 

11. Related Parties

 

Prior to the Company converting from an LLC to a C-corporation in March 2021, the Company had two Managing Members. One of the Managing Members remained the Company’s majority stockholder upon the close of the Company’s IPO and serves as the Company’s President, Chief Executive Officer, and Chairman of the Board of Directors. The other Managing Member remained a beneficial owner upon the close of the Company’s IPO and serves as the Company’s Lead Director of the Board of Directors. Hereinafter these two Managing Members, and their affiliates, are referred to collectively as the Principal Stockholders after the completion of the IPO.

 

During 2020, the Managing Members and other related parties loaned the Company $1,145,000 as subordinated convertible promissory notes. Additionally, during the first quarter of 2021, the Managing Members and other related parties loaned the Company $1,255,000 as subordinated convertible promissory notes. Refer to Note 4 – Subordinated Convertible Promissory Notes for further discussion.

 

During the third quarter of 2021, the Company amended the conversion terms of its Series 1d preferred stock, as described in Note 6 – Equity Securities. As a result of the Series 1d preferred stock amendments, the Company presented a deemed dividend of approximately $2.3 million for the year ended December 31, 2021, approximately $1.2 million of which related to Series 1d preferred shares owned by the Company’s Principal Stockholders and their affiliates.

 

 
26

Table of Contents

 

ITEM 2: MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and the related notes and the other financial information included elsewhere in this Quarterly Report. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed below and elsewhere in this Quarterly Report, particularly those under “Risk Factors.”

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties, and other factors, which may be beyond our control, and which may cause our actual results, performance, or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as “may,” “can,” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “seek,” “estimate,” “continue,” “plan,” “point to,” “project,” “predict,” “could,” “intend,” “target,” “potential” and other similar words and expressions of the future.

 

There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include, but are not limited to:

 

 

·

our lack of operating history;

 

 

 

 

·

the expectation that we will incur significant operating losses for the foreseeable future and will need significant additional capital;

 

 

 

 

·

our current and future capital requirements to support our development and commercialization efforts for our product candidates and our ability to satisfy our capital needs;

 

 

 

 

·

our dependence on our product candidates, which are still in various stages of clinical development;

 

 

 

 

·

our ability to acquire sufficient quantities of raw material needed to manufacture our drug product;

 

 

 

 

·

our, or that of our third-party manufacturers, ability to manufacture cGMP quantities of our product candidates as required for pre-clinical and clinical trials and, subsequently, our ability to manufacture commercial quantities of our product candidates;

 

 

 

 

·

our ability to complete required clinical trials for our product candidates and obtain approval from the FDA or other regulatory agencies in different jurisdictions;

 

 

 

 

·

our lack of a sales and marketing organization and our ability to commercialize our product candidates if we obtain regulatory approval;

 

 

 

 

·

our dependence on third parties to manufacture our product candidates;

 

 

 

 

·

our reliance on third-party CROs to conduct our clinical trials;

 

 
27

Table of Contents

 

 

·

our ability to maintain or protect the validity of our intellectual property;

 

 

 

 

·

our ability to internally develop new inventions and intellectual property;

 

 

 

 

·

interpretations of current laws and the passages of future laws;

 

 

 

 

·

acceptance of our business model by investors;

 

 

 

 

·

the accuracy of our estimates regarding expenses and capital requirements;

 

 

 

 

·

our ability to adequately support organizational and business growth; and

 

 

 

 

·

the continued spread of COVID-19 and the resulting global pandemic and its impact on our preclinical studies and clinical studies.

 

The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may cause our actual results to differ from those anticipate in our forward-looking statements. Please see “Risk Factors” for additional risks which could adversely impact our business and financial performance.

 

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this report or the date of the document incorporated by reference into this report. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. We have expressed our expectations, beliefs and projections in good faith and we believe they have a reasonable basis. However, we cannot assure you that our expectations, beliefs, or projections will result or be achieved or accomplished.

 

Overview

 

We are a clinical-stage medical dermatology company focused on identifying, developing, and commercializing innovative pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases we believe represent significant market opportunities. 

 

Dermatological diseases such as acne vulgaris (or acne), psoriasis vulgaris (or psoriasis), papulopustular acne rosacea (or rosacea), hyperhidrosis and various aesthetic skin quality issues, affect millions of people worldwide each year, and may negatively impact their quality of life and emotional well-being. While there are multiple current treatment options for each of these indications on the market, we believe that  current therapies come with significant drawbacks, including underwhelming efficacy, cumbersome application regimens, and significant tolerability issues, all of which we believe may lead to poor patient compliance. A majority of these indications are first treated with topical products; however, many patients frequently switch treatments or discontinue treatment altogether due to patient dissatisfaction. This is primarily due to slow and modest response rates, the early onset of negative side effects, onerous application schedules, and long duration of therapy. Given the limitations with current topical therapies, we believe there is a significant opportunity to address the needs of frustrated patients searching for topical products that satisfy their dermatological and lifestyle needs.

 

Our two product candidates, DMT310 and DMT410, both incorporate our proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions and satisfy the unmet need of patients. Our Spongilla technology is derived from a naturally grown freshwater sponge, Spongilla lacustris or Spongilla, which is processed into a powder that is then mixed with a fluidizing agent immediately prior to application, to form an easily applicable paste. Spongilla is a unique freshwater sponge that only grows in commercial quantities in select regions of the world and under specific environmental conditions, all of which give it its distinctive anti-microbial, anti-inflammatory, and mechanical properties. The combination of these environmental conditions, the proprietary harvesting protocols developed with our exclusive supplier, and our post-harvest processing procedures produce a pharmaceutical product candidate that optimizes the mechanical components as well as the chemical components of the sponge to create a product candidate with multiple mechanisms of action for the treatment of inflammatory skin conditions and aesthetic applications.

 

 
28

Table of Contents

 

We believe our Spongilla technology platform will enable us to develop and formulate singular and combination products that are able to target the topical delivery of chemical compounds into the dermis for a variety of dermatology indications. We believe the combination of Spongilla’s mechanical and chemical components (which we believe have demonstrated, in-vitro, anti-microbial and anti-inflammatory properties), add to the versatility of our Spongilla technology platform’s effectiveness as a singular product, in the treatment of a wide variety of medical skin diseases like acne, rosacea, and psoriasis. We also believe the mechanical properties of our Spongilla technology allows for the intradermal delivery of a variety of large molecules, like botulinum toxin, monoclonal antibodies, or dermal filler, to target treatment sites, through topical application.

 

Our lead product candidate, DMT310, is intended to utilize our Spongilla technology for once weekly treatment of a variety of skin diseases, with our initial focus being the treatment of acne vulgaris, which has a U.S. market size of approximately 50 million patients. We have shown DMT310’s ability to treat the multiple causes of acne in a Phase 2b study where we initially saw a 45% reduction in inflammatory lesions after four treatments, with statistically significant results at all time points for all three primary endpoints (reduction in inflammatory lesions, reduction in non-inflammatory lesions, and improvement in Investigator Global Assessment). Based on the multiple mechanisms of action and anti-inflammatory effect seen with DMT310 acne trial, we moved DMT310 into clinical trials for two additional indications: psoriasis and rosacea. In October 2021, we completed a Phase 1b proof of concept, or POC, trial in psoriasis where we saw encouraging results warranting further investigation. In June 2022, we completed enrollment of a Phase 2 clinical trial of DMT310 for the treatment of rosacea with results expected in December 2022.

 

DMT310 consists of two grams of powder processed from a naturally grown freshwater sponge, Spongilla lacustris. The patient mixes the powder with a fluidizing agent (hydrogen peroxide) immediately prior to application by the patient to form an easy-to-apply paste. The paste is left on the skin for approximately ten to fifteen minutes, after which time it is washed off with water. Due to the unique combination of DMT310’s mechanical components and chemical components, and based on our Phase 2 acne data, we believe patients will only need to apply DMT310 once weekly to produce a desired treatment effect. The mechanical components of the Spongilla powder consist of many microscopic siliceous, needle-like spicules that, when massaged into the skin, penetrate the stratum corneum (the skin’s outermost protective layer) and create microchannels into the dermis where pro-inflammatory cytokines and bacteria reside. We believe that the penetration of the spicules leads to the opening of microchannels, which allow oxygen to enter pilosebaceous glands, helping to kill C. acnes, which grow in an anaerobic (without oxygen) environment (C. acnes is the bacteria that cause inflammatory lesions in acne patients). The spicules also cause turnover of the top layer of dead skin, thereby increasing collagen production. We believe the newly created microchannels provide a conduit for DMT310’s naturally occurring chemical compounds to be delivered to the dermis and pilosebaceous glands, helping to kill the C. acnes. In addition to these anti-microbial compounds, DMT310 also appears to have anti-inflammatory chemical compounds, as demonstrated in in vitro experiments, that inhibit inflammation through the reduction of C.acnes stimulated IL-8 production and by inhibiting IL-17A and IL-17F expression in human cell lines. Also, during in vitro studies of DMT310’s organic compounds, we observed the inhibition of the lipogenesis of sebocytes, which may translate to a reduction in sebum (an oily and waxy substance produced by the human body’s sebaceous glands) production and the oiliness of the skin in patients, which was observed by a number of clinical investigators in our Phase 2 acne studies. We believe the combination of these biological and mechanical effects of the spicules could be important factors in treating multiple inflammatory skin diseases, as seen in our clinical trials.

 

Our second product candidate utilizing our Spongilla technology is DMT410, our combination treatment. DMT410 is intended to consist of one treatment of our proprietary sponge powder followed by one topical application of botulinum toxin for delivery into the dermis. Currently, botulinum toxin is only approved to be delivered to the dermis by intradermal injections, which can be painful for the patient and time-consuming for the physician. However, we believe DMT410’s ability to topically deliver botulinum toxin into the dermis could have similar levels of efficacy to existing delivery techniques, with fewer tolerability issues, and a quicker application time, possibly replacing the need for intradermal injections. We first tested DMT410 in a Phase 1 POC trial of axillary hyperhidrosis patients, which saw 80% of patients achieve a reduction in gravimetric sweat production greater than 50% four weeks after a single treatment. With almost 40% of the hyperhidrosis market currently being treated with intradermal injections of botulinum toxin, we believe there is significant opportunity for DMT410. Based on DMT410’s ability to effectively deliver botulinum toxin to the dermis as observed in the Phase 1 axillary hyperhidrosis trial, we also conducted a Phase 1 POC trial of DMT410 for the treatment of multiple aesthetic skin conditions, including reduction of pore size, sebum production, and fine lines, among others. In November 2021, we announced top-line results from this trial, where we saw promising data that we believe warrants further investigation of DMT410. We are currently in the process of discussing partnering opportunities with botulinum toxin companies to move the DMT410 program into Phase 2 studies.

 

 
29

Table of Contents

 

We have a limited operating history. Since our inception, our operations have focused on developing DMT310 and DMT410, organizing and staffing our company, raising capital, establishing our supply chain and manufacturing processes, further characterizing the multiple mechanisms of action of our Spongilla technology, building an intellectual property portfolio, and conducting non-clinical and clinical trials. We do not have any product candidates approved for marketing and have not generated any revenue from product sales. We have funded our operations primarily through the sale of our equity securities and debt securities. Since inception, we have raised an aggregate of approximately $51.9 million of gross proceeds from the sale of our debt and equity securities, including the securities sold in our IPO.

 

We have not generated any revenue to date and have incurred significant operating losses. Our net losses were $2.4 million and $7.9 million for the three and nine months ended September 30, 2022, respectively, and as of September 30, 2022, we had an accumulated deficit of $43.9 million. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:

 

 

·

complete development of DMT310 for the treatment of acne, including non-clinical studies and Phase 3 clinical trials;

 

 

 

 

·

prepare and file for regulatory approval of DMT310 for the treatment of moderate-to-severe acne;

 

 

 

 

·

continue development of DMT310 for the treatment of rosacea, including a Phase 2 clinical trial and Phase 3 clinical trials;

 

 

 

 

·

continue development of DMT310 for the treatment of psoriasis, including a Phase 2 clinical trial and Phase 3 clinical trials;

 

 

·

identify a botulinum toxin partner for DMT410 for the treatment of aesthetic and medical skin conditions;

 

 

 

 

·

prepare for commercialization of DMT310, if approved, including the hiring of sales and marketing personnel;

 

 

 

 

·

begin to manufacture our product candidates for Phase 2 and Phase 3 trials and commercial sale;

 

 

 

 

·

hire additional research and development and selling, general and administrative personnel;

 

 

 

 

·

maintain, expand, and protect our intellectual property portfolio; and

 

 

 

 

·

incur additional costs associated with operating as a public company.

 

We will need additional financing to support our operations. We may seek to fund our operations through public or private equity or debt financings or other sources. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital when needed or on favorable terms would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenues to achieve profitability, and we may never do so.

 

 
30

Table of Contents

 

COVID-19 Update

 

The COVID-19 pandemic continues to have a major impact in the US and around the world. The availability of vaccines holds promise for the future, though new variants of the virus and potential waning immunity from vaccines may result in continued impact from this pandemic in the future, which could adversely impact our operations. To date, we have managed delays and disruptions without significant impact in planned and ongoing preclinical trials, manufacturing, or shipping. Potential impacts to our business include delays in planned and ongoing preclinical and clinical trials including enrollment of patients, disruptions in time and resources provided by independent clinical investigators, CROs, and other third-party service providers, temporary closures of our facilities, disruptions or restrictions on our employees’ ability to travel, and delays in manufacturing and/or shipments to and from third-party suppliers and contract manufacturers for APIs and drug product, including Spongilla.

 

We have taken temporary precautionary measures intended to help minimize the risk of the virus to our employees, including having our employees to work remotely and suspending all non-essential travel worldwide for our employees. We cannot presently predict the scope and severity of the planned and potential shutdowns or disruptions of businesses and government agencies, such as the Securities and Exchange Commission, or the SEC, or FDA.

 

Critical Accounting Policies and Use of Estimates

 

We have based our management’s discussion and analysis of financial condition and results of operations on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those related to clinical development expenses, stock-based compensation expense, and the fair value of equity instruments which result in deemed dividends. We base our estimates on historical experience and on various other factors that we believe to be appropriate under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

 

While our significant accounting policies are more fully discussed in Note 2 - Summary of Significant Accounting Policies to our unaudited financial statements contained within this Form 10-Q, we believe that the following accounting policies are critical to the process of making significant judgments and estimates in the preparation of our financial statements.

 

Research and Development Expenses

 

We rely on third parties to conduct our clinical studies and to provide services, including data management, statistical analysis, and electronic compilation. Once our clinical trials begin, at the end of each reporting period, we will compare the payments made to each service provider to the estimated progress towards completion of the related project. Factors that we will consider in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of our vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, we will record net prepaid or accrued expenses related to these costs.

 

Fair Value of Common Stock and Stock-Based Compensation

 

Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period. The Company’s policy permits the valuation of stock-based awards granted to non-employees to be measured at fair value at the grant date.

 

Determining the appropriate fair value of share-based awards requires the use of subjective assumptions, including the fair value of our common shares for awards prior to our IPO, and for options, the expected life of the option and expected share price volatility. We use the Black-Scholes option pricing model to value our option awards. The assumptions used in calculating the fair value of share-based awards represents our best estimates and involve inherent uncertainties and the application of judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.

 

 
31

Table of Contents

 

Fluctuations in Operating Results

 

Our results of operations have fluctuated significantly from period to period in the past and are likely to continue to do so in the future. We anticipate that our quarterly and annual results of operations will be impacted for the foreseeable future by several factors, including the progress and timing of expenditures related to the development of our product candidates. We cannot predict with certainty what the full impact of the COVID-19 pandemic may have on our business, results of operations, financial condition, and prospects. Due to these fluctuations, we believe that the period-to-period comparisons of our operating results are not a good indication of our future performance.

 

Results of Operations

 

Three Months Ended September 30, 2022 and 2021

 

The following table summarizes our results of operations for the three months ended September 30, 2022 and 2021:

 

 

 

Three Months Ended September 30,

 

 

 

2022

 

 

2021

 

 

Difference

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

$1,553,295

 

 

$799,779

 

 

$753,516

 

General and administrative

 

 

892,777

 

 

 

912,490

 

 

 

(19,713 )

Total operating expenses

 

 

2,446,072

 

 

 

1,712,269

 

 

 

733,803

 

Losses from operations

 

 

(2,446,072 )

 

 

(1,712,269 )

 

 

(733,803 )

Other income and expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Interest (income) expense, net

 

 

(21,486 )

 

 

651

 

 

 

(22,137 )

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$(2,424,586 )

 

$(1,712,920 )

 

$(711,666 )

 

Research and Development Expenses

 

Research and development expenses increased by $0.8 million from $0.8 million for the three months ended September 30, 2021, compared $1.6 million for the three months ended September 30, 2022. The increase in research and development expense was the result of $0.3 million of increased clinical trial expenses from the ongoing DMT310 rosacea study, an increase of $0.3 million related to non-clinical activities, and increased chemistry, manufacturing, and controls, or CMC, expenses, of $0.2 million.

 

General and Administrative Expenses

 

General and administrative expenses were $0.9 million for the three months ended September 30, 2022 and September 30, 2021. Increases in insurance and public company costs were offset by decreases in legal costs for the three months ended September 30, 2022.

 

Other income and expenses

 

The Company opened a cash sweep account during the third quarter of 2022 and has begun earning interest income via overnight deposits totaling $21,486, net, for the three months ended September 30, 2022.

 

 
32

Table of Contents

 

Nine Months Ended September 30, 2022, and 2021

 

The following table summarizes our results of operations for the nine months ended September 30, 2022, and 2021:

 

 

 

Nine Months Ended September 30,

 

 

 

2022

 

 

2021

 

 

Difference

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

$4,761,686

 

 

$2,347,564

 

 

$2,414,122

 

General and administrative

 

 

3,201,111

 

 

 

2,956,444

 

 

 

244,667

 

Total operating expenses

 

 

7,962,797

 

 

 

5,304,008

 

 

 

2,658,789

 

Loss from operations

 

 

(7,962,797 )

 

 

(5,304,008 )

 

 

(2,658,789 )

Other income and expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Interest (income) expense, net

 

 

(21,486 )

 

 

45,613

 

 

 

(67,099 )

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$(7,941,311 )

 

$(5,349,621 )

 

$(2,591,690 )

 

Research and Development Expenses

 

Research and development expenses increased by $2.4 million from $2.3 million for the nine months ended September 30, 2021, compared to $4.8 million for the nine months ended September 30, 2022. The increase in research and development expense was the result of $1.4 million of increased clinical trial expenses from the ongoing DMT310 rosacea study, $0.5 million in increased non-clinical expenses, $0.2 million in increased CMC expenses, as well as increased employee and personnel expenses of $0.4 million.

 

General and Administrative Expenses

 

General and administrative expenses increased by $0.2 million from $3.0 million for the nine months ended September 30, 2021, compared to $3.2 million for the nine months ended September 30, 2022. The increase in general and administrative expenses was the result of increased insurance and public company costs of $0.9 million, offset by decreased legal costs of $0.1 million and $0.6 million of decreased stock-based compensation expense.

 

Other income and expenses

 

Other income and expenses changed by $67,099 from $45,613 representing interest expense, net, for the nine months ended September 30, 2021 compared to interest income, net, of $21,486 for the nine months ended September 30, 2022. The Company opened a cash sweep account during the third quarter of 2022 and has begun earning interest income via overnight deposits. The prior year interest expense related to the amortization of debt discount and interest expense for previously outstanding debt. As of December 31, 2021, the Company no longer had any debt outstanding.

 

Cash Flows

 

The following table summarizes our cash flows from operating and financing activities:

 

 

 

Nine Months Ended

September 30,

 

 

 

2022

 

 

2021

 

Statements of cash flows data:

 

 

 

 

 

 

Total net cash provided by (used in):

 

 

 

 

 

 

Operating activities

 

$(7,008,636 )

 

$(3,889,483 )

Financing activities

 

$4,276,652

 

 

$15,962,424

 

Increase (decrease) in cash and cash equivalents

 

$(2,731,984 )

 

$12,072,941

 

 

 
33

Table of Contents

 

Operating activities

 

Cash used in operations of $7.0 million for the nine months ended September 30, 2022, was the result of the net loss of $7.9 million and an increase in prepaid expenses and other current assets of $0.1 million, offset by non-cash stock-based compensation of $0.7 million and an increase in accrued and other current liabilities of $0.3 million.

 

Cash used in operations of $3.9 million for the nine months ended September 30, 2021 was the result of the net loss of $5.3 million and an increase in prepaid expenses and other current assets of $1.0 million, offset by non-cash stock-based compensation of $1.4 million and an increase in accounts payable and accrued and other current liabilities of $1.0 million.

 

Financing activities

 

Cash provided by financing activities of $4.3 million for the nine months ended September 30, 2022, was the result of the net proceeds received from the issuance of common stock and warrants issued in April 2022 from a private placement of the Company’s securities.

 

Cash provided by financing activities of $16.0 million for the nine months ended September 30, 2021 was the result of net proceeds of $15.4 million from our initial public offering, $1.6 million from the issuance of convertible subordinated promissory notes, proceeds of $0.6 million from the issuance of Series 1d Preferred Units, offset by $1.0 million payment for the redemption of 5,221,156 shares of Series 1c preferred stock and $0.6 million of principal and final payments on debt.

 

Liquidity and Capital Resources

 

Since our inception, we have not generated any revenue or commercialized any products. As of September 30, 2022, our cash and cash equivalents totaled $8.1 million, and we had an accumulated deficit of $43.9 million. For the nine months ended September 30, 2022, and the year ended December 31, 2021, we used cash of $7.0 million and $5.7 million, respectively, in operations. As a result of our initial public offering of common stock and warrants to purchase common stock in August 2021 for net proceeds of $15.4 million, as well as our private placement of common stock and warrants to purchase common stock in April 2022 for net proceeds of $4.3 million, our cash balances are expected to fund operations into the third quarter of 2023. We anticipate that we will continue to incur net losses for the foreseeable future.

 

Historically, our principal sources of cash have included proceeds from the issuance of common and preferred equity and proceeds from the issuance of debt. Our principal uses of cash have included cash used in operations (including clinical development of our product candidates and general and administrative expenses) and payments for license rights. We expect that the principal uses of cash in the future will be for continuing operations, funding of research and development, and general working capital requirements. We expect that as research and development expenses continue to grow, we will need to raise additional capital to sustain operations and research and development activities.

 

Funding Requirements

 

We plan to focus in the near term on the development, regulatory approval, and potential commercialization of DMT310 for the treatment of acne, psoriasis, and rosacea. We anticipate we will incur net losses for the next several years as we complete clinical development of DMT310 for the treatment of acne, psoriasis and rosacea and continue research and development of DMT410 for the treatment of aesthetic and medical skin conditions. In addition, we plan to seek opportunities to identify, acquire or in license and develop additional drug candidates, potentially build commercial capabilities, and expand our corporate infrastructure. We may not be able to complete the development and initiate commercialization of these programs if, among other things, our clinical trials are not successful or if the FDA does not approve our drug candidate arising out of our current clinical trials when we expect, or at all.

 

Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, clinical costs, external research and development services, legal and other regulatory expenses, and administrative and overhead costs. Our future funding requirements will be heavily determined by the resources needed to support development of our drug candidates.

 

 
34

Table of Contents

 

As a publicly traded company, we will incur significant legal, accounting, and other expenses that we were not required to incur as a private company. In addition, the Sarbanes-Oxley Act of 2002, as well as rules adopted by the Securities and Exchange Commission, or SEC, and Nasdaq, requires public companies to implement specified corporate governance practices that were not applicable to us as a private company. We expect these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly.

 

We believe that our existing cash and cash equivalents, along with the proceeds from a private placement of our securities which closed in April 2022 (the “Private Placement”), will be sufficient to fund our operating expenses and capital expenditure requirements into the third quarter of 2023. We have based this estimate of cash runway on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We anticipate that we will continue to incur net losses for the foreseeable future. These factors raise substantial doubt about our ability to continue as a going concern for the one-year period following the date that these financial statements were issued. We will require additional capital to conduct Phase 3 studies for DMT310 for the treatment of acne, continue development of DMT310, and to pursue in licenses or acquisitions of other drug candidates. Additional funds may not be available on a timely basis, on favorable terms, or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business strategy. If we are unable to raise sufficient additional capital, we may need to substantially curtail our planned operations and the pursuit of our growth strategy.

 

We may raise additional capital through the sale of equity or convertible debt securities. In such an event, the terms of these securities may include liquidation or other preferences that adversely affect the rights of a holder of our common stock.

 

Because of the numerous risks and uncertainties associated with research, development, and commercialization of pharmaceutical drugs, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on many factors, including:

 

 

·

the number and characteristics of the drug candidates we pursue;

 

 

 

 

·

the scope, progress, results, and costs of researching and developing our drug candidates, and conducting preclinical studies and clinical trials;

 

 

 

 

·

the timing of, and the costs involved in, obtaining regulatory approvals for our drug candidates;

 

 

 

 

·

the cost of manufacturing our drug candidates and any drugs we successfully commercialize;

 

 

 

 

·

our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;

 

 

 

 

·

the costs involved in preparing, filing, prosecuting, maintaining, defending, and enforcing patent claims, including litigation costs and the outcome of such litigation; and

 

 

 

 

·

the timing, receipt and amount of sales of, or milestone payments related to or royalties on, our current or future drug candidates, if any.

 

To continue to grow our business over the longer term, we plan to commit substantial resources to research and development, clinical trials of our product candidates, and other operations and potential product acquisitions and in licensing. We have evaluated and expect to continue to evaluate a wide array of strategic transactions as part of our plan to acquire or in license and develop additional products and product candidates to augment our internal development pipeline. Strategic transaction opportunities that we may pursue could materially affect our liquidity and capital resources and may require us to incur additional indebtedness, seek equity capital or both. In addition, we may pursue development, acquisition or in licensing of approved or development products in new or existing therapeutic areas or continue the expansion of our existing operations. Accordingly, we expect to continue to opportunistically seek access to additional capital to license or acquire additional products, product candidates or companies to expand our operations, or for general corporate purposes. Strategic transactions may require us to raise additional capital through one or more public or private debt or equity financings or could be structured as a collaboration or partnering arrangement. We have no arrangements, agreements, or understandings in place at the present time to enter into any acquisition, in licensing or similar strategic business transaction.

 

 
35

Table of Contents

 

Contractual Obligations and Commitments

 

We do not currently lease any office space.

 

We enter into contracts in the normal course of business with contract research organizations for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts generally provide for termination upon notice, and therefore we believe that our non-cancelable obligations under these agreements are not material.

 

JOBS Act Accounting Election

 

We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (“the JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

 

Recent Accounting Pronouncements

 

See Item 1 of Part I, “Notes to Financial Statements — Note 2 — Summary of Significant Accounting Policies” for a discussion of recent accounting pronouncements.

 

ITEM 3: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

 

ITEM 4: CONTROLS AND PROCEDURES

 

 
36

Table of Contents

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2022. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

 

Based on the evaluation of our disclosure controls and procedures as of September 30, 2022, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level. 

 

Evaluation of Changes in Internal Control over Financial Reporting

 

There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the period to which this report relates that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. From time to time, we make changes to our internal control over financial reporting that are intended to enhance its effectiveness and which do not have a material effect on our overall internal control over financial reporting.

 

 
37

Table of Contents

 

PART II – OTHER INFORMATION

 

ITEM 1: LEGAL PROCEEDINGS

 

None.

 

ITEM 1A: RISK FACTORS

 

As of the date of this Quarterly Report on Form 10-Q, there have been no material changes from the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission, or SEC, on March 28, 2022. Any of these factors could result in a significant or material adverse effect on our result of operations or financial conditions. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. We may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.

 

ITEM 2: UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

On August 12, 2021, our registration statement on Form S-1 (Registration No. 333-256997) and the related registration statement (File No. 333-258772) was declared effective by the SEC for our initial public offering pursuant to which we sold an aggregate of 2,571,428 shares of its common stock and accompanying warrants to purchase up to 2,571,428 shares of common stock. Each share of common stock was sold together with one warrant to purchase one share of common stock with an exercise price of $7.00 per share at a combined offering price of $7.00, for gross proceeds of approximately $18.0 million, before deducting expenses. Maxim Group LLC acted as the sole book-running manager for the offering. On August 17, 2021, we closed the sale of the shares of Common Stock and warrants to purchase shares of Common Stock, resulting in net proceeds to us of approximately $15.4 million after deducting underwriting discounts and commissions and other offering expenses. No payments were made by us to directors, officers or persons owning ten percent or more of our Common Stock or to their associates, or to our affiliates. There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus filed with the SEC on August 16, 2021 pursuant to Rule 424(b).

 

ITEM 3: DEFAULTS UPON SENIOR SECURITIES

 

None noted.

 

ITEM 4: MINE SAFETY DISCLOSURES 

 

Not applicable.

 

ITEM 5: OTHER INFORMATION

 

None.

 

 
38

Table of Contents

 

ITEM 6: EXHIBITS

 

Exhibit

No.

 

Description

3.1

 

Amendment to Amended and Restated Bylaws, dated September 21, 2022 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on September 23, 2022).

 

 

 

31.1

 

Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).

 

 

 

31.2

 

Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).

 

 

 

32.1**

 

Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b).

101.INS*

 

XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

101.SCH*

 

Inline XBRL Taxonomy Extension Schema Document

101.CAL*

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*

 

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE*

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

 

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibits 101)

 

* Filed herewith.

** Furnished, not filed.

† Indicates a management contract or compensation plan, contract or arrangement.

 

 
39

Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Dermata Therapeutics, Inc.

 

 

 

 

 

Date: November 10, 2022

By:

/s/ Gerald T. Proehl

 

 

 

Gerald T. Proehl

 

 

 

President and Chief Executive Officer

 

 

 

(Principal Executive Officer)

 

 

 

 

 

 

 By:

/s/ Kyri K. Van Hoose

 

 

 

Kyri K. Van Hoose

 

 

 

Senior Vice President, Chief Financial Officer

 

 

 

(Principal Financial Officer and Principal Accounting Officer)

 

 

 
40

 

 EX-31.1 2 drma_ex311.htm CERTIFICATION drma_ex311.htm

 

EXHIBIT 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Gerald T. Proehl, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q for the period ended September 30, 2022 of Dermata Therapeutics, Inc. (the “Registrant”);

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

 

 

4.

The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

 

 

a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

 

 

b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

 

 

c)

evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

 

 

d)

disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

 

5.

The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

 

 

a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

 

 

 

 

b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

 

Date: November 10, 2022

/s/ Gerald T. Proehl

 

Gerald T. Proehl

 

President and Chief Executive Officer

 

(Principal Executive Officer)

 

 

 EX-31.2 3 drma_ex312.htm CERTIFICATION drma_ex312.htm

 

EXHIBIT 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Kyri K. Van Hoose, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q for the period ended September 30, 2022 of Dermata Therapeutics, Inc. (the “Registrant”);

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

 

 

4.

The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

 

 

a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

 

 

b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

 

 

c)

evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

 

 

d)

disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

 

5.

The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

 

 

a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

 

 

 

 

b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

 

Date: November 10, 2022

/s/ Kyri K. Van Hoose

 

Kyri K. Van Hoose

 

Chief Financial Officer

 

(Principal Financial and Accounting Officer)

 

 

 EX-32.1 4 drma_ex321.htm CERTIFICATION drma_ex321.htm

 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the quarterly report of Dermata Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of Gerald T. Proehl, as Chief Executive Officer, and Kyri K. Van Hoose, as Chief Financial Officer, certifies in his or her capacity as such officer of the Company, that to such officer’s knowledge, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002:

 

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

 

 

 

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 10, 2022

By:

/s/ Gerald T. Proehl

 

 

 

Gerald T. Proehl

 

 

 

Chief Executive Officer

 

 

 

(Principal Executive Officer)

 

 

 

 

 

 

By:

/s/ Kyri K. Van Hoose

 

 

 

Kyri K. Van Hoose

 

 

 

Chief Financial Officer

 

 

 

(Principal Financial and Accounting Officer)

 

 

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

 

 EX-101.SCH 5 drma-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - Statements of Operations (unaudited) link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - Statements of Stockholder's Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 000007 - Disclosure - Organization and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - Balance Sheet Details link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - Subordinated Convertible Promissory Notes link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - LongTerm Debt link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - Equity Securities link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - Equity Incentive Plan link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - 401(k) Plan link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - License Agreements link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - Related Parties link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - Balance Sheet Details (Tables) link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - Equity Incentive Plan (Tables) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - Organization and Basis of Presentation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - Summary of Significant Accounting Policies (Details 1) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - Balance Sheet Details (Details) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - Subordinated Convertible Promissory Notes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - LongTerm Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - Equity Securities (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - Equity Incentive Plan (Details) link:presentationLink link:calculationLink link:definitionLink 000031 - Disclosure - Equity Incentive Plan (Details 1) link:presentationLink link:calculationLink link:definitionLink 000032 - Disclosure - Equity Incentive Plan (Details 2) link:presentationLink link:calculationLink link:definitionLink 000033 - Disclosure - Equity Incentive Plan (Details 3) link:presentationLink link:calculationLink link:definitionLink 000034 - Disclosure - Equity Incentive Plan (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000035 - Disclosure - License Agreements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000036 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000037 - Disclosure - Related Parties (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 drma-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Ex Transition Period Entity Common Stock Shares Outstanding Document Quarterly Report Document Transition Report Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Trading Symbol Security Exchange Name Entity Interactive Data Current Balance Sheets Assets: Cash and cash equivalents Prepaid expenses and other current assets Total assets [Assets] Liabilities and Stockholders' Equity: Liabilities: Accounts payable Accrued and other current liabilities Total liabilities [Liabilities] Commitments and Contingencies (see Note 10) Stockholders' Equity: Common Stock, par value $0.0001, 250,000,000 shares authorized and 12,102,214 shares issued and outstanding as of September 30, 2022; and 90,000,000 shares authorized and 8,328,629 shares issued and outstanding as of December 31, 2021, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity [Stockholders' Equity Attributable to Parent] Total liabilities and stockholders' equity [Liabilities and Equity] Common stock shares, par value Common stock shares, authorized Common stock, shares issued Common stock shares, outstanding Statements of Operations (unaudited) Operating expenses: Research and development [Research and Development Expense] General and administrative [General and Administrative Expense] Total operating expenses [Operating Costs and Expenses] Loss from operations [Operating Income (Loss)] Other income and expenses: Interest (income) expense, net Net loss [Net Income (Loss) Attributable to Parent] Deemed dividend upon the redemption of 5,221,156 shares of Series 1c preferred stock (see Note 6) Deemed dividend upon the amendment of terms of the Series 1d convertible preferred stock (see Note 6) Net loss attributable to common stockholders [Net loss attributable to common stockholders] Net loss per share of common stock, basic and diluted Weighted-average basic and diluted common units/shares Statements of Stockholder's Equity (Unaudited) Statement [Table] Statement [Line Items] Equity Components [Axis] Common Stock Additional Paid-In Capital Retained Earnings (Accumulated Deficit) Common Classes A Member Common Classes B Member Series One Preferred Member Sereies One A Preferred Member Series One A Warrants Member Series One B Preferred Member Series One C Preferred Member Series One D Preferred Member Preferred Stock Member Preferred Stock Warrants Member Balance, shares [Shares, Issued] Balance, amount Series 1d Preferred Units issued, amount Class B Common Units forfeited, shares Class B Common Units forfeited Series 1d Preferred Units issued, shares Conversion of Common Units to Common Stock, shares Conversion of Common Units to Common Stock, amount Conversion of Preferred Units to Preferred Stock, shares Conversion of Preferred Units to Preferred Stock, amount Conversion of Warrant Units to Preferred Stock Warrants, shares Conversion of Warrant Units to Preferred Stock Warrants, amount Stock-based compensation Net loss Redemption of Series 1c preferred shares Conversion of Preferred Stock to Common Stock Conversion of Preferred Stock Warrants to Common Stock Warrants Conversion of Convertible Debt to Common Stock Issuance of Common Stock and warrants, net issuance costs Redemption of Series 1c preferred shares, shares Redemption of Series 1c preferred shares, amount Conversion of Preferred Stock to Common Stock, shares Conversion of Preferred Stock to Common Stock, amount Conversion of Preferred Stock Warrants to Common Stock Warrants, shares Conversion of Preferred Stock Warrants to Common Stock Warrants, amount Conversion of Convertible Debt to Common Stock, shares Conversion of Convertible Debt to Common Stock, amount Issuance of Common Stock and warrants, net issuance costs, shares Issuance of Common Stock and warrants, net issuance costs, amount Issuance of common stock and warrants, net of issuance costs, shares Issuance of common stock and warrants, net of issuance costs, amount Issuance of common stock upon exercise of pre-funded warrants, shares Issuance of common stock upon exercise of pre-funded warrants, amount Issuance of restricted stock unit awards Balance, shares Balance, amount Statements of Cash Flows (unaudited) Cash flows from operating activities: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation [Share-Based Payment Arrangement, Noncash Expense] Amortization of debt discount costs Increase/(decrease) in cash resulting from changes in: Prepaid expenses and other current assets [Increase (Decrease) in Prepaid Expense] Accounts payable [Increase (Decrease) in Accounts Payable] Accrued and other current liabilities [Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities] Net cash used in operating activities: [Net Cash Provided by (Used in) Operating Activities] Cash flows from financing activities: Proceeds from issuance of common stock and warrants, net of issuance costs Proceeds from issuances of common stock upon exercises of pre-funded warrants Redemption of Series 1c preferred stock Payments on debt Net proceeds from issuance of convertible subordinated promissory notes Proceeds from issuance of Series 1d preferred units Net cash provided by financing activities: [Net Cash Provided by (Used in) Financing Activities] Net increase (decrease) in cash and cash equivalents [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect] Cash and cash equivalents at beginning of period [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents] Cash and cash equivalents at end of period Supplemental disclosures: Cash paid for interest Cash paid for taxes Non-cash financing activities: Conversion of common and preferred units and warrants to common and preferred stock and warrants Conversion of convertible subordinated promissory notes to Series 1d preferred units Deemed dividend upon amendment to the terms of the Series 1d convertible preferred stock Conversion of convertible subordinated promissory notes and accrued interest to common shares at IPO Conversion of preferred stock to common stock at IPO Organization and Basis of Presentation Organization and Basis of Presentation Business Description and Basis of Presentation [Text Block] Summary of Significant Accounting Policies Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Balance Sheet Details Balance Sheet Details Supplemental Balance Sheet Disclosures [Text Block] Subordinated Convertible Promissory Notes Subordinated Convertible Promissory Notes [Subordinated Convertible Promissory Notes] LongTerm Debt Long-Term Debt Equity Securities Equity Securities Stockholders' Equity Note Disclosure [Text Block] Equity Incentive Plan Equity Incentive Plan Share-Based Payment Arrangement [Text Block] 401(k) Plan 401(k) Plan Postemployment Benefits Disclosure [Text Block] License Agreements License Agreements Insurance Disclosure [Text Block] Commitments and Contingencies Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Related Parties Related Parties Related Party Transactions Disclosure [Text Block] Use of Estimates Segment Information Deferred Financing Costs Cash and Cash Equivalents Fair Value Measurement Interest Income Patent Costs Research and Development Income Taxes Stock-Based Compensation Comprehensive Loss Net Loss Per Common Unit/Share Recent Accounting Pronouncements Schedule of earnings per share, basic and diluted Schedule of potentially diluted basic earnings Schedule of balance sheet details Weighted-average assumptions used for the stock option grants Schedule of stock-based compensation expense Schedule of stock option activity Schedule of restricted stock unit Organization and Basis of Presentation (Details Narrative) Class of Stock [Axis] Short-Term Debt, Type [Axis] Initial Public Offering [Member] Common Stock [Member] Convertible Notes [Member] Series 1a Preferred Stock Accumulated deficit [Accumulated deficit] Total cash Common Stock Exercise Price Net Cash Used In Operation Sale of stock Conversion of stock Warrant exercise price Warrants to purchase one share of common stock Combined Offering Price Common stock outstanding Incremental number of warrants issued at IPO Option exercise price Gross Proceeds from warrants purchase of common stock Issuance costs Accrued interest Conversion of stock amount Warrants exercisable into common stock Summary of Significant Accounting Policies (Details) Net Loss Deemed dividend upon redemption of 5,221,156 shares of Series 1c convertible preferred stock Deemed dividend upon amendment of the terms to the Series 1d convertible preferred stock Net loss attributable to common stockholders Basic and diluted net loss per common unit/share [Basic and diluted net loss per common unit/share] Weighted-average basic and diluted common units/shares [Weighted-average basic and diluted common units/shares] Financial Instrument [Axis] Stock Option [Member] Common Stock Warrants [Member] Total potentially dilutive securities Deferred offering costs Deferred Financing Costs [Debt Issuance Costs, Net] Balance Sheet Location [Axis] Balance Sheet [Member] Prepaid insurance Prepaid research and development costs Prepaid other Interest receivable Prepaid external development costs Deferred offering costs Total prepaid expenses and other current assets Accrued research and development costs Accrued compensation and benefits Accrued legal fees Accrued board compensation Accrued other Total accrued and other current liabilities Total prepaid expenses Subordinated Convertible Promissory Notes (Details Narrative) Range [Axis] Auction Market Preferred Securities, Stock Series [Axis] Series 1d Preferred Stock Notes Payable [Member] Minimum Maximum Series A Subordinated convertible promissory notes Notes payable Notes payable related parties Notes payable non related parties Maturity date Bear interest rate 20% Discount rate for preferred shares Stock converted Discount Interest payable Debt conversion amount converted Debt conversion converted instrument shares issued Increase convertible promissory notes Proceeds from Series A financing Net of debt discount costs Amortized debt discount costs Plan Name [Axis] Loan and Security Agreement with Silicon Valley Bank Series 1a Preferred Units Non-refundable amendment fee Long term debt Final Principal Payment Final Payment Amendment fee Payments for its long-term debt Proceeds from borrowing Bearing interest prime rate (percentage) Estimated fair value of warrant units Warrant units to purchase stocks Exercise price per share Provision for final payment Related Party Transaction [Axis] Class of Warrant or Right [Axis] Title of Individual [Axis] Loan and Security Agreement with Silicon Valley Bank License Agreement Villani, Inc Series 1c Preferred Units Common Stock and Preferred Stock Class B Common Units Warrants [Member] Common Warrants Loan and Security Agreement Common and Pre-Funded Warrants [Member] IPO Series 1b Preferred Units Convertible Promissory Notes Class A Common Units Underwriter IPO Warrants Board of Directors Common stock, shares available for issuances Pre-funded warrants to purchase common share Common stock, shares issued [Common stock, shares issued] Net consideration Evergreen provision resulted in increase Increasing shares authorized for issuance Common stock outstanding Common stocks, authorized Warrant outstanding Warrants, expire date Conversion price per share Fair value price per share Preferred unit interest rate Preferred stock, Conversion of Stock, Shares Converted Common stock, shares issued Exercise price per share Description of difference Deemed dividend Preferred units, issued Stock-based compensation expense Debt Conversion, Converted Instrument, Principal Amount Proceeds from issuance of warrant Proceeds from issuance of preferred units Warrant units to purchase stocks Warrants exercised Consideration of warrants exercised Common Stock, Conversion of Stock, Warrant Exercisable Net of issuance costs Financing from current and new investors Cash proceeds Cash received from conversion of convertible note issued Accrued interest on the convertible note Remaining balance committed to financing payable amount Fair value Exercise price per share PIPE Common Stock, Conversion of Stock, Shares Issued Common Stock, Conversion of Stock, Shares Issued Underwriters' discounts and offering expenses Preferred and common stock par value per share Common stock, shares sold Pre funded Pre funded outstanding Warrants sold to purchase one share of common stock Warrants sold to purchase one share of common stock, Exercise price Offering price Options exercised to purchase additional warrants, Exercise price Proceeds from issuance initial public offering Common units issued Common units issued consideration Common units issued as profits interest Thresholds price per share minimum Class B common unit issued Thresholds price per share maximum Exercisable warrant outstanding Exercise price Offering price [Offering price] Additional shares of warrant Closing trading price Conversion of stock units into warrants, shares issued Warrants, issued Warrants sold to purchase share of common stock Warrants sold to purchase share of common stock, Exercise price Percentage of public offering price Warrants sold to purchase share of common stock, Exercise price Subordinated convertible promissory notes interest Subordinated convertible promissory notes [Convertible Subordinated Debt, Current] Subordinated convertible promissory notes converted into shares units Net issuance cost Stock units, fair value Description of warrant stock-based compensation expense Warrants, fair value Warrants, exercised during period Outstanding Exercise price [Exercise price] Estimated fair value of common stock issued Preferred Units, surrendered Carrying value Deemed dividend [Dividends, Preferred Stock, Stock] Debt Conversion, Converted Instrument, Accrued Interest Consideration Percentages of initial public per share offering price Description of reverse split Grant date fair value Risk-free interest rate Dividend yield Expected life in years Expected volatility Income Statement Location [Axis] Research and development [Research and development] General and administrative [General and administrative] Stock-based compensation expense [Share-Based Payment Arrangement, Expense] Number of Options Outstanding, Beginning balance [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number] Number of Options Outstanding, Options granted Number of Options Outstanding, Options Cancelled Number of Options Outstanding, Ending balance Number of Options Outstanding, Options exercisable Weighted-Average Exercise Price, Beginning balance [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price] Weighted-Average Exercise Price, Options granted Weighted-Average Exercise Price, Options exercised Weighted-Average Exercise Price, Options cancelled Weighted-Average Exercise Price, Ending balance Weighted-Average Exercise Price, Options exercisable Weighted-Average Remaining Contractual Term (in Years) Weighted-Average Remaining Contractual Term (in Years), Options exercisable Award Type [Axis] RSU's outstanding [Member] Restricted stock unit, Beginning balance Restricted stock unit, granted RSUs settled RSUs cancelled Balance at September 30, 2022, Ending balance Related Party [Axis] 2021 Omnibus Equity Incentive Plan [Member] RSU's outstanding [Member] Director [Member] Unrecognized stock based compensation expenses Stock-based compensation expense Class B Common Units profits interests converted due to the conversion from an LLC to a C-Corporation Class B Common Units profits interests converted into options Additional shares reserved for future issuance Incremental stock-based compensation expense Weighted-Average Recognized Remaining Contractual Term (in Years) Common share, authorized Unrecognized stock based compensation expense fair market value Stock awards granted, exercisable period Common stock, authorized Stock awards granted, vesting period Common stock traded price Stock compensation for services Class B Common Units profits interests converted into options, exercise price License Agreements (Details Narrative) License Agreement (Second Amendment) Villani, Inc License Agreements [License Agreements] Preferred units, issued Outstanding loan forgiven Percentage of fully diluted capitalization Proceeds from stock issued Maximum future milestone payments Payments made to related party after IPO closed Future milestone payments payable upon the achievement of specified development and sales milestones Additional Research And Development Expense Subordinated convertible promissory notes DividendsPreferredStock Convertible promissory notes EX-101.CAL 7 drma-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 8 drma-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 9 drma-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover - shares
 9 Months Ended
Sep. 30, 2022
Nov. 10, 2022
Document Information Line Items    
Entity Registrant Name DERMATA THERAPEUTICS, INC.  
Entity Central Index Key 0001853816  
Document Type 10-Q  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity Small Business true  
Entity Shell Company false  
Entity Emerging Growth Company true  
Entity Current Reporting Status Yes  
Document Period End Date Sep. 30, 2022  
Entity Filer Category Non-accelerated Filer  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2022  
Entity Ex Transition Period true  
Entity Common Stock Shares Outstanding   12,102,214
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 001-40739  
Entity Incorporation State Country Code DE  
Entity Tax Identification Number 86-3218736  
Entity Address Address Line 1 3525 Del Mar Heights Rd  
Entity Address Address Line 2 322  
Entity Address City Or Town San Diego  
Entity Address State Or Province CA  
Entity Address Postal Zip Code 92130  
City Area Code 858  
Local Phone Number 800-2543  
Security 12b Title Common Stock, $0.0001 Par Value  
Trading Symbol DRMA  
Security Exchange Name NASDAQ  
Entity Interactive Data Current Yes  
Warrants [Member]    
Document Information Line Items    
Security 12b Title Common Stock Purchase Warrants  
Trading Symbol DRMAW  
Security Exchange Name NASDAQ  
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Balance Sheets - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Assets:    
Cash and cash equivalents $ 8,066,822 $ 10,798,806
Prepaid expenses and other current assets 908,067 825,134
Total assets 8,974,889 11,623,940
Liabilities:    
Accounts payable 483,741 515,245
Accrued and other current liabilities 1,020,581 1,001,591
Total liabilities 1,504,322 1,516,836
Stockholders' Equity:    
Common Stock, par value $0.0001, 250,000,000 shares authorized and 12,102,214 shares issued and outstanding as of September 30, 2022; and 90,000,000 shares authorized and 8,328,629 shares issued and outstanding as of December 31, 2021, respectively 1,210 833
Additional paid-in capital 51,392,942 46,088,546
Accumulated deficit (43,923,585) (35,982,275)
Total stockholders' equity 7,470,567 10,107,104
Total liabilities and stockholders' equity $ 8,974,889 $ 11,623,940
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
Balance Sheets    
Common stock shares, par value $ 0.0001 $ 0.0001
Common stock shares, authorized 250,000,000 90,000,000
Common stock, shares issued 12,102,214 8,328,629
Common stock shares, outstanding 12,102,214 8,328,629
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Statements of Operations (unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating expenses:        
Research and development $ 1,553,295 $ 799,779 $ 4,761,686 $ 2,347,564
General and administrative 892,777 912,490 3,201,111 2,956,444
Total operating expenses 2,446,072 1,712,269 7,962,797 5,304,008
Loss from operations (2,446,072) (1,712,269) (7,962,797) (5,304,008)
Other income and expenses:        
Interest (income) expense, net (21,486) 651 (21,486) 45,613
Net loss (2,424,586) (1,712,920) (7,941,311) (5,349,621)
Deemed dividend upon the redemption of 5,221,156 shares of Series 1c preferred stock (see Note 6) 0 269,038 0 269,038
Deemed dividend upon the amendment of terms of the Series 1d convertible preferred stock (see Note 6) 0 2,293,199 0 2,293,199
Net loss attributable to common stockholders $ (2,424,586) $ (4,275,157) $ (7,941,311) $ (7,911,858)
Net loss per share of common stock, basic and diluted $ (0.20) $ (0.86) $ (0.75) $ (2.69)
Weighted-average basic and diluted common units/shares 12,276,394 4,980,306 10,622,277 2,945,351
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Statements of Stockholder's Equity (Unaudited) - USD ($)
Total
Common Stock
Additional Paid-In Capital
Retained Earnings (Accumulated Deficit)
Common Classes A Member
Common Classes B Member
Series One Preferred Member
Sereies One A Preferred Member
Series One A Warrants Member
Series One B Preferred Member
Series One C Preferred Member
Series One D Preferred Member
Preferred Stock Member
Preferred Stock Warrants Member
Balance, shares at Dec. 31, 2020         508,777 1,767,477 6,906,244 5,018,750 1,419,228 6,500,000 46,553,188      
Balance, amount at Dec. 31, 2020 $ (3,177,939) $ 0 $ 0 $ (28,079,798) $ 10,430 $ 2,342,853 $ 6,833,877 $ 4,380,081 $ 723,431 $ 4,119,595 $ 6,491,592 $ 0 $ 0 $ 0
Series 1d Preferred Units issued, amount 5,034,801 0 0 0 0 $ 0 0 0 0 0 0 5,034,801 0 0
Class B Common Units forfeited, shares           (22,494)                
Class B Common Units forfeited 0 $ 0 0 0 $ 0 $ 0 0 0 0 0 0 $ 0 0 0
Series 1d Preferred Units issued, shares                       6,065,989    
Conversion of Common Units to Common Stock, shares   1,911,009     (508,777) (1,744,983)                
Conversion of Common Units to Common Stock, amount 0 $ 191 2,353,092 0 $ (10,430) $ (2,342,853) $ 0 $ 0 0 $ 0 $ 0 $ 0 $ 0 0
Conversion of Preferred Units to Preferred Stock, shares             (6,906,244) (5,018,750)   (6,500,000) (46,553,188) (6,065,989) 71,044,171  
Conversion of Preferred Units to Preferred Stock, amount 0 0 26,852,842 0 0 0 $ (6,833,877) $ (4,380,081) $ 0 $ (4,119,595) $ (6,491,592) $ (5,034,801) $ 7,104 $ 0
Conversion of Warrant Units to Preferred Stock Warrants, shares                 (1,419,228)         1,419,228
Conversion of Warrant Units to Preferred Stock Warrants, amount 0 0 723,289 0 0 0 0 0 $ (723,431) 0 0 0 0 $ 142
Stock-based compensation 1,160,049 0 1,160,049 0 0 0 0 0 0 0 0 0 0 0
Net loss (2,304,908) $ 0 0 (2,304,908) 0 0 0 0 0 0 0 0 $ 0 $ 0
Balance, shares at Mar. 31, 2021   1,911,009                     71,044,171 1,419,228
Balance, amount at Mar. 31, 2021 712,003 $ 191 31,089,272 (30,384,706) $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 0 $ 7,104 $ 142
Balance, shares at Dec. 31, 2020         508,777 1,767,477 6,906,244 5,018,750 1,419,228 6,500,000 46,553,188      
Balance, amount at Dec. 31, 2020 (3,177,939) $ 0 0 (28,079,798) $ 10,430 $ 2,342,853 $ 6,833,877 $ 4,380,081 $ 723,431 $ 4,119,595 $ 6,491,592 0 $ 0 $ 0
Net loss (5,349,621)                          
Balance, shares at Sep. 30, 2021   8,328,629                        
Balance, amount at Sep. 30, 2021 12,490,555 $ 833 45,919,140 (33,429,418) 0 0 0              
Balance, shares at Mar. 31, 2021   1,911,009                     71,044,171 1,419,228
Balance, amount at Mar. 31, 2021 712,003 $ 191 31,089,272 (30,384,706) 0 0 0 0 0 0 0 0 $ 7,104 $ 142
Stock-based compensation 113,987 0 113,987 0 0 0 0 0 0 0 0 0 0 0
Net loss (1,331,792) $ 0 0 (1,331,792) 0 0 0 0 0 0 0 0 $ 0 $ 0
Balance, shares at Jun. 30, 2021   1,911,009                     71,044,171 1,419,228
Balance, amount at Jun. 30, 2021 (505,802) $ 191 31,203,259 (31,716,498) 0 0 0 0 0 0 0 0 $ 7,104 $ 142
Stock-based compensation 142,655   142,655   0 0 0 0 0 0        
Net loss (1,712,920)     (1,712,920) 0 0 0 0 0 0        
Redemption of Series 1c preferred shares         0 0 0 0 0 0        
Conversion of Preferred Stock to Common Stock         0 0 0 0 0 0        
Conversion of Preferred Stock Warrants to Common Stock Warrants         0 0 0 0 0 0        
Conversion of Convertible Debt to Common Stock         0 0 0 0 0 0        
Issuance of Common Stock and warrants, net issuance costs         0 0 0 $ 0 $ 0 $ 0        
Redemption of Series 1c preferred shares, shares                         (5,221,156)  
Redemption of Series 1c preferred shares, amount (1,000,000) $ 0 (999,478) 0             0 0 $ (522) 0
Conversion of Preferred Stock to Common Stock, shares   3,813,973                     (65,823,015)  
Conversion of Preferred Stock to Common Stock, amount 0 $ 381 6,200 0             0 0 $ (6,582) $ 0
Conversion of Preferred Stock Warrants to Common Stock Warrants, shares                           (1,419,228)
Conversion of Preferred Stock Warrants to Common Stock Warrants, amount     142               $ 0 $ 0 $ 0 $ (142)
Conversion of Convertible Debt to Common Stock, shares   32,219                        
Conversion of Convertible Debt to Common Stock, amount 180,434 $ 3 180,430                      
Issuance of Common Stock and warrants, net issuance costs, shares   2,571,428                        
Issuance of Common Stock and warrants, net issuance costs, amount 15,386,189 $ 257 15,385,932                      
Balance, shares at Sep. 30, 2021   8,328,629                        
Balance, amount at Sep. 30, 2021 12,490,555 $ 833 45,919,140 (33,429,418) $ 0 $ 0 $ 0              
Balance, shares at Dec. 31, 2021   8,328,629                        
Balance, amount at Dec. 31, 2021 10,107,104 $ 833 46,088,546 (35,982,275)                    
Stock-based compensation 531,566 0 531,566 0                    
Net loss (2,786,151) $ 0 0 (2,786,151)                    
Balance, shares at Mar. 31, 2022   8,328,629                        
Balance, amount at Mar. 31, 2022 7,852,519 $ 833 46,620,112 (38,768,426)                    
Balance, shares at Dec. 31, 2021   8,328,629                        
Balance, amount at Dec. 31, 2021 10,107,104 $ 833 46,088,546 (35,982,275)                    
Net loss (7,941,311)                          
Balance, shares at Sep. 30, 2022   12,102,214                        
Balance, amount at Sep. 30, 2022 7,470,567 $ 1,210 51,392,942 (43,923,585)                    
Balance, shares at Mar. 31, 2022   8,328,629                        
Balance, amount at Mar. 31, 2022 7,852,519 $ 833 46,620,112 (38,768,426)                    
Stock-based compensation 205,947 0 205,947 0                    
Net loss (2,730,573) $ 0 0 (2,730,573)                    
Issuance of common stock and warrants, net of issuance costs, shares   898,585                        
Issuance of common stock and warrants, net of issuance costs, amount 4,276,365 $ 90 4,276,275 0                    
Issuance of common stock upon exercise of pre-funded warrants, shares   875,000                        
Issuance of common stock upon exercise of pre-funded warrants, amount 87 $ 87 0 0                    
Issuance of restricted stock unit awards 55,625 $ 0 55,625 0                    
Balance, shares at Jun. 30, 2022   10,102,214                        
Balance, amount at Jun. 30, 2022 9,659,970 $ 1,010 51,157,959 (41,498,999)                    
Stock-based compensation 179,358 0 179,358 0                    
Net loss (2,424,586) $ 0 0 (2,424,586)                    
Issuance of common stock upon exercise of pre-funded warrants, shares   2,000,000                        
Issuance of common stock upon exercise of pre-funded warrants, amount 200 $ 200 0 0                    
Issuance of restricted stock unit awards 55,625 $ 0 55,625 0                    
Balance, shares at Sep. 30, 2022   12,102,214                        
Balance, amount at Sep. 30, 2022 $ 7,470,567 $ 1,210 $ 51,392,942 $ (43,923,585)                    
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Statements of Cash Flows (unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash flows from operating activities:    
Net loss $ 7,941,311 $ 5,349,621
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation 709,435 1,416,691
Amortization of debt discount costs 0 14,126
Increase/(decrease) in cash resulting from changes in:    
Prepaid expenses and other current assets (82,933) (1,007,393)
Accounts payable (31,504) 665,587
Accrued and other current liabilities 337,677 371,127
Net cash used in operating activities: (7,008,636) (3,889,483)
Cash flows from financing activities:    
Proceeds from issuance of common stock and warrants, net of issuance costs 4,276,365 15,386,189
Proceeds from issuances of common stock upon exercises of pre-funded warrants 287 0
Redemption of Series 1c preferred stock 0 (1,000,000)
Payments on debt 0 (556,482)
Net proceeds from issuance of convertible subordinated promissory notes 0 1,562,717
Proceeds from issuance of Series 1d preferred units 0 570,000
Net cash provided by financing activities: 4,276,652 15,962,424
Net increase (decrease) in cash and cash equivalents (2,731,984) 12,072,941
Cash and cash equivalents at beginning of period 10,798,806 530,400
Cash and cash equivalents at end of period 8,066,822 12,603,341
Supplemental disclosures:    
Cash paid for interest 0 1,420
Cash paid for taxes 800 1,400
Non-cash financing activities:    
Conversion of common and preferred units and warrants to common and preferred stock and warrants 0 29,936,660
Conversion of convertible subordinated promissory notes to Series 1d preferred units 0 4,464,801
Deemed dividend upon amendment to the terms of the Series 1d convertible preferred stock 0 2,293,199
Conversion of convertible subordinated promissory notes and accrued interest to common shares at IPO 0 180,434
Conversion of preferred stock to common stock at IPO $ 0 $ 6,582
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Basis of Presentation
 9 Months Ended
Sep. 30, 2022
Organization and Basis of Presentation  
Organization and Basis of Presentation

1. Organization and Basis of Presentation

 

Dermata Therapeutics, Inc., (the “Company”), was formed in December 2014 as a Delaware limited liability company (“LLC”) under the name Dermata Therapeutics, LLC. On March 24, 2021, the Company converted from an LLC to a Delaware C-corporation and changed its name to Dermata Therapeutics, Inc. Any references in these Notes to Financial Statements to equity securities as “units” refer to pre-conversion equity securities and any references to “shares” or “stock” in these Notes to Financial Statements refer to post-conversion equity securities. The Company is a clinical-stage biotechnology company focused on the treatment of medical and aesthetic skin conditions and diseases.

 

Initial Public Offering

 

On August 17, 2021, the Company completed its initial public offering (“IPO”), in which it sold 2,571,428 shares of its common stock together with 2,571,428 warrants to purchase one share of common stock with an exercise price of $7.00 per share, at a combined offering price of $7.00. Additionally, the underwriters exercised their option to purchase an additional 385,714 warrants to purchase common stock with an exercise price of $7.00 per share. The Company received net cash proceeds of approximately $15.4 million from the IPO after deducting underwriters’ discounts and offering expenses of approximately $2.6 million.

 

Each of the following occurred in connection with the completion of the IPO in August 2021:

 

 

-

The sale of 2,571,428 shares of common stock along with 2,957,142 warrants to purchase common stock.

 

 

 

 

-

The conversion of 65,823,015 shares of convertible preferred stock into an aggregate of 3,813,973 shares of common stock.

 

 

 

 

-

The conversion of $175,000 principal amount of outstanding convertible promissory notes and accrued interest of $5,434 into 32,219 shares of common stock.

 

 

 

 

-

The conversion of 1,419,228 Series 1a preferred warrants into 69,212 warrants exercisable into common stock.

 

Each purchaser in the IPO received one share of common stock and one warrant to purchase one share of common stock at a combined offering price of $7.00. Each warrant to purchase common stock entitles the holder to purchase one share of common stock, are immediately exercisable, and expire five years from the date of issuance. The Company evaluated the terms of the warrants issued and determined that they should be classified as equity instruments.

 

The Company’s shares of common stock and warrants are listed on the Nasdaq Stock Market LLC under the symbols “DRMA,” and “DRMAW,” respectively, and both began trading in August 2021.

 

After the IPO, there were no shares of preferred stock or preferred stock warrants outstanding. Prior to the IPO, the Company had 1,911,009 shares of common stock outstanding after giving effect for the Company’s reverse stock split in July 2021.

 

Reverse Stock Split

 

On July 1, 2021, the Company effected a reverse split of shares of the Company’s common stock at a ratio of 1-for-20.5 pursuant to an amendment to the Company’s certificate of incorporation approved by the Company’s board of directors and stockholders. The par value was not adjusted as a result of the reverse split. All issued and outstanding common stock shares and per share amounts contained in the financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented, and the conversion ratios for the Company’s outstanding preferred stock was adjusted accordingly. See Note 6 – Equity Securities for additional information.

Liquidity and Going Concern Uncertainty

 

Since its inception, the Company has devoted substantially all of its resources to research and development activities and has not generated any revenue or commercialized any product candidates. As of September 30, 2022, cash and cash equivalents totaled $8.1 million and the Company had an accumulated deficit of $43.9 million. For the nine months ended September 30, 2022 and the year ended December 31, 2021, the Company used cash of $7.0 million and $5.7 million, respectively, in operations. The Company’s cash balances are expected to fund operations into the third quarter of 2023. The Company anticipates that it will continue to incur net losses for the foreseeable future. These factors raise substantial doubt about the Company’s ability to continue as a going concern for the one-year period following the date that these financial statements were issued.

 

Historically, the Company’s principal sources of cash have included proceeds from the issuance of common and preferred equity units and proceeds from the issuance of debt. The Company’s principal uses of cash have included cash used in operations and payments for license rights. The Company expects that the principal uses of cash in the future will be for continuing operations, funding of research and development, conducting preclinical studies and clinical trials, and general working capital requirements. The Company expects that as research and development expenses continue to grow, it will need to raise additional capital to sustain operations and research and development. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

 

Management’s Plan to Continue as a Going Concern

 

To continue as a going concern, the Company will need, among other things, to raise additional capital resources. Until the Company can generate significant cash from operations, management’s plans to obtain such resources for the Company include proceeds from offerings of the Company’s equity securities or debt, or transactions involving product development, technology licensing or collaboration. Management can provide no assurance that any sources of a sufficient amount of financing or collaboration agreements will be available to the Company on favorable terms, if at all. Additionally, the COVID-19 pandemic continues to evolve and has already disrupted global financial markets. The Company’s ability to raise additional capital may be adversely impacted by potential worsening of global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the pandemic. If the disruption persists or deepens, the Company could experience an inability to access additional capital.

 

The Company has raised additional capital through the initial public offering of its common stock and warrants and through a private placement financing; however, management’s current plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern.

 

Basis of Presentation

 

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, the accompanying financial statements reflect all adjustments (consisting of normal recurring adjustments) that are necessary for a fair statement of the financial position, results of operations, cash flows, and stockholders’ equity for the interim periods presented. Interim results are not necessarily indicative of results for a full year. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ materially from those estimates.
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2022
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

 

Use of Estimates

 

The Company’s financial statements are prepared in accordance with GAAP. The preparation of the Company’s financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, including those related to accrued research and development expenses, stock-based compensation, and the estimated fair values of equity instruments. Management evaluates its estimates on an ongoing basis. The Company bases its estimates on various assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

 

Segment Information

 

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company’s chief operating decision maker view the Company’s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceuticals. The Company operates in only one segment.

 

Deferred Financing Costs

 

The Company capitalizes certain legal, accounting, and other fees and costs that are directly attributable to in-process equity financings as deferred offering costs until such financings are completed. Upon the completion of an equity financing, these costs are recorded as a reduction of additional paid-in capital of the related offering. Upon the completion of the IPO in August 2021, approximately $2.6 million of offering costs related to the IPO were reclassified to additional paid-in capital. As of December 31, 2021, the Company had deferred financing costs of $0.06 million and as of September 30, 2022, the Company had no deferred financing costs.

 

Cash and Cash Equivalents

 

The Company deposits its cash with reputable financial institutions that are insured by the Federal Deposit Insurance Corporation (“FDIC”). This cash is held in checking, cash sweep, and money market accounts. At times, deposits held may exceed the amount of insurance provided by the FDIC. The Company maintains an insured cash sweep account in which cash from its main operating checking account is invested overnight in highly liquid, short-term investments. The Company considers all highly liquid investments with a maturity date of 90 days or less at the date of purchase to be cash equivalents. The Company has not experienced any losses in its cash and cash equivalents and believes they are not exposed to significant credit risk.

 

Fair Value Measurement

 

The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company believes the carrying amount of cash and cash equivalents, accounts payable, accrued expenses and debt approximate their estimated fair values due to the short-term maturities of these financial instruments.

 

Interest Income

 

Interest income consists of interest income earned on cash equivalents from interest bearing demand accounts.

Patent Costs

 

                Patent costs related to obtaining and maintaining patent protection in both the United States and other countries are expensed as incurred. Patents costs are classified as general and administrative expenses.

 

Research and Development 

 

Research and development costs consist of expenses incurred in connection with the development of the Company’s product candidates. Such expenses include expenses incurred under agreements with contract research organizations, manufacturing and supply scale-up expenses and the cost of acquiring and manufacturing preclinical and clinical trial supply, outsourced laboratory services, including materials and supplies used to support the Company’s research and development activities, and payments made for license fees and milestones that have not been demonstrated to have commercial value. Such costs are expensed in the periods in which they are incurred. Upfront payments and milestone payments for licensed technology are expensed as research and development as incurred or when the milestone is achieved or is determined to be probable of being achieved. Advanced payments for goods or services to be received in the future for research and development activities are recorded as prepaid expenses and expensed as the related goods are received or services are performed.

 

Income Taxes

 

From inception until March 24, 2021, the Company operated as a limited liability company taxed as a partnership. Therefore, any income tax liability or benefit through that date accrued to the Company’s members. Since March 24, 2021, the Company has operated as a C-Corporation and accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

 

The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.

 

The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.

 

Stock-Based Compensation

 

In March 2021, the Company’s board of directors and shareholders approved the 2021 Omnibus Equity Incentive Plan (“the 2021 Plan”). For stock options granted under the 2021 Plan, the Company measures and recognizes compensation expense for all stock-based awards made to employees, directors, and non-employees, based on estimated fair values recognized using the straight-line method over the requisite service period. The fair value of options to purchase common stock granted to employees is estimated on the grant date using the Black-Scholes valuation model. The calculation of stock-based compensation expense requires that the Company make certain assumptions and judgments about variables used in the Black-Scholes model, including the expected term of the stock-based award, expected volatility of the underlying common stock, dividend yield, and the risk-free interest rate. Forfeitures are accounted for in the period they occur. Restricted stock units (“RSUs”) granted under the 2021 Plan are measured at the grant date fair value of the common stock, with corresponding compensation expense recognized ratably over the requisite service period. Refer to Note 7- Equity Incentive Plan for further discussion.

Comprehensive Loss

 

Comprehensive loss includes net loss and other comprehensive income (loss) for the periods presented. The Company did not have other comprehensive income (loss) items such as unrealized gains and losses and so for the three and nine months ended September 30, 2022, and September 30, 2021, comprehensive loss was equal to the net loss.

 

Net Loss Per Common Unit/Share

 

On March 24, 2021, the Company converted from an LLC to a C-corporation. Upon the conversion, each outstanding common unit and preferred unit was converted into one share of common stock and preferred stock, respectively. Common units had similar rights and characteristics of common stock issued upon the conversion. In calculating net loss per share, the Company retrospectively applied the effects of the conversion to the number of common units outstanding prior to the conversion. Net loss per share for periods prior to the conversion to a C-corporation refers to net loss per common unit.

 

Basic net loss per unit/share is calculated by dividing net loss attributable to common unitholders or shareholders by the weighted-average number of units or shares outstanding during the period, contingently issuable restricted stock units for which no future service is required as a condition to the delivery of the underlying common stock, and pre-funded warrants because their exercise requires only nominal consideration for the delivery of shares (collectively, “basic shares”), without consideration of common unit or share equivalents. Diluted net loss per unit or share is calculated by adjusting basic shares outstanding for the dilutive effect of common unit or share equivalents outstanding for the period. For purposes of the diluted net loss per unit or share calculation, preferred units or shares, profit interests, and warrants to purchase preferred units or shares are considered to be common unit or share equivalents but are excluded from the calculation of diluted net loss per common unit or share if their effect would be anti-dilutive.

 

As the Company has reported a net loss for the periods presented, diluted net loss per common unit or share is the same as the basic net loss per common unit or share for the periods presented.

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$(2,424,586 )

 

$(1,712,920 )

 

$(7,941,311 )

 

$(5,349,621 )

Deemed dividend upon redemption of 5,221,156 shares of Series 1c convertible preferred stock

 

$-

 

 

$269,038

 

 

$-

 

 

$269,038

 

Deemed dividend upon amendment of the terms to the

Series 1d convertible preferred stock

 

$-

 

 

$2,293,199

 

 

$-

 

 

$2,293,199

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to common stockholders

 

$(2,424,586 )

 

$(4,275,157 )

 

$(7,941,311 )

 

$(7,911,858 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted net loss per common unit/share

 

$(0.20 )

 

$(0.86 )

 

$(0.75 )

 

$(2.69 )

Weighted-average basic and diluted common units/shares

 

 

12,276,394

 

 

 

4,980,306

 

 

 

10,622,277

 

 

 

2,945,351

 

 

The common unit or share equivalents that are not included in the calculation of diluted net loss per common unit or share but could potentially dilute basic earnings per share in the future are as follows:

 

 

 

As of September 30,

 

 

 

2022

 

 

2021

 

Common stock options

 

 

1,056,326

 

 

 

523,199

 

Common stock warrants

 

 

6,993,813

 

 

 

3,091,657

 

Total potentially dilutive securities

 

 

8,050,139

 

 

 

3,614,856

 

Recent Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard-setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Balance Sheet Details
 9 Months Ended
Sep. 30, 2022
Balance Sheet Details  
Balance Sheet Details

3. Balance Sheet Details

 

The following provides certain balance sheet details:

 

 

 

September 30,

 

 

December 31,

 

 

 

2022

 

 

2021

 

Prepaid expenses and other current assets

 

 

 

 

 

 

Prepaid insurance

 

$806,661

 

 

$769,416

 

Prepaid research and development costs

 

 

52,100

 

 

 

-

 

Prepaid other

 

 

36,413

 

 

 

-

 

Interest receivable

 

 

12,893

 

 

 

-

 

Deferred offering costs

 

 

-

 

 

 

55,718

 

Total prepaid expenses and other current assets

 

$908,067

 

 

$825,134

 

 

 

 

 

 

 

 

 

 

Accrued and other current liabilities

 

 

 

 

 

 

 

 

Accrued research and development costs

 

$633,293

 

 

$235,384

 

Accrued compensation and benefits

 

 

317,089

 

 

 

766,207

 

Accrued legal fees

 

 

13,801

 

 

 

-

 

Accrued board compensation

 

 

55,625

 

 

 

-

 

Accrued other

 

 

773

 

 

 

-

 

Total accrued and other current liabilities

 

$1,020,581

 

 

$1,001,591

 
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Subordinated Convertible Promissory Notes
 9 Months Ended
Sep. 30, 2022
Subordinated Convertible Promissory Notes  
Subordinated Convertible Promissory Notes

4. Subordinated Convertible Promissory Notes

 

In July and October 2020, the Company issued an aggregate of $3,000,000 of subordinated convertible promissory notes (the “Notes”). Notes in the amount of $1,145,000 were issued to existing investors who are also related parties (See Note 11 - Related Parties), $1,730,000 were issued to existing investors who are not related parties and notes in the amount of $125,000 were issued to new investors. The Notes bore interest at 4% per annum and were to mature on July 17, 2021. The Notes were subordinated to the Company’s long-term debt and were convertible into a qualified Series A financing of at least $10 million at a 20% discount to the lowest price per unit paid by investors for that financing. Under authoritative accounting guidance, this contingent beneficial conversion feature was to be measured and recognized when the contingency is resolved. The Notes were recorded upon issuance net of debt discount costs of $28,301. The Company recognized $14,126 of amortized debt discount costs during the nine months ended September 30, 2021.

 

On January 27, 2021, the Company amended the terms of the Notes to increase the maximum amount of convertible promissory notes to be issued from $3,000,000 to $5,000,000, to allow for the conversion of the convertible promissory notes into shares of common stock upon a Qualified Initial Public Offering with aggregate gross proceeds to the Company of at least $10,000,000 at a 20% discount to the lowest price per share paid by investors for that financing and to extend the maturity date to December 31, 2021. In connection with this amendment, Notes in the amount of $1,255,000 were issued to existing investors who are also related parties (See Note 11 - Related Parties) and $311,000 were issued to existing investors who are not related parties.

In March 2021, the Company further amended the terms of the Notes to allow for the conversion of the Notes into Series 1d Preferred Units at the same price as purchasers of Series 1d Preferred Units. As of March 15, 2021, $4,391,000 of the Notes, along with related interest of $73,801, were converted to 5,379,247 Series 1d Preferred Units. Since the Notes did not convert at a discount, there was no beneficial conversion feature.

 

The Company considers the above modification of the Notes in March 2021 to be a substantial modification requiring extinguishment accounting under Accounting Standards Codification (“ASC”) 470-50-40-10. Based upon an independent valuation of the reacquisition price of the Notes, the difference between the reacquisition price and the net carrying amount of the Notes immediately prior to the modification is not material to the financial statements.

 

In connection with the Company’s IPO in August 2021, the outstanding principal of the Notes and accrued interest totaling $180,434 converted into 32,219 shares of common stock. Upon this conversion, since the conversion contained a 20% discount, the Company measured the beneficial conversion feature and determined that it was not material to the financial statements.

 

As of December 31, 2021, and September 30, 2022, the Company had no promissory notes outstanding.

XML 20 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
LongTerm Debt
 9 Months Ended
Sep. 30, 2022
LongTerm Debt  
Long-Term Debt

5. Long-Term Debt

 

In February 2017, the Company entered into a Loan and Security Agreement with Silicon Valley Bank (“SVB”) whereas SVB agreed to provide term loans to the Company in two tranches. The first tranche of $2,500,000 was drawn in February 2017 and bore interest at a rate of 1.5% above the prime rate, which was 3.25% as of December 31, 2020, with principal and interest payable monthly through February 9, 2021. The second tranche was not utilized.

 

In connection with the Loan and Security Agreement, SVB also received warrant units to purchase, at any time after February 9, 2017 and prior to February 9, 2027, 187,978 Series 1a Preferred Units or the equivalent Series A Preferred Units had they purchased Series 1a Preferred Units, if Series A Preferred Units are issued, at a price of $1.00 per unit. The estimated fair value of these warrant units of $104,630 (See Note 6 – Equity Securities), as well as costs associated with the term loan, including provision for a final payment of $225,000, were recorded as a discount to outstanding debt and amortized to interest expense utilizing the effective interest method over the underlying term of the loan.

 

In June 2019, the Company and SVB entered into a First Amendment to the Loan and Security Agreement whereby if the Company did not achieve certain capital milestones by December 1, 2019, term loan principal payments would be deferred from December 21, 2019 through May 1, 2020 with the deferred principal payments being payable in equal monthly installments, in addition to those principal payments already scheduled to be paid, starting on June 1, 2020 and extending through the February 9, 2021 maturity date of the term loan. In addition, if those principal payments were deferred for that six-month period, a non-refundable amendment fee of $100,000 would be due and payable on the earliest to occur of the maturity date, the prepayment of the term loan or the occurrence of an event of default. The capital milestones were not achieved by December 1, 2019 and, therefore, the defined principal repayments were deferred.

 

The non-refundable amendment fee of $100,000, as well as $12,280 of costs associated with the amendment, were recorded as a discount to outstanding debt and were amortized to interest expense utilizing the effective interest method over the remaining underlying term of the loan.

 

In January and February 2021, the Company paid the final principal payments of $231,482 under the SVB Loan and Security Agreement. The Company also paid the final payment fee of $225,000 in February 2021 and the amendment fee of $100,000 in March 2021. For the nine months ended September 30, 2021, the Company paid a total of $556,482 to SVB as final payments for its long-term debt.

 

As of December 31, 2021, and September 30, 2022, the Company had no long-term debt outstanding.
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity Securities
 9 Months Ended
Sep. 30, 2022
Equity Securities  
Equity Securities

6. Equity Securities

 

Common Stock and Preferred Stock

 

On March 24, 2021, the Company entered into a Plan of Conversion (“Conversion”) whereby the Company converted from an LLC under the laws of the State of Delaware to a Delaware C-corporation with the name Dermata Therapeutics, Inc. In connection with the Conversion, each fully paid preferred and common unit in the LLC was converted into a like number of shares of preferred and common stock of the Company with a par value of $0.0001 per share. The Shares issued had the same rights, preferences and privileges that had accrued to the pre-converted Units. Any references in these Notes to Financial Statements to equity securities as “units” refer to pre-conversion equity securities and any references to “shares” or “stock” in these Notes to Financial Statements refer to post-conversion equity securities.

 

On July 1, 2021, the Company effected a reverse split of shares of the Company’s common stock at a ratio of 1-for-20.5 pursuant to an amendment to the Company’s certificate of incorporation approved by the Company’s board of directors and stockholders. The par value was not adjusted as a result of the reverse split. All issued and outstanding common stock share and per share amounts contained in the financial statements have been retroactively adjusted to reflect this reverse split for all periods presented.

 

On August 17, 2021, the Company completed its IPO, in which it sold 2,571,428 shares of its common stock together with 2,571,428 warrants to purchase one share of common stock with an exercise price of $7.00 per share at a combined offering price of $7.00. Additionally, the underwriters exercised their option to purchase an additional 385,714 warrants with an exercise price of $7.00 per warrant. The Company received net cash proceeds of approximately $15.4 million from the IPO after deducting underwriters’ discounts and offering expenses of approximately $2.6 million.

 

Each of the following occurred in connection with the completion of the IPO in August 2021:

 

 

-

The sale of 2,571,428 shares of common stock along with 2,957,142 warrants to purchase common stock.

 

 

 

 

-

The conversion of 65,823,015 shares of convertible preferred stock into an aggregate of 3,813,973 shares of common stock.

 

 

 

 

-

The conversion of $175,000 principal amount of outstanding convertible promissory notes and accrued interest of $5,434 into 32,219 shares of common stock.

 

 

 

 

-

The conversion of 1,419,228 Series 1a preferred warrants into 69,212 warrant shares exercisable into common stock.

 

After the IPO, there were no shares of preferred stock or preferred stock warrants outstanding. Prior to the IPO, the Company had 1,911,009 shares of common stock outstanding after giving effect for the Company’s reverse stock split in July 2021.

 

On April 25, 2022, the Company closed a private placement (“PIPE”), in which it sold 898,585 shares of its common stock together with 2,875,000 pre-funded warrants to purchase one share of common stock with an exercise price of $0.0001 per share (“Pre-funded Warrant”), and 3,773,585 warrants to purchase one share of common stock with an exercise price of $1.325 per share (“PIPE Common Warrant”) at a combined offering price of $1.325. The Company received net cash proceeds of approximately $4.3 million from the PIPE after deducting underwriters’ discounts and offering expenses of approximately $0.7 million. The PIPE Common Warrant related to this private placement will expire on May 12, 2027. During the quarter ended June 30, 2022, 875,000 of the Pre-funded Warrants were exercised. Further, during the quarter ended September 30, 2022, 2,000,000 of the Pre-funded Warrants were exercised. No Pre-Funded Warrants were outstanding as of September 30, 2022.

 

The Company’s total common stock issued and outstanding was 12,102,214 and 8,328,629 shares as of September 30, 2022, and December 31, 2021, respectively.

 

Series 1 Preferred Units

 

From the Company’s formation on December 8, 2014 through 2016, the Company issued 6,906,244 Series 1 Preferred Units for net consideration of $6,833,877. The Company’s Series 1 Preferred Units were converted to preferred stock during the first quarter of 2021. Additionally, in August 2021, the Company converted all preferred stock into common stock. No Series 1 Preferred Units were outstanding as of December 31, 2021 and September 30, 2022.

Series 1a Preferred Units

 

In 2016, the Company issued 5,000,000 Series 1a Preferred Units in exchange for cash of $5,000,000 and net of issuance costs of $19,868. Purchasers of the Series 1a Preferred Units also received 1,250,000 Warrant Units to purchase an additional amount of Series 1a Preferred Units. The estimated fair value of the warrant units was recorded as a separate component of members’ equity (deficit) in the accompanying balance sheet as of December 31, 2020 with an offset to the Series 1a proceeds. In June 2020, 18,750 of the warrants were exercised for consideration of $18,750, which consideration was received in July 2020. The Company’s Series 1a Preferred Units were converted to preferred stock during the first quarter of 2021. Additionally, in August 2021, the Company converted all preferred stock into common stock. No Series 1a Preferred Units were outstanding as of December 31, 2021 and September 30, 2022.

 

Series 1b Preferred Units

 

In 2018, the Company issued 6,500,000 Series 1b Preferred Units in exchange for cash of $6,500,000 and net of issuance costs of $40,405. Purchasers of the Series 1b Preferred Units also received 1,268,279 Class B Common Units. The estimated fair value of the Class B Common units has been recorded as a component of members’ equity (deficit) in the accompanying balance sheet as of December 31, 2020 with an offset to the Series 1b proceeds. The Company’s Series 1b Preferred Units were converted to preferred stock during the first quarter of 2021. Additionally, in August 2021, the Company converted all preferred stock into common stock. No Series 1b Preferred Units were outstanding as of December 31, 2021 and September 30, 2022.

 

Series 1c Preferred Units

 

On June 14, 2019, the Company closed participation in a $5,785,000 Series 1c financing from current and new investors. As of December 31, 2019, cash of $5,535,000, including $150,000 from the conversion of a convertible note issued to a Managing Member of the Company for a loan made to the Company, net of issuance costs of $25,857, had been received. The accrued interest on the convertible note in the amount of $1,487 was also converted into Series 1c Preferred Units. The remaining balance of $250,000 committed to the financing was paid in the amounts of $125,000 in May 2020 and $125,000 in June 2020.

 

In June 2019, 5,221,156 Series 1c Preferred Units were issued in connection with the settlement and license agreement, and in July 2021, the Company redeemed these units/shares in connection with an amendment to the settlement and license agreement. See Note 9 – License Agreements for more information.

 

The Company’s Series 1c Preferred Units were converted to preferred stock during the first quarter of 2021. Additionally, in August 2021, the Company converted all preferred stock into common stock. No Series 1c Preferred Units were outstanding as of December 31, 2021 and September 30, 2022.

 

Series 1d Preferred Units

 

In March 2021, the Company issued 686,742 Series 1d Preferred Units at a cost of $0.83 per unit for total proceeds of $570,000. In addition, as described in Note 4 – Subordinated Convertible Promissory Notes, as of March 15, 2021, $4,391,000 of convertible promissory notes, along with related interest of $73,801, were converted into 5,379,247 Series 1d Preferred Units. The outstanding Series 1d Preferred Units were converted to preferred stock during the first quarter of 2021. Additionally, in August 2021, the Company converted all preferred stock into common stock. No Series 1d Preferred Units were outstanding as of December 31, 2021 and September 30, 2022.

Class A Common Units

 

During 2014 and 2015, the Company issued 508,777 Class A Common Units in exchange for consideration of $10,430. The Class A Common Units outstanding converted to common stock during the first quarter of 2021. No Class A Common Units were outstanding as of December 31, 2021 and September 30, 2022.

 

Class B Common Units

 

The Company had 1,767,477 Class B Common Units outstanding as of December 31, 2020. This includes 133,953 Class B Common Units issued for consideration of $2,853 and 1,268,279 Class B Common Units issued in connection with the issuance of the Series 1b Preferred Units, which were assigned an estimated fair value of $2,340,000. The remaining 365,245 Class B Common Units were issued as a profits interest as that term is defined by Revenue Procedure 93-27, 1993-2 C.B. 343, as clarified by Revenue Procedure 2001-43, 2001-2 C.B. 191, with participation thresholds from $0.001 to $0.36. During the first quarter 2020, the Company issued 2,439 Class B Common Units, all of which represented a profits interest. During the first quarter of 2021, 22,494 Class B Common Units were forfeited as a result of employee resignations. The remaining Class B Common Units outstanding converted to common stock during the first quarter of 2021. No Class B Common Units were outstanding as of December 31, 2021 and September 30, 2022.  

 

Liquidation Preference

 

Prior to the Company’s IPO in August 2021, the Company’s preferred units were subject to liquidation preferences contained herein. So long as there were no Series A Preferred Units outstanding at the time of a liquidity event, any liquidity event proceeds would have been distributed as follows: First, the Series 1d Preferred Units had a two times preference in liquidation over the Series 1c Preferred Units and then participated with the Series 1c, 1b and 1a Preferred Units once the Series 1c Preferred Unit preferences had been satisfied. Second, proceeds to Series 1c Preferred Unit holders sufficient to cover two times their Series 1c investment; third, proceeds to Series 1, Series 1a, Series 1b, Series 1c, and Series 1d Preferred Unit holders sufficient to cover interest at the rate of 8% per annum on the Series 1 Preferred Units, the Series 1a Preferred Units, the Series 1b Preferred Units, the Series 1c Preferred Units, and Series 1d Preferred Units; fourth, proceeds to the Series 1, Series 1a, Series 1b and Series 1c Preferred Unit holders sufficient to cover the unit value of Series 1 Preferred Units, Series 1a Preferred Units, Series 1b Preferred Units, Series 1c Preferred Units, and Series 1d Preferred Units; fifth, to Class A and Class B Common holders proceeds sufficient to cover their pro-rata portion of distributions made to Series 1, Series 1a, Series 1b, Series 1c, and Series 1d Preferred Unit holders, provided that no Class B Common Units would share in any distribution until after the point at which the amount per Class A Common Unit exceeds the amount of such Class B Common Unit’s Participation Threshold; and sixth, a pro-rata distribution of the remaining proceeds to all equity holders. Upon the issuance of Series A Preferred Units, each Series 1 Preferred Unit, each Series 1a Preferred Unit, each Series 1b Preferred Unit, each Series 1c Preferred Unit and each Series 1d Preferred Unit would have automatically converted into the number of Series A Preferred Units equal to the sum of the unit value of the Series 1, Series 1a, Series 1b, Series 1c or Series 1d Preferred Units plus all accumulated preferred return as of the conversion date that would have been due with respect to such Series 1, Series 1a, Series 1b, Series 1c or Series 1d Preferred Units in the case of a liquidity event. As of December 31, 2021 and September 30, 2022, no Series A Preferred Units had been issued, and no preferred stock remained outstanding.

 

Conversion Rights

 

Prior to the Company’s IPO in August 2021, the Company’s preferred units were subject to conversion rights contained herein. Upon the first issuance by the Company of any Series A Preferred Units, each Series 1 Preferred Unit and each Series 1a Preferred Unit and each Series 1b Preferred Unit and each Series 1c Preferred Unit and each Series 1d Preferred Unit would have automatically been converted into the number of Series A Preferred Units equal to the sum of the Unit Value with respect to such Series 1 Preferred Unit or Series 1a Preferred Unit or Series 1b Preferred Unit or Series 1c Preferred Unit or Series 1d Preferred Unit as of the conversion date divided by the product of 0.80 multiplied by the Unit Value of the Series 1 Preferred Units or Series 1a Preferred Units or Series 1b Preferred Units or Series 1c Preferred Units or Series 1d Preferred Unit issued on the conversion date. The Series A Preferred Units issued to the Series 1 Preferred Members and Series 1a Preferred Members and Series 1b Preferred Members and Series 1c Preferred Members and Series 1d Preferred Members upon conversion of such Series 1 Preferred Units and Series 1a Preferred Units and such Series 1b Preferred Units and Series 1c Preferred Units and Series 1d Preferred Units would have had the same rights, privileges and preferences as the other Series A Preferred Units issued by the Company on the conversion date. The Company considered the classification of the Preferred Units and concluded that they were appropriately included as a component of equity since each class of Preferred Units participates in the same form of consideration received upon a change in control. As of December 31, 2021 and September 30, 2022, no preferred units or stock remained outstanding.

Stockholders’ Agreements

 

On March 24, 2021, in connection with the conversion of Dermata Therapeutics, LLC into a Delaware corporation, the Company entered into a Stockholders’ Agreement (as amended, the Stockholders’ Agreement) with all of its then-existing stockholders, including Proehl Investment Ventures, LLC and Hale Biopharma Ventures, LLC. The Stockholders’ Agreement among other things, provided for certain restrictions on transfer of the Company’s shares of capital stock, set forth agreements and understandings with respect to how shares of its capital stock held by the stockholders party thereto will have been voted on, or tendered in connection with, an acquisition of the Company and provided for certain voting rights with respect to the election of directors. In addition, pursuant to the Stockholders’ Agreement, holders of the Company’s Series 1a Preferred Stock were entitled to purchase, at any time prior to March 14, 2026, such number of shares of the Company’s Series 1a Preferred Stock as such Series 1a Stockholder shall request, up to an aggregate number of shares of Series 1a Preferred Stock not to exceed the product of 25% and the aggregate number of shares Series 1a Preferred Stock then held by such Series 1a Stockholder (or the Series 1a Preferred Warrant Rights). The shares of Series 1a Preferred Stock purchased pursuant to any Series 1a Preferred Warrant Right had a per share purchase price of $20.50 (subject to appropriate adjustment in the event of any stock dividend, stock split, combination, or other similar recapitalization). Upon the consummation of the Company’s IPO of common stock, each Series 1a Preferred Stock Warrant became exercisable for the same number of shares of Common Stock with the same per share exercise price of $20.50 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination, or other similar recapitalization). The Stockholders’ Agreement would have automatically terminated upon the earliest of (a) immediately prior to the consummation of the Company’s initial public offering of common stock, and (b) the consummation of a sale of the Company, subject to certain conditions. The Company completed the IPO of common stock in August 2021, thereby terminating the Stockholders’ Agreement.

 

On June 29, 2021, with effectiveness on July 1, 2021, the Company’s board of directors amended its Certificate of Incorporation to adjust the conversion price and certain conversion mechanics of the Company’s issued and outstanding Series 1d Preferred Stock, whereby each share of Series 1d Preferred stock would convert into such number of Common Stock as determined by dividing (i) the product of (a) the Original Issue Price for the Series 1d Preferred Stock, multiplied by (b) 1.2, rounded to the nearest whole cent, by (ii) the 80% of the initial public per share offering price in the IPO. The Series 1d conversion shall not be subject to further adjustment for any stock split.

 

On June 29, 2021, with effectiveness on July 1, 2021, the Company’s board of directors approved an amendment to the 2021 Plan to increase the number of shares of Common Stock available for issuances from 593,340 to 1,648,213 shares. Effective January 1, 2022, an evergreen provision contained in the Company's 2021 Omnibus Equity Incentive Plan, or the 2021 Plan, added one percent of common shares outstanding as of December 31, 2021 to the 2021 Plan. This evergreen provision resulted in an increase of 83,286 shares to the 2021 Plan, increasing shares authorized for issuance under the 2021 Plan to 1,731,499 as of January 1, 2022.

 

On June 29, 2021, the Company’s board of directors approved a 1-for-20.5 reverse split of all outstanding shares of common stock, effected on July 1, 2021 (no fractional shares were issued). Except as otherwise noted, all references to share and per share amounts related to common stock and common units have been restated to reflect the reverse stock split.

 

On July 12, 2021, the Company’s board of directors amended its Certificate of Incorporation to further adjust the conversion price and certain conversion mechanics of the Company’s issued and outstanding Series 1d Preferred Stock. The two amendments to the Series 1d Preferred Stock conversion terms were combined for purposes of accounting for the amendments. In order to determine if these amendments resulted in a modification or extinguishment of the Series 1d Preferred Stock, pursuant to the related authoritative guidance, the Company engaged an independent third-party valuation firm to assist with determining the fair value of the Series 1d Preferred Stock immediately before the change in conversion terms, as well as immediately after the change in conversion terms. This resulted in a substantive increase in fair value, and as such, the Company determined the amendments resulted in extinguishment accounting. Accordingly, the Company applied ASC 260, Earnings per Share, and ASC 470, Debt, by analogy to determine the appropriate measurement and presentation. The Company compared the fair value of the Series 1d Preferred Stock, as amended, to its carrying value and recorded the resulting difference of approximately $2.3 million as a deemed dividend for the Series 1d preferred shareholders. The Company recorded the deemed dividend to additional paid-in capital during the quarter ended September 30, 2021. Because the Company is in an accumulated deficit position, the deemed dividend increased the net loss attributable to the common shareholders for the three and nine months ended September 30, 2021.

On July 30, 2021, the Company entered into a Second Amendment to the License and Settlement Agreement (or, the Second License Amendment), whereby, for the settlement of certain disputes arising under the License Agreement, the Company agreed to exchange the shares of Series 1c Preferred Stock owned by Villani, Inc. (“Villani”) for an increase of milestone payments and royalty rates due to Villani under the License Agreement. On July 30, 2021, Villani surrendered 5,221,156 shares of Series 1c Preferred Stock to the Company and on August 17, 2021, the Company paid to Villani $1.0 million upon the close of the Company’s initial public offering for the redemption of the Series 1c shares. The Company determined that the deemed dividend to Villani for the Series 1c preferred share redemption was the difference between the $1.0 million paid for the shares and the carrying value of the shares of $730,962, resulting in a deemed dividend of $269,038. This deemed dividend of $269,038 was recorded to additional paid-in capital during the quarter ended September 30, 2021. Because the Company is in an accumulated deficit position, the deemed dividend increased the net loss attributable to common shareholders for the three and nine months ended September 30, 2021.

 

On August 14, 2021, the Company’s board of directors approved an amendment to the Company’s Certificate of Incorporation to increase the number of shares of Common Stock authorized to 90,000,000.

 

On July 11, 2022, the Company filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to increase the number of authorized shares of the Company’s common stock from 90,000,000 shares to 250,000,000 shares. The increase in the number of authorized shares was approved by the holders of a majority of the outstanding shares of common stock of the Company at its annual meeting on July 11, 2022.

 

Warrants

 

Warrants issued at IPO

 

On August 17, 2021, the Company completed its IPO, in which it sold 2,571,428 shares of its common stock together with 2,571,428 warrants to purchase one share of common stock with an exercise price of $7.00 per share at a combined offering price of $7.00. The underwriters exercised their option to purchase an additional 385,714 warrants with an exercise price of $7.00, increasing the number of warrants issued at IPO to 2,957,142. Each warrant is immediately exercisable at the option of the holder and expires five years from the date of issuance.

 

The Company evaluated the terms of the warrants issued at the IPO and determined that they should be classified as equity instruments based upon accounting guidance provided in ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging. Since the Company determined that the warrants were equity classified, the Company recorded the proceeds from the IPO, net of issuance costs, within common stock at par value and the balance of proceeds to additional paid in capital. The fair value of each warrant on August 17, 2021 was $0.9995 based on the closing trading price on that day.

 

As of September 30, 2022, the Company had 2,957,142 warrants outstanding resulting from the IPO with an exercise price of $7.00 and which expire August 17, 2026. As of September 30, 2022, the outstanding warrants are exercisable into 2,957,142 shares of common stock whose fair value was $0.52 per share, based on the closing trading price on that day.

Underwriter IPO Warrants

 

Upon the closing of the Company's IPO in August 2021, the Company issued to the underwriters warrants to purchase 128,571 of shares of common stock at an exercise price equal to 115% of the public offering price, or $8.05 per share, exercisable for a period of five years, or until August 2026. As of September 30, 2022, the Company had 128,571 warrants outstanding resulting from the underwriter IPO warrants with an exercise price of $8.05 and which expire August 17, 2026. As of September 30, 2022, the outstanding warrants are exercisable for 128,571 shares of common stock whose fair value was $0.52 per share, based on the closing trading price on that day.

 

Warrants issued with Class B Common Units

 

In March 2021, the Company granted Class B Common Units Profits interests to certain former employees and consultants. In connection with the conversion from an LLC to a C-Corporation, the Company converted 65,303 of vested Units to fully vested Common Stock Warrants with an exercise price of $5.74. These Common Stock Warrants issuances were considered a modification under ASC 718, Stock Compensation, in which the fair value of the Class B Common Units profits interests were measured at the modification date and compared to the fair value of the common stock warrants, with the difference of $279,812 recorded as stock-based compensation expense in the first quarter of 2021.

 

As of September 30, 2022, the Company had 65,303 common warrants outstanding related to the prior Class B Common Units with an exercise price of $5.74 and which expire December 31, 2024. As of September 30, 2022, the outstanding warrants are exercisable into 65,303 shares of common stock whose fair value was $0.52 per share, based on the closing trading price on that day.

 

Warrants issued with Series 1a Preferred Units

 

In connection with the issuance of 5,000,000 Series 1a Preferred Units in November 2016, each Series 1a Preferred Member received Warrant Units to purchase from the Company, at any time after November 15, 2016 and on or prior to November 15, 2021, such number of Series 1a Preferred Units as such Series 1a Preferred Member shall request, up to an aggregate number of Series 1a Preferred Units not to exceed the product of 25% and the aggregate number of Series 1a Preferred Units then held by such Series 1a Preferred Member, which was 1,231,250 units at December 31, 2020. The exercise price for each Warrant Unit was $1.00, subject to adjustment for unit splits and combinations. The warrants had a 5-year term. The Company received total proceeds of $5,000,000 for the Series 1a Preferred Units and warrants which were allocated on a relative fair value basis to the Units and warrants resulting in a relative fair value of $4,381,199 and $618,801, respectively. The estimated fair value of the Series 1a Warrant Units was recorded as a separate component of members’ equity (deficit) in the accompanying financial statements as of December 31, 2020. In June 2020, 18,750 of the warrants were exercised for consideration of $18,750, which consideration was received in July 2020.

 

In connection with the Loan and Security Agreement, SVB also received Warrant Units to purchase, at any time after February 9, 2017 and prior to February 9, 2027, 187,978 Series 1a Preferred Units or the equivalent Series A Preferred Units had they purchased Series 1a Preferred Units, if Series A Preferred Units are issued, at an exercise price of $1.00 per unit. On March 24, 2021, in connection with the conversion from an LLC to a C-Corporation, each warrant to purchase Series 1a Preferred Units in the LLC was automatically converted into a warrant to purchase, upon the same terms and conditions, shares of Series 1a Preferred Stock of the Company.

 

In July 2021, the Company effected a reverse split of shares of the Company’s common stock at a ratio of 1-for-20.5, and the conversion ratio of the preferred stock was adjusted accordingly. In August 2021, in connection with the Company’s IPO, the outstanding Series 1a preferred warrants were converted into 69,212 common warrants.

 

As of September 30, 2022, the Company had 69,212 common warrants outstanding related to the prior Series 1a preferred warrants with an exercise price of $20.50 and which expire November 15, 2026. As of September 30, 2022, the outstanding warrants are exercisable into 69,212 shares of common stock whose fair value was $0.52 per share, based on the closing trading price on that day.

Common and Pre-Funded Warrants issued with PIPE

 

In April 2022, the Company completed the PIPE, in which it sold 898,585 shares of its common stock together with 2,875,000 Pre-funded Warrants to purchase one share of common stock with an exercise price of $0.0001 per share, and 3,773,585 PIPE Common Warrants to purchase one share of common stock with an exercise price of $1.325 per share, at a combined offering price of $1.325. Each PIPE Common Warrant is immediately exercisable at the option of the holder and expires May 13, 2027.

 

During the quarter ended June 30, 2022, 875,000 of the Pre-funded Warrants were exercised. During the quarter ended September 30, 2022, the remaining 2,000,000 Pre-funded Warrants were exercised. No additional Pre-funded Warrants are outstanding as of September 30, 2022.

 

As of September 30, 2022, the Company had 3,773,585 PIPE Common Warrants outstanding with an exercise price of $1.325 and which expire May 13, 2027. As of September 30, 2022, the outstanding PIPE Common Warrants are exercisable into 3,773,585 shares of common stock whose fair value was $0.52 per share, based on the closing trading price on that day.
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity Incentive Plan
 9 Months Ended
Sep. 30, 2022
Equity Incentive Plan  
Equity Incentive Plan

7. Equity Incentive Plan

 

Under the Company’s 2021 Omnibus Equity Incentive Plan (the “2021 Plan”), the Company may grant options to purchase common stock, restricted stock awards, performance stock awards, incentive bonus awards, other cash-based awards or directly issue shares of common stock to employees, directors, and consultants of the Company. Effective January 1, 2022, an evergreen provision contained in the Company’s 2021 Plan increased the total number of shares of common shares issuable under the 2021 Plan in an amount equal to one percent of the Company’s common shares outstanding as of December 31, 2021. This evergreen provision resulted in an additional 83,286 common shares issuable pursuant to the 2021 Plan, increasing the total authorized shares available for issuance under the 2021 Plan to 1,731,499 as of January 1, 2022. Stock awards may be granted at an exercise price per share of not less than 100% of the fair market value at the date of grant. Stock awards granted are exercisable over a maximum term of 10 years from the date of grant and generally vest over a period of four years for employees and one year for directors of the Company’s board and consultants.

 

As of September 30, 2022, there remain an additional 547,447 shares reserved for issuance under the 2021 Plan.

 

Fair Value Measurement

 

The Company uses the Black-Scholes option valuation model, which requires the use of highly subjective assumptions, to determine the fair value of stock-based awards. The fair value of each employee stock option is estimated on the grant date under the fair value method using the Black-Scholes model. The estimated fair value of each stock option is then expensed over the requisite service period, which is generally the vesting period. The assumptions and estimates that the Company uses in the Black-Scholes model are as follows:

 

 

·

Fair Value of Common Stock. The estimated fair value of the common stock underlying the Company’s stock option plan was determined by management by considering various factors as discussed below. All options to purchase shares of the Company’s common stock are intended to be exercisable at a price per share not less than the per-share fair value of the Company’s common stock underlying those options on the date of grant. In the absence of a public trading market for the Company’s common stock, before the initial public offering, on each grant date, the Company developed an estimate of the fair value of its common stock based on the information known to the Company on the date of grant, upon a review of any recent events and their potential impact on the estimated fair value per share of the common stock and in part on input from an independent third-party valuation firm. After the Company’s initial public offering, the fair value of common stock is measured as the Company’s closing price of common stock on the date of grant.

 

 

 

 

·

Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes valuation model on the implied yield available on U.S. Treasury zero-coupon issues with a term equivalent to that of the expected term of the options.

 

 

 

 

·

Expected Term. The expected term represents the period that the Company’s stock-based awards are expected to be outstanding. Because of the limitations on the sale or transfer of the Company’s common stock as a privately held company, the Company does not believe its historical exercise pattern is indicative of the pattern it will experience as a publicly traded company. The Company plans to continue to use the SAB 110 simplified method until it has sufficient trading history as a publicly traded company.

 

·

Volatility. The Company determines the price volatility based on the historical volatilities of industry peers as it has limited trading history for its common stock price. Industry peers consist of several public companies in the biotechnology industry with comparable characteristics, including clinical trials progress and therapeutic indications.

 

 

 

 

·

Dividend Yield. The expected dividend assumption is based on the Company’s current expectations about its anticipated dividend policy. To date, the Company has not declared any dividends to common shareholders, and therefore the Company has used an expected dividend yield of zero.

 

The following table presents the weighted-average assumptions used for the stock option grants:

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Grant date fair value

 

$0.45

 

 

$4.54

 

 

$1.46

 

 

$4.87

 

Risk-free rate

 

 

2.9%

 

 

0.98%

 

 

1.5%

 

 

0.92%

Dividend yield

 

 

0.00%

 

 

0.00%

 

 

0.0%

 

 

0.00%

Expected life in years

 

 

6.1

 

 

 

5.8

 

 

 

5.4

 

 

 

5.7

 

Expected volatility

 

 

132%

 

 

125%

 

 

123%

 

 

122%

 

Stock-based Compensation Expense

 

In general, stock-based compensation is allocated to research and development expense or general and administrative expense according to the classification of cash compensation paid to the employee, director, or consultant to whom the stock award was granted.

 

On March 24, 2021, in connection with the conversion from an LLC to a C-Corporation, the Company converted 277,448 of Class B Common Units profits interests, for which no consideration had been received, into 277,448 options to purchase common stock at an exercise price of $5.74 to $6.314 per share. The fair value of common stock prior to IPO was determined in part based upon input from an independent third-party valuation firm. The Company considered the conversion of these Class B Common Units profits interests as a modification under ASC 718, Stock Compensation, in which the fair value of the Class B Common Units profits interests was measured at the modification date and compared to the fair value of the common stock options, with the difference of $1,339,993 resulting in incremental stock-based compensation expense. Related to the options, the Company recorded $849,564 of stock-based compensation expense recorded in the first quarter of 2021.

 

In December 2021, the Company’s board of directors authorized a stock option grant in lieu of a cash bonus for the Company’s Chairman and Chief Executive Officer. The stock-based compensation expense of $0.4 million related to the stock option grant was booked to the fiscal year ended December 31, 2021; however, the impact to additional paid-in capital was not booked until the first quarter of 2022, when the stock option award was granted.

The following table summarizes the total stock-based compensation expense related to stock options and RSUs included in the Company’s statements of operations:

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Research and development

 

$54,907

 

 

$30,075

 

 

$163,417

 

 

$310,046

 

General and administrative

 

 

180,076

 

 

 

112,580

 

 

 

546,018

 

 

 

1,106,645

 

 

 

$234,983

 

 

$142,655

 

 

$709,435

 

 

$1,416,691

 

 

Stock Option Award Activity

 

A summary of the Company’s Equity Plan stock option activity is as follows:

 

 

 

Number of

Options

Outstanding

 

 

Weighted-

Average

Exercise

Price

 

 

Weighted-

Average

Remaining

Contractual

Term (in

Years)

 

Balance at December 31, 2021

 

 

523,199

 

 

$5.84

 

 

 

8.8

 

Options granted

 

 

533,127

 

 

 

1.75

 

 

 

-

 

Options exercised

 

 

-

 

 

 

-

 

 

 

-

 

Options cancelled

 

 

-

 

 

 

-

 

 

 

-

 

Balance at September 30, 2022

 

 

1,056,326

 

 

$3.77

 

 

 

8.5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options exercisable at September 30, 2022

 

 

586,100

 

 

$4.32

 

 

 

8.6

 

 

The aggregate intrinsic value of options exercisable as of September 30, 2022 is calculated as the difference between the exercise price of the underlying options and the closing market price of the Company’s common stock on that date, which was $0.52 per share. The intrinsic value of options outstanding and exercisable as of September 30, 2022 was $385.

 

As of September 30, 2022, total unrecognized compensation cost related to stock options was approximately $1.1 million and the weighted average period over which this cost is expected to be recognized is 2.5 years.

 

 Restricted Stock Unit Award Activity

 

A summary of the Company’s Equity Plan restricted stock unit, or RSU, award activity is as follows:

 

 

 

Number of

RSU’s outstanding

 

Balance at December 31, 2021

 

 

-

 

RSUs granted

 

 

127,726

 

RSUs settled

 

 

-

 

RSUs cancelled

 

 

-

 

Balance at September 30, 2022

 

 

127,726

 

 

During the three and nine months ended September 30, 2022, the Company issued to certain of the Company’s directors 80,589 and 127,726 RSUs, respectively, as partial compensation for their services during 2022. The Company recognized stock-based compensation expense of approximately $0.1 million during the three and nine months ended September 30, 2022 related to the restricted stock unit awards. There were no RSUs outstanding during 2021 and there is no unrecognized compensation expense related to outstanding RSUs as of September 30, 2022.  
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
401(k) Plan
 9 Months Ended
Sep. 30, 2022
401(k) Plan  
401(k) Plan

8. 401(k) Plan

 

The Company sponsors a 401(k) savings plan for all eligible employees. The Company may make discretionary matching contributions to the plan to be allocated to employee accounts based upon employee deferrals and compensation. To date, the Company has not made any matching contributions into the savings plan.
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
License Agreements
 9 Months Ended
Sep. 30, 2022
License Agreements

9. License Agreements

 

On March 31, 2017, the Company entered into a license agreement, as amended (the “License Agreement”) with Villani, Inc. whereby Villani has granted the Company an exclusive, sub-licensable, royalty-bearing license (the “License”) under the Licensed Patents (as defined in the License Agreement), to formulate, develop, seek regulatory approval for, make or sell products that contain Spongilla lacustris (alone or in combination with other active or inactive ingredients) for the treatment of diseases, disorders and conditions of the skin, including but not limited to acne, rosacea, psoriasis, atopic dermatitis, seborrheic dermatitis, actinic keratosis and eczema that were developed using certain licensed know-how (“Licensed Products”). The Company is responsible for the development (including manufacturing, packaging, non-clinical studies, clinical trials and obtaining regulatory approval and commercialization (including marketing, promotion, distribution, etc.)) for all Licensed Products. In partial consideration of the License, the Company forgave its previous outstanding loan to Villani in the amount of $400,000.

 

The original License Agreement was amended in 2019 and, in consideration of the receipt of certain know-how and patents, the Company issued to Villani 5,221,156 Series 1c Preferred Units equal to 5% of the Company’s fully diluted capitalization, valued at $730,962. Pursuant to the amended License Agreement, the Company was required to make future milestone payments to Villani in an aggregate amount of up to $20.25 million upon the achievement of specified development and sales milestones, payable in cash or in equity, at the option of Villani, as well as single-digit royalty payments on net sales.

 

On July 30, 2021, the Company further amended the License Agreement in the Second Amendment to the License and Settlement Agreement (the “Second Amendment”). In consideration of the Second Amendment, Villani exchanged the 5,221,156 Series 1c Preferred Shares issued to Villani in 2019 for an increase in milestone payments and royalty rates payable pursuant to the License Agreement and the Company paid Villani $1 million after the close of the IPO. Pursuant to the Second Amendment, the Company is required to make future milestone payments to Villani in an aggregate amount of up to $40.5 million upon the achievement of specified development and sales milestones, payable in cash or in equity, at the option of Villani, as well as single-digit royalty payments on net sales. The Second Amendment includes customary terms relating to, among others, indemnification, intellectual property protection, confidentiality, remedies, and warranties. See Note 6 – Equity Securities for additional information regarding the Company’s redemption of the Series 1c Preferred Shares from Villani.

XML 25 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2022
Commitments and Contingencies  
Commitments and Contingencies

10. Commitments and Contingencies

 

Clinical Trials

 

During 2021, the Company initiated a clinical trial which completed patient enrollment in June 2022; however, the Company had not completed data analysis for the clinical trial by September 30, 2022. Accordingly, the Company anticipates additional research and development expense of $0.1 to $0.2 million to be incurred during the fourth quarter of fiscal year 2022 related to this ongoing clinical trial.

 

Coronavirus Pandemic

 

On March 11, 2020, the World Health Organization declared the outbreak of a coronavirus (COVID-19) pandemic. Significant uncertainties may arise with respect to potential shutdowns of operations or government orders to cease activities due to emergency declarations, inability to operate, employee shortages, or claims for business interruption insurance, etc. Each of these matters may have a significant impact on the future results of the Company.

Supplier Agreement

 

As a result of Russia’s invasion of Ukraine, the United States, the United Kingdom, and the European Union governments, among others, have developed coordinated sanctions and export-control measure packages against Russian individuals and entities. The Company is currently a party to an exclusive supply agreement for the supply of the Spongilla raw material used in DMT310 and DMT410. The counterparty to this supply agreement is a Russian entity. The imposition of enhanced export controls and economic sanctions on transactions with Russia and Russian entities by the United States, the United Kingdom, and/or the European Union could prevent the Company from performing under this existing contract or any future contract it may enter or may prevent the Company from remitting payment for raw material purchased from the Company’s supplier. The Company has received two shipments of raw material from its supplier during fiscal year 2022 containing additional quantities of Spongilla raw material which will provide the Company with sufficient quantities of Spongilla to initiate and complete two Phase 3 studies in moderate-to-severe acne and support filing a new drug application for DMT310 in acne upon the successful completion of two Phase 3 studies. Depending on the extent and breadth of new sanctions or export controls that may be imposed against Russia, otherwise or as a result of the impact of the war in Ukraine, it is possible that the Company’s ability to obtain additional supply of the Spongilla raw material used in DMT310 and DMT410 could be negatively impacted, which could adversely affect its business, results of operations, and financial condition.

 

Legal Proceedings

 

In the normal course of business, the Company may be involved in legal proceedings or threatened legal proceedings. The Company is not a party to any legal proceedings or aware of any threatened legal proceedings which are expected to have a material adverse effect on its financial condition, results of operations or liquidity.

XML 26 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Parties
 9 Months Ended
Sep. 30, 2022
Related Parties  
Related Parties

11. Related Parties

 

Prior to the Company converting from an LLC to a C-corporation in March 2021, the Company had two Managing Members. One of the Managing Members remained the Company’s majority stockholder upon the close of the Company’s IPO and serves as the Company’s President, Chief Executive Officer, and Chairman of the Board of Directors. The other Managing Member remained a beneficial owner upon the close of the Company’s IPO and serves as the Company’s Lead Director of the Board of Directors. Hereinafter these two Managing Members, and their affiliates, are referred to collectively as the Principal Stockholders after the completion of the IPO.

 

During 2020, the Managing Members and other related parties loaned the Company $1,145,000 as subordinated convertible promissory notes. Additionally, during the first quarter of 2021, the Managing Members and other related parties loaned the Company $1,255,000 as subordinated convertible promissory notes. Refer to Note 4 – Subordinated Convertible Promissory Notes for further discussion.

 

During the third quarter of 2021, the Company amended the conversion terms of its Series 1d preferred stock, as described in Note 6 – Equity Securities. As a result of the Series 1d preferred stock amendments, the Company presented a deemed dividend of approximately $2.3 million for the year ended December 31, 2021, approximately $1.2 million of which related to Series 1d preferred shares owned by the Company’s Principal Stockholders and their affiliates.

XML 27 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2022
Summary of Significant Accounting Policies  
Use of Estimates

The Company’s financial statements are prepared in accordance with GAAP. The preparation of the Company’s financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, including those related to accrued research and development expenses, stock-based compensation, and the estimated fair values of equity instruments. Management evaluates its estimates on an ongoing basis. The Company bases its estimates on various assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.
Segment Information

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company’s chief operating decision maker view the Company’s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceuticals. The Company operates in only one segment.
Deferred Financing Costs

The Company capitalizes certain legal, accounting, and other fees and costs that are directly attributable to in-process equity financings as deferred offering costs until such financings are completed. Upon the completion of an equity financing, these costs are recorded as a reduction of additional paid-in capital of the related offering. Upon the completion of the IPO in August 2021, approximately $2.6 million of offering costs related to the IPO were reclassified to additional paid-in capital. As of December 31, 2021, the Company had deferred financing costs of $0.06 million and as of September 30, 2022, the Company had no deferred financing costs.

Cash and Cash Equivalents

The Company deposits its cash with reputable financial institutions that are insured by the Federal Deposit Insurance Corporation (“FDIC”). This cash is held in checking, cash sweep, and money market accounts. At times, deposits held may exceed the amount of insurance provided by the FDIC. The Company maintains an insured cash sweep account in which cash from its main operating checking account is invested overnight in highly liquid, short-term investments. The Company considers all highly liquid investments with a maturity date of 90 days or less at the date of purchase to be cash equivalents. The Company has not experienced any losses in its cash and cash equivalents and believes they are not exposed to significant credit risk.
Fair Value Measurement

The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company believes the carrying amount of cash and cash equivalents, accounts payable, accrued expenses and debt approximate their estimated fair values due to the short-term maturities of these financial instruments.
Interest Income

Interest income consists of interest income earned on cash equivalents from interest bearing demand accounts.

Patent Costs

                Patent costs related to obtaining and maintaining patent protection in both the United States and other countries are expensed as incurred. Patents costs are classified as general and administrative expenses.

Research and Development

Research and development costs consist of expenses incurred in connection with the development of the Company’s product candidates. Such expenses include expenses incurred under agreements with contract research organizations, manufacturing and supply scale-up expenses and the cost of acquiring and manufacturing preclinical and clinical trial supply, outsourced laboratory services, including materials and supplies used to support the Company’s research and development activities, and payments made for license fees and milestones that have not been demonstrated to have commercial value. Such costs are expensed in the periods in which they are incurred. Upfront payments and milestone payments for licensed technology are expensed as research and development as incurred or when the milestone is achieved or is determined to be probable of being achieved. Advanced payments for goods or services to be received in the future for research and development activities are recorded as prepaid expenses and expensed as the related goods are received or services are performed.

Income Taxes

From inception until March 24, 2021, the Company operated as a limited liability company taxed as a partnership. Therefore, any income tax liability or benefit through that date accrued to the Company’s members. Since March 24, 2021, the Company has operated as a C-Corporation and accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

 

The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.

 

The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.
Stock-Based Compensation

In March 2021, the Company’s board of directors and shareholders approved the 2021 Omnibus Equity Incentive Plan (“the 2021 Plan”). For stock options granted under the 2021 Plan, the Company measures and recognizes compensation expense for all stock-based awards made to employees, directors, and non-employees, based on estimated fair values recognized using the straight-line method over the requisite service period. The fair value of options to purchase common stock granted to employees is estimated on the grant date using the Black-Scholes valuation model. The calculation of stock-based compensation expense requires that the Company make certain assumptions and judgments about variables used in the Black-Scholes model, including the expected term of the stock-based award, expected volatility of the underlying common stock, dividend yield, and the risk-free interest rate. Forfeitures are accounted for in the period they occur. Restricted stock units (“RSUs”) granted under the 2021 Plan are measured at the grant date fair value of the common stock, with corresponding compensation expense recognized ratably over the requisite service period. Refer to Note 7- Equity Incentive Plan for further discussion.

Comprehensive Loss

Comprehensive loss includes net loss and other comprehensive income (loss) for the periods presented. The Company did not have other comprehensive income (loss) items such as unrealized gains and losses and so for the three and nine months ended September 30, 2022, and September 30, 2021, comprehensive loss was equal to the net loss.
Net Loss Per Common Unit/Share

On March 24, 2021, the Company converted from an LLC to a C-corporation. Upon the conversion, each outstanding common unit and preferred unit was converted into one share of common stock and preferred stock, respectively. Common units had similar rights and characteristics of common stock issued upon the conversion. In calculating net loss per share, the Company retrospectively applied the effects of the conversion to the number of common units outstanding prior to the conversion. Net loss per share for periods prior to the conversion to a C-corporation refers to net loss per common unit.

 

Basic net loss per unit/share is calculated by dividing net loss attributable to common unitholders or shareholders by the weighted-average number of units or shares outstanding during the period, contingently issuable restricted stock units for which no future service is required as a condition to the delivery of the underlying common stock, and pre-funded warrants because their exercise requires only nominal consideration for the delivery of shares (collectively, “basic shares”), without consideration of common unit or share equivalents. Diluted net loss per unit or share is calculated by adjusting basic shares outstanding for the dilutive effect of common unit or share equivalents outstanding for the period. For purposes of the diluted net loss per unit or share calculation, preferred units or shares, profit interests, and warrants to purchase preferred units or shares are considered to be common unit or share equivalents but are excluded from the calculation of diluted net loss per common unit or share if their effect would be anti-dilutive.

 

As the Company has reported a net loss for the periods presented, diluted net loss per common unit or share is the same as the basic net loss per common unit or share for the periods presented.

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$(2,424,586 )

 

$(1,712,920 )

 

$(7,941,311 )

 

$(5,349,621 )

Deemed dividend upon redemption of 5,221,156 shares of Series 1c convertible preferred stock

 

$-

 

 

$269,038

 

 

$-

 

 

$269,038

 

Deemed dividend upon amendment of the terms to the

Series 1d convertible preferred stock

 

$-

 

 

$2,293,199

 

 

$-

 

 

$2,293,199

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to common stockholders

 

$(2,424,586 )

 

$(4,275,157 )

 

$(7,941,311 )

 

$(7,911,858 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted net loss per common unit/share

 

$(0.20 )

 

$(0.86 )

 

$(0.75 )

 

$(2.69 )

Weighted-average basic and diluted common units/shares

 

 

12,276,394

 

 

 

4,980,306

 

 

 

10,622,277

 

 

 

2,945,351

 

 

The common unit or share equivalents that are not included in the calculation of diluted net loss per common unit or share but could potentially dilute basic earnings per share in the future are as follows:

 

 

 

As of September 30,

 

 

 

2022

 

 

2021

 

Common stock options

 

 

1,056,326

 

 

 

523,199

 

Common stock warrants

 

 

6,993,813

 

 

 

3,091,657

 

Total potentially dilutive securities

 

 

8,050,139

 

 

 

3,614,856

 
Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard-setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2022
Summary of Significant Accounting Policies  
Schedule of earnings per share, basic and diluted

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$(2,424,586 )

 

$(1,712,920 )

 

$(7,941,311 )

 

$(5,349,621 )

Deemed dividend upon redemption of 5,221,156 shares of Series 1c convertible preferred stock

 

$-

 

 

$269,038

 

 

$-

 

 

$269,038

 

Deemed dividend upon amendment of the terms to the

Series 1d convertible preferred stock

 

$-

 

 

$2,293,199

 

 

$-

 

 

$2,293,199

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to common stockholders

 

$(2,424,586 )

 

$(4,275,157 )

 

$(7,941,311 )

 

$(7,911,858 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted net loss per common unit/share

 

$(0.20 )

 

$(0.86 )

 

$(0.75 )

 

$(2.69 )

Weighted-average basic and diluted common units/shares

 

 

12,276,394

 

 

 

4,980,306

 

 

 

10,622,277

 

 

 

2,945,351

 
Schedule of potentially diluted basic earnings

 

 

As of September 30,

 

 

 

2022

 

 

2021

 

Common stock options

 

 

1,056,326

 

 

 

523,199

 

Common stock warrants

 

 

6,993,813

 

 

 

3,091,657

 

Total potentially dilutive securities

 

 

8,050,139

 

 

 

3,614,856

 
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Balance Sheet Details (Tables)
 9 Months Ended
Sep. 30, 2022
Balance Sheet Details  
Schedule of balance sheet details

 

 

September 30,

 

 

December 31,

 

 

 

2022

 

 

2021

 

Prepaid expenses and other current assets

 

 

 

 

 

 

Prepaid insurance

 

$806,661

 

 

$769,416

 

Prepaid research and development costs

 

 

52,100

 

 

 

-

 

Prepaid other

 

 

36,413

 

 

 

-

 

Interest receivable

 

 

12,893

 

 

 

-

 

Deferred offering costs

 

 

-

 

 

 

55,718

 

Total prepaid expenses and other current assets

 

$908,067

 

 

$825,134

 

 

 

 

 

 

 

 

 

 

Accrued and other current liabilities

 

 

 

 

 

 

 

 

Accrued research and development costs

 

$633,293

 

 

$235,384

 

Accrued compensation and benefits

 

 

317,089

 

 

 

766,207

 

Accrued legal fees

 

 

13,801

 

 

 

-

 

Accrued board compensation

 

 

55,625

 

 

 

-

 

Accrued other

 

 

773

 

 

 

-

 

Total accrued and other current liabilities

 

$1,020,581

 

 

$1,001,591

 
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity Incentive Plan (Tables)
 9 Months Ended
Sep. 30, 2022
Equity Incentive Plan  
Weighted-average assumptions used for the stock option grants

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Grant date fair value

 

$0.45

 

 

$4.54

 

 

$1.46

 

 

$4.87

 

Risk-free rate

 

 

2.9%

 

 

0.98%

 

 

1.5%

 

 

0.92%

Dividend yield

 

 

0.00%

 

 

0.00%

 

 

0.0%

 

 

0.00%

Expected life in years

 

 

6.1

 

 

 

5.8

 

 

 

5.4

 

 

 

5.7

 

Expected volatility

 

 

132%

 

 

125%

 

 

123%

 

 

122%
Schedule of stock-based compensation expense

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Research and development

 

$54,907

 

 

$30,075

 

 

$163,417

 

 

$310,046

 

General and administrative

 

 

180,076

 

 

 

112,580

 

 

 

546,018

 

 

 

1,106,645

 

 

 

$234,983

 

 

$142,655

 

 

$709,435

 

 

$1,416,691

 
Schedule of stock option activity

 

 

Number of

Options

Outstanding

 

 

Weighted-

Average

Exercise

Price

 

 

Weighted-

Average

Remaining

Contractual

Term (in

Years)

 

Balance at December 31, 2021

 

 

523,199

 

 

$5.84

 

 

 

8.8

 

Options granted

 

 

533,127

 

 

 

1.75

 

 

 

-

 

Options exercised

 

 

-

 

 

 

-

 

 

 

-

 

Options cancelled

 

 

-

 

 

 

-

 

 

 

-

 

Balance at September 30, 2022

 

 

1,056,326

 

 

$3.77

 

 

 

8.5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options exercisable at September 30, 2022

 

 

586,100

 

 

$4.32

 

 

 

8.6

 
Schedule of restricted stock unit

 

 

Number of

RSU’s outstanding

 

Balance at December 31, 2021

 

 

-

 

RSUs granted

 

 

127,726

 

RSUs settled

 

 

-

 

RSUs cancelled

 

 

-

 

Balance at September 30, 2022

 

 

127,726

 
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Basis of Presentation (Details Narrative) - USD ($)
 1 Months Ended 9 Months Ended 12 Months Ended
Aug. 17, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Accumulated deficit   $ (43,900,000)    
Total cash   8,100,000    
Common Stock Exercise Price $ 7.00      
Net Cash Used In Operation   $ 7,000,000.0   $ 5,700,000
Sale of stock 2,571,428      
Conversion of stock 65,823,015      
Warrant exercise price   $ 7.00    
Common stock outstanding   12,102,214   8,328,629
Conversion of stock amount   $ 0 $ 6,582  
Convertible Notes [Member]        
Conversion of stock 32,219      
Accrued interest $ 5,434      
Conversion of stock amount $ 175,000      
Initial Public Offering [Member]        
Sale of stock 2,571,428      
Warrant exercise price $ 7.00      
Warrants to purchase one share of common stock 2,571,428      
Combined Offering Price $ 7.00      
Common stock outstanding 1,911,009      
Incremental number of warrants issued at IPO 385,714      
Option exercise price $ 7.00      
Gross Proceeds from warrants purchase of common stock $ 15,400,000      
Issuance costs $ 2,600,000      
Common Stock [Member]        
Conversion of stock 3,813,973      
Series 1a Preferred Stock        
Conversion of stock 1,419,228      
Warrants exercisable into common stock 69,212      
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Summary of Significant Accounting Policies (Details)                
Net Loss $ (2,424,586) $ (2,730,573) $ (2,786,151) $ (1,712,920) $ (1,331,792) $ (2,304,908) $ (7,941,311) $ (5,349,621)
Deemed dividend upon redemption of 5,221,156 shares of Series 1c convertible preferred stock 0     269,038     0 269,038
Deemed dividend upon amendment of the terms to the Series 1d convertible preferred stock 0     2,293,199     0 2,293,199
Net loss attributable to common stockholders $ (2,424,586)     $ (4,275,157)     $ (7,941,311) $ (7,911,858)
Basic and diluted net loss per common unit/share $ (0.20)     $ (0.86)     $ (0.75) $ (2.69)
Weighted-average basic and diluted common units/shares 12,276,394     4,980,306     10,622,277 2,945,351
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies (Details 1) - shares
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Total potentially dilutive securities 8,050,139 3,614,856
Stock Option [Member]    
Total potentially dilutive securities 1,056,326 523,199
Common Stock Warrants [Member]    
Total potentially dilutive securities 6,993,813 3,091,657
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Summary of Significant Accounting Policies (Details)    
Deferred offering costs $ 2,600  
Deferred Financing Costs   $ 60
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Balance Sheet Details (Details) - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Deferred offering costs $ 2,600,000  
Total prepaid expenses and other current assets 908,067 $ 825,134
Accrued other 1,020,581 1,001,591
Balance Sheet [Member]    
Prepaid insurance 806,661 769,416
Prepaid research and development costs 52,100 0
Prepaid other 36,413 0
Interest receivable 12,893 0
Prepaid external development costs 52,100  
Deferred offering costs 0 5,571,800,000
Total prepaid expenses and other current assets 908,067 825,134
Accrued research and development costs 633,293 235,384
Accrued compensation and benefits 317,089 766,207
Accrued legal fees 13,801 0
Accrued board compensation 55,625 0
Accrued other 773 0
Total accrued and other current liabilities 1,020,581 1,001,591
Total prepaid expenses $ 398,543 $ 825,134
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Subordinated Convertible Promissory Notes (Details Narrative) - USD ($)
 1 Months Ended 9 Months Ended
Aug. 31, 2021
Aug. 17, 2021
Jan. 27, 2021
Oct. 31, 2020
Sep. 30, 2021
Mar. 15, 2021
Subordinated convertible promissory notes       $ 3,000,000    
Notes payable       1,145,000    
Notes payable related parties     $ 1,255,000 1,730,000    
Notes payable non related parties     $ 311,000 $ 125,000    
Maturity date     Dec. 31, 2021 Jul. 17, 2021    
Bear interest rate       4.00%    
20% Discount rate for preferred shares     $ 10,000,000      
Stock converted   5,379,247        
Discount       20.00%    
Series A            
Proceeds from Series A financing       $ 10,000,000    
Net of debt discount costs       $ 28,301    
Amortized debt discount costs         $ 14,126  
Minimum            
Increase convertible promissory notes     $ 3,000,000      
Maximum            
Discount     20.00%      
Increase convertible promissory notes     $ 5,000,000      
Notes Payable [Member]            
Discount 20.00%          
Debt conversion amount converted $ 180,434          
Debt conversion converted instrument shares issued 32,219          
Series 1d Preferred Stock            
Notes payable           $ 4,391,000
Interest payable           $ 73,801
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
LongTerm Debt (Details Narrative) - USD ($)
 1 Months Ended 2 Months Ended 9 Months Ended
Mar. 31, 2021
Feb. 28, 2021
Feb. 28, 2017
Feb. 28, 2021
Sep. 30, 2022
Sep. 30, 2021
Mar. 24, 2021
Dec. 31, 2020
Dec. 31, 2016
Non-refundable amendment fee $ 100,000       $ 100,000        
Long term debt         $ 12,280        
Final Principal Payment       $ 231,482          
Final Payment   $ 225,000              
Amendment fee $ 100,000                
Payments for its long-term debt           $ 556,482      
Exercise price per share         $ 7.00        
Series 1a Preferred Units                  
Warrant units to purchase stocks                 1,250,000
Exercise price per share         $ 20.50   $ 20.50    
Loan and Security Agreement with Silicon Valley Bank                  
Non-refundable amendment fee         $ 100,000        
Final Principal Payment       $ 231,482          
Final Payment   $ 225,000              
Proceeds from borrowing     $ 2,500,000            
Bearing interest prime rate (percentage)     1.50%         3.25%  
Estimated fair value of warrant units     $ 104,630            
Loan and Security Agreement with Silicon Valley Bank | Series 1a Preferred Units                  
Estimated fair value of warrant units     $ 104,630            
Warrant units to purchase stocks     187,978            
Exercise price per share     $ 1.00            
Provision for final payment     $ 225,000            
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity Securities (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jul. 12, 2021
Jun. 29, 2021
Mar. 15, 2021
Jun. 14, 2019
Apr. 25, 2022
Aug. 31, 2021
Aug. 17, 2021
Mar. 31, 2021
Mar. 24, 2021
Oct. 31, 2020
Jun. 30, 2020
May 31, 2020
Nov. 30, 2016
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2016
Jun. 30, 2022
Aug. 14, 2021
Jul. 31, 2021
Jul. 30, 2021
Jul. 01, 2021
Jun. 30, 2021
Mar. 23, 2021
Dec. 31, 2020
Mar. 31, 2020
Jun. 30, 2019
Mar. 31, 2017
Feb. 28, 2017
Dec. 31, 2015
Common stock, shares available for issuances   593,340                                             1,648,213                
Pre-funded warrants to purchase common share         2,875,000                                                        
Common stock, shares issued                             6,906,244                                    
Net consideration                             $ 6,833,877                                    
Evergreen provision resulted in increase                             83,286                                    
Increasing shares authorized for issuance                             1,731,499             250,000,000                      
Common stock outstanding                             12,102,214   8,328,629                                
Common stocks, authorized                             90,000,000   90,000,000         90,000,000                      
Warrant outstanding                             2,957,142                                    
Warrants, expire date                             August 17, 2026                                    
Conversion price per share                             $ 0.80                                    
Fair value price per share                             $ 0.52                                    
Preferred unit interest rate                             8                                    
Preferred stock, Conversion of Stock, Shares Converted             65,823,015                                                    
Common stock, shares issued                             12,102,214   8,328,629                                
Exercise price per share                             $ 7.00                                    
Description of difference The Company compared the fair value of the Series 1d Preferred Stock, as amended, to its carrying value and recorded the resulting difference of approximately $2.3 million as a deemed dividend for the Series 1d preferred shareholders.                                                                
Deemed dividend                           $ 1,200,000     $ 2,300,000                                
Preferred units, issued                                               5,221,156   5,221,156              
Stock-based compensation expense                             $ 709,435 $ 1,416,691                                  
Debt Conversion, Converted Instrument, Principal Amount                   $ 1,145,000                                              
Proceeds from issuance of warrant                             $ 87 $ 0                                  
stock-based compensation expense                 $ 849,564               $ 400,000                                
Board of Directors                                                                  
Percentages of initial public per share offering price                             80.00%                                    
Description of reverse split   1-for-20.5 reverse split                                                              
Common Warrants                                                                  
Warrant outstanding                             69,212                                    
Exercise price per share                             $ 20.50                                    
Fair value Exercise price per share                             $ 0.52                                    
Exercisable warrant outstanding                             69,212                                    
Warrants, issued           69,212                                                      
Underwriter IPO Warrants                                                                  
Warrants, expire date                             August 17, 2026                                    
Fair value Exercise price per share                             $ 0.52                                    
Exercisable warrant outstanding                             128,571                                    
Warrants sold to purchase share of common stock           128,571                 128,571                                    
Warrants sold to purchase share of common stock, Exercise price Percentage of public offering price           115.00%                                                      
Warrants sold to purchase share of common stock, Exercise price           $ 8.05                 $ 8.05                                    
Series 1d Preferred Stock                                                                  
Conversion price per share               $ 0.83           $ 0.83                                      
Preferred units, issued               686,742           686,742                                      
Proceeds from issuance of preferred units               $ 570,000                                                  
Subordinated convertible promissory notes interest     $ 73,801                                                            
Subordinated convertible promissory notes     $ 4,391,000                                                            
Subordinated convertible promissory notes converted into shares units     5,379,247                                                            
Series 1a Preferred Units                                                                  
Common stock outstanding                                                       5,018,750          
Preferred stock, Conversion of Stock, Shares Converted           1,419,228                                                      
Exercise price per share                 $ 20.50           20.50                                    
Preferred units, issued                                       5,000,000                          
Proceeds from issuance of preferred units                                       $ 5,000,000                          
Warrant units to purchase stocks                                       1,250,000                          
Warrants exercised                     18,750                                            
Consideration of warrants exercised                     $ 18,750                                            
Common Stock, Conversion of Stock, Warrant Exercisable           69,212                                                      
Series 1c Preferred Units                                                                  
Common stock outstanding                                                       46,553,188          
Preferred units, issued                                                           5,221,156      
Net of issuance costs                                   $ 25,857                              
Financing from current and new investors       $ 5,785,000                                                          
Cash proceeds                                   5,535,000                              
Cash received from conversion of convertible note issued                                   $ 150,000                              
Accrued interest on the convertible note       1,487                                                          
Remaining balance committed to financing payable amount       $ 250,000             125,000 $ 125,000                                          
Common Stock and Preferred Stock                                                                  
Common stock outstanding                                             1,911,009                    
Exercise price per share         $ 0.0001     $ 5.74           $ 5.74                                      
Fair value Exercise price per share                             $ 0.52                                    
PIPE Common Stock, Conversion of Stock, Shares Issued                             3,773,585                                    
Common Stock, Conversion of Stock, Shares Issued           3,813,973                                                      
Underwriters' discounts and offering expenses         $ 700,000   $ 2,600,000                                                    
Preferred and common stock par value per share                 $ 0.0001                                                
Common stock, shares sold         898,585 2,571,428 2,571,428                                                    
Pre funded         2,875,000                   2,000,000           875,000                        
Pre funded outstanding                             2,000,000                                    
Warrants sold to purchase one share of common stock           2,957,142 2,571,428               3,773,585                                    
Warrants sold to purchase one share of common stock, Exercise price         $ 1.325   $ 7.00               $ 1.325                                    
Offering price             7.00                                                    
Options exercised to purchase additional warrants, Exercise price             $ 7.00                                                    
Proceeds from issuance initial public offering         $ 4,300,000   $ 15,400,000                                                    
Common Stock and Preferred Stock | Convertible Promissory Notes                                                                  
Debt Conversion, Converted Instrument, Principal Amount           $ 175,000                                                      
Common Stock, Conversion of Stock, Shares Issued           32,219                                                      
Debt Conversion, Converted Instrument, Accrued Interest           $ 5,434                                                      
Class B Common Units                                                                  
Common stock outstanding                                                       1,767,477          
Common units issued               22,494           22,494                           133,953 2,439        
Common units issued consideration                                                       $ 2,853          
Common units issued as profits interest                                                       365,245          
Thresholds price per share minimum                                                       $ 0.001          
Class B common unit issued                                                       1,268,279          
Thresholds price per share maximum                                                       $ 0.36          
Class B Common Units | Warrants [Member]                                                                  
Warrant outstanding                             65,303                                    
Exercise price per share     $ 0.52         $ 5.74           $ 5.74 $ 5.74                                    
Stock-based compensation expense                           $ 279,812                                      
Fair value Exercise price per share                             $ 0.52                                    
Exercisable warrant outstanding                             65,303                                    
Conversion of stock units into warrants, shares issued               65,303                                                  
Common and Pre-Funded Warrants [Member]                                                                  
Exercise price per share                             $ 0.0001                                    
Common stock, shares sold                             898,585                                    
Pre funded outstanding                             2,000,000                                    
Warrants sold to purchase one share of common stock                             3,773,585                                    
Warrants sold to purchase one share of common stock, Exercise price                             $ 1.325                                    
Offering price                             $ 1.325                                    
Outstanding                             3,773,585                                    
Exercise price                             $ 1.325                                    
Series 1b Preferred Units                                                                  
Preferred units, issued                                     6,500,000                            
Proceeds from issuance of preferred units                                     $ 6,500,000                            
Net of issuance costs                                     $ 40,405                            
Common units issued                                                       1,268,279          
Estimated fair value of common stock issued                                                       $ 2,340,000          
Series 1b Preferred Units | Warrants [Member]                                                                  
Exercise price per share               $ 5.74           $ 5.74                                      
Preferred units, issued                                       5,000,000                          
Proceeds from issuance of warrant               $ 65,303         $ 5,000,000                                        
Consideration of warrants exercised                     $ 18,750                                            
Net issuance cost                                       $ 19,868                          
Stock units, fair value                                       618,801                          
Description of warrant                         up to an aggregate number of Series 1a Preferred Units not to exceed the product of 25% and the aggregate number of Series 1a Preferred Units then held by such Series 1a Preferred Member, which was 1,231,250 units at December 31, 2020. The exercise price for each Warrant Unit was $1.00, subject to adjustment for unit splits and combinations. The warrants had a 5-year term.                                        
stock-based compensation expense               $ 279,812                                                  
Warrants, fair value                                       $ 4,381,199                          
Warrants, exercised during period                     18,750                                            
Class A Common Units                                                                  
Common units issued                                                                 508,777
Consideration                                                                 $ 10,430
Loan and Security Agreement with Silicon Valley Bank | Series 1a Preferred Units                                                                  
Exercise price per share                                                               $ 1.00  
Warrant units to purchase stocks                                                               187,978  
License Agreement | Villani, Inc                                                                  
Preferred units, issued                                                             1.0    
Preferred Units, surrendered                                               5,221,156                  
Carrying value             730,962                                                    
Deemed dividend             $ 269,038               $ 269,038                                    
Loan and Security Agreement | Series 1a Preferred Units                                                                  
Exercise price per share                                                     $ 1.00            
Warrant units to purchase stocks                                                     187,978            
IPO | Warrants [Member]                                                                  
Warrant outstanding                             2,957,142                                    
Warrant units to purchase stocks             2,957,142                                                    
Fair value Exercise price per share                             $ 0.52                                    
Common stock, shares sold             2,571,428                                                    
Warrants sold to purchase one share of common stock             2,571,428                                                    
Warrants sold to purchase one share of common stock, Exercise price             $ 7.00                                                    
Exercisable warrant outstanding                             2,957,142                                    
Exercise price             7.00               $ 7.00                                    
Offering price             $ 7.00                                                    
Additional shares of warrant             385,714                                                    
Closing trading price             $ 0.9995                                                    
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity Incentive Plan (Details) - Stock Option [Member] - $ / shares
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Grant date fair value $ 0.45 $ 4.54 $ 1.46 $ 4.87
Risk-free interest rate 2.90% 0.98% 1.50% 0.92%
Dividend yield 0.00% 0.00% 0.00% 0.00%
Expected life in years 6.1 5.8 5.4 5.7
Expected volatility 132.00% 125.00% 123.00% 122.00%
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity Incentive Plan (Details 1) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Mar. 24, 2021
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Stock-based compensation expense $ 1,339,993 $ 234,983 $ 142,655 $ 163,417 $ 1,416,691
Research and development          
Stock-based compensation expense   54,907 30,075 546,018 310,046
General and administrative          
Stock-based compensation expense   $ 180,076 $ 112,580 $ 709,435 $ 1,106,645
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity Incentive Plan (Details 2) - Stock Option [Member] - $ / shares
 9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Number of Options Outstanding, Beginning balance 523,199  
Number of Options Outstanding, Options granted 533,127  
Number of Options Outstanding, Ending balance 1,056,326 523,199
Number of Options Outstanding, Options exercisable 586,100  
Weighted-Average Exercise Price, Beginning balance $ 5.84  
Weighted-Average Exercise Price, Options granted 1.75  
Weighted-Average Exercise Price, Options exercised 0  
Weighted-Average Exercise Price, Options cancelled 0  
Weighted-Average Exercise Price, Ending balance 3.77 $ 5.84
Weighted-Average Exercise Price, Options exercisable $ 4.32  
Weighted-Average Remaining Contractual Term (in Years) 8 years 7 months 6 days 8 years 9 months 18 days
Weighted-Average Remaining Contractual Term (in Years), Options exercisable 8 years 6 months  
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity Incentive Plan (Details 3) - RSU's outstanding [Member]
 9 Months Ended
Sep. 30, 2022
shares
Restricted stock unit, granted 127,726
Balance at September 30, 2022, Ending balance 127,726
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity Incentive Plan (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Mar. 24, 2021
Sep. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Unrecognized stock based compensation expenses   $ 385     $ 385    
Stock-based compensation expense $ 849,564           $ 400,000
Class B Common Units profits interests converted due to the conversion from an LLC to a C-Corporation 277,448            
Class B Common Units profits interests converted into options 277,448            
Additional shares reserved for future issuance   547,447     547,447    
Incremental stock-based compensation expense $ 1,339,993 $ 234,983   $ 142,655 $ 163,417 $ 1,416,691  
Weighted-Average Recognized Remaining Contractual Term (in Years)         2 years 6 months    
Stock-based compensation expense         $ 709,435 $ 1,416,691  
Common share, authorized   80,589     80,589    
Common stock, authorized   250,000,000     250,000,000   90,000,000
RSU's outstanding [Member] | Director [Member]              
Stock-based compensation expense     $ 100,000   $ 100,000.0    
Stock compensation for services     80,589   127,726    
2021 Omnibus Equity Incentive Plan [Member]              
Unrecognized stock based compensation expense   $ 1,100,000     $ 1,100,000    
fair market value         100.00%    
Stock awards granted, exercisable period         10 years    
Common stock, authorized   1,731,499     1,731,499    
Stock awards granted, vesting period         four years for employees and one year for directors of the Company’s board and consultants    
Common stock traded price   $ 0.52     $ 0.52    
Minimum              
Class B Common Units profits interests converted into options, exercise price $ 6.314            
Maximum              
Class B Common Units profits interests converted into options, exercise price $ 5.74            
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
License Agreements (Details Narrative) - USD ($)
 1 Months Ended
Jul. 30, 2021
Mar. 31, 2017
Jun. 30, 2021
Preferred units, issued 5,221,156   5,221,156
License Agreement (Second Amendment) | Villani, Inc      
Payments made to related party after IPO closed $ 1,000,000    
Future milestone payments payable upon the achievement of specified development and sales milestones $ 4,050,000    
License Agreements | Villani, Inc      
Preferred units, issued   5,221,156  
Outstanding loan forgiven   $ 400,000  
Percentage of fully diluted capitalization   5.00%  
Proceeds from stock issued   $ 730,962  
Maximum future milestone payments   $ 202,500  
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies (Details Narrative)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
USD ($)
Minimum  
Additional Research And Development Expense $ 10
Maximum  
Additional Research And Development Expense $ 20
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Parties (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Oct. 31, 2020
Mar. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Related Parties        
Subordinated convertible promissory notes $ 1,145,000      
DividendsPreferredStock     $ 120,000 $ 230,000
Convertible promissory notes   $ 1,255,000   $ 1,255,000
XML 47 drma_10q_htm.xml IDEA: XBRL DOCUMENT 0001853816 2022-01-01 2022-09-30 0001853816 2020-01-01 2020-03-31 0001853816 2020-01-01 2020-12-31 0001853816 srt:MinimumMember 2022-01-01 2022-09-30 0001853816 srt:MaximumMember 2022-01-01 2022-09-30 0001853816 drma:LicenseAgreementSecondAmendmentMember drma:VillaniIncMember 2021-07-30 0001853816 drma:LicenseAgreementSecondAmendmentMember drma:VillaniIncMember 2021-07-07 2021-07-30 0001853816 drma:LicenseAgreementsMember drma:VillaniIncMember 2017-03-01 2017-03-31 0001853816 drma:LicenseAgreementsMember drma:VillaniIncMember 2017-03-31 0001853816 2021-07-30 0001853816 srt:MinimumMember 2021-03-24 0001853816 srt:MaximumMember 2021-03-24 0001853816 drma:TwoThousandTwentyOneOmnibusEquityIncentivePlanMember 2022-01-01 2022-09-30 0001853816 us-gaap:RestrictedStockUnitsRSUMember drma:DirectorsMember 2022-01-01 2022-09-30 0001853816 2021-03-01 2021-03-24 0001853816 us-gaap:RestrictedStockUnitsRSUMember drma:DirectorsMember 2022-01-01 2022-03-31 0001853816 drma:TwoThousandTwentyOneOmnibusEquityIncentivePlanMember 2022-09-30 0001853816 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001853816 us-gaap:StockOptionMember 2021-01-01 2021-12-31 0001853816 us-gaap:StockOptionMember 2022-09-30 0001853816 us-gaap:StockOptionMember 2021-12-31 0001853816 drma:GeneralandadministrativeMember 2021-01-01 2021-09-30 0001853816 drma:GeneralandadministrativeMember 2022-01-01 2022-09-30 0001853816 drma:GeneralandadministrativeMember 2021-07-01 2021-09-30 0001853816 drma:GeneralandadministrativeMember 2022-07-01 2022-09-30 0001853816 drma:ResearchanddevelopmentMember 2021-01-01 2021-09-30 0001853816 drma:ResearchanddevelopmentMember 2021-07-01 2021-09-30 0001853816 drma:ResearchanddevelopmentMember 2022-07-01 2022-09-30 0001853816 drma:ResearchanddevelopmentMember 2022-01-01 2022-09-30 0001853816 us-gaap:StockOptionMember 2021-07-01 2021-09-30 0001853816 us-gaap:StockOptionMember 2022-07-01 2022-09-30 0001853816 drma:BoardOfDirectorsMember 2021-06-27 2021-06-29 0001853816 drma:BoardOfDirectorsMember 2022-09-30 0001853816 drma:LicenseAgreementMember drma:VillaniIncMember 2021-08-01 2021-08-17 0001853816 drma:LicenseAgreementMember drma:VillaniIncMember 2022-01-01 2022-09-30 0001853816 drma:LicenseAgreementMember drma:VillaniIncMember 2021-08-17 0001853816 drma:LicenseAgreementMember drma:VillaniIncMember 2021-07-30 0001853816 drma:UnderwriterIPOWarrantsMember 2021-08-31 0001853816 drma:WarrantsMember drma:SeriesOneBPreferredUnitsMember 2021-03-01 2021-03-31 0001853816 drma:WarrantsMember drma:SeriesOneBPreferredUnitsMember 2016-11-01 2016-11-30 0001853816 drma:SeriesOneDPreferredStockMember 2021-03-13 2021-03-15 0001853816 drma:CommonWarrantsMember 2021-08-31 0001853816 drma:WarrantsMember drma:ClassBCommonUnitsMember 2021-03-01 2021-03-31 0001853816 drma:WarrantsMember drma:ClassBCommonUnitsMember 2021-01-01 2021-03-31 0001853816 drma:ClassBCommonUnitsMember 2021-03-31 0001853816 drma:ClassBCommonUnitsMember 2020-03-31 0001853816 drma:ClassACommonUnitsMember 2015-12-31 0001853816 drma:SeriesOneBPreferredUnitsMember 2020-12-31 0001853816 drma:CommonStockAndPreferredStockMember 2022-06-30 0001853816 drma:CommonStockAndPreferredStockMember 2021-08-17 0001853816 drma:CommonStockAndPreferredStockMember 2021-08-31 0001853816 drma:CommonStockAndPreferredStockMember 2021-03-24 0001853816 drma:CommonStockAndPreferredStockMember 2022-04-01 2022-04-25 0001853816 drma:CommonStockAndPreferredStockMember 2021-08-01 2021-08-17 0001853816 drma:ConvertiblePromissoryNotesMember drma:CommonStockAndPreferredStockMember 2021-08-01 2021-08-31 0001853816 drma:CommonStockAndPreferredStockMember 2021-08-01 2021-08-31 0001853816 drma:CommonStockAndPreferredStockMember 2022-01-01 2022-09-30 0001853816 drma:SeriesOneCPreferredUnitsMember 2020-06-01 2020-06-30 0001853816 drma:SeriesOneCPreferredUnitsMember 2020-05-01 2020-05-31 0001853816 drma:SeriesOneCPreferredUnitsMember 2019-06-01 2019-06-14 0001853816 drma:SeriesOneCPreferredUnitsMember 2019-12-31 0001853816 drma:SeriesOneCPreferredUnitsMember 2019-06-14 0001853816 drma:SeriesOneCPreferredUnitsMember 2019-01-01 2019-12-31 0001853816 drma:WarrantsMember drma:SeriesOneBPreferredUnitsMember 2016-01-01 2016-12-31 0001853816 drma:WarrantsMember drma:SeriesOneBPreferredUnitsMember 2020-06-01 2020-06-30 0001853816 drma:SeriesOneAPreferredUnitsMember 2020-06-01 2020-06-30 0001853816 drma:SeriesOneDPreferredStockMember 2021-03-01 2021-03-31 0001853816 drma:SeriesOneBPreferredUnitsMember 2018-01-01 2018-12-31 0001853816 drma:SeriesOneAPreferredUnitsMember 2016-01-01 2016-12-31 0001853816 drma:LicenseAgreementMember drma:VillaniIncMember 2017-03-31 0001853816 drma:SeriesOneCPreferredUnitsMember 2019-06-30 0001853816 drma:SeriesOneBPreferredUnitsMember 2018-12-31 0001853816 drma:SeriesOneAPreferredUnitsMember 2016-12-31 0001853816 drma:WarrantsMember drma:SeriesOneBPreferredUnitsMember 2016-12-31 0001853816 drma:WarrantsMember drma:IPOsMember 2021-08-17 0001853816 2021-07-10 2021-07-12 0001853816 drma:CommonandPreFundedWarrantsMember 2022-09-30 0001853816 drma:WarrantsMember drma:SeriesOneBPreferredUnitsMember 2021-03-31 0001853816 drma:SeriesOneAPreferredUnitsMember 2022-09-30 0001853816 drma:WarrantsMember drma:ClassBCommonUnitsMember 2021-03-31 0001853816 drma:WarrantsMember drma:ClassBCommonUnitsMember 2021-03-15 0001853816 drma:CommonStockAndPreferredStockMember 2022-09-30 0001853816 drma:SeriesOneAPreferredUnitsMember 2021-03-24 0001853816 drma:CommonStockAndPreferredStockMember 2022-04-25 0001853816 drma:LoanAndSecurityAgreementMember drma:SeriesOneAPreferredUnitsMember 2021-03-23 0001853816 drma:CommonStockAndPreferredStockMember 2021-03-31 0001853816 drma:SeriesOneAPreferredUnitsMember 2021-08-01 2021-08-31 0001853816 drma:SeriesOneDPreferredStockMember 2021-03-31 0001853816 drma:UnderwriterIPOWarrantsMember 2022-01-01 2022-09-30 0001853816 drma:UnderwriterIPOWarrantsMember 2022-09-30 0001853816 drma:CommonWarrantsMember 2022-09-30 0001853816 drma:WarrantsMember drma:ClassBCommonUnitsMember 2022-09-30 0001853816 drma:WarrantsMember drma:IPOsMember 2022-09-30 0001853816 drma:ClassBCommonUnitsMember 2020-12-31 0001853816 drma:CommonStockAndPreferredStockMember 2021-07-31 0001853816 drma:SeriesOneCPreferredUnitsMember 2020-12-31 0001853816 drma:SeriesOneAPreferredUnitsMember 2020-12-31 0001853816 2021-08-14 0001853816 2022-04-01 2022-04-25 0001853816 2021-07-01 0001853816 2021-06-29 0001853816 drma:LoanAndSecurityAgreementWithSiliconValleyBankMember 2021-02-01 2021-02-28 0001853816 drma:LoanAndSecurityAgreementWithSiliconValleyBankMember 2021-01-01 2021-02-28 0001853816 drma:LoanAndSecurityAgreementWithSiliconValleyBankMember drma:SeriesOneAPreferredUnitsMember 2017-02-01 2017-02-28 0001853816 drma:LoanAndSecurityAgreementWithSiliconValleyBankMember drma:SeriesOneAPreferredUnitsMember 2017-02-28 0001853816 drma:LoanAndSecurityAgreementWithSiliconValleyBankMember 2020-12-31 0001853816 drma:LoanAndSecurityAgreementWithSiliconValleyBankMember 2017-02-28 0001853816 drma:LoanAndSecurityAgreementWithSiliconValleyBankMember 2022-09-30 0001853816 drma:LoanAndSecurityAgreementWithSiliconValleyBankMember 2017-02-01 2017-02-28 0001853816 2021-03-01 2021-03-31 0001853816 2021-02-01 2021-02-28 0001853816 2021-01-01 2021-02-28 0001853816 us-gaap:SeriesAMember 2021-01-01 2021-09-30 0001853816 us-gaap:SeriesAMember 2020-10-01 2020-10-31 0001853816 us-gaap:SeriesAMember 2020-10-31 0001853816 srt:MinimumMember 2021-01-01 2021-01-27 0001853816 srt:MaximumMember 2021-01-01 2021-01-27 0001853816 us-gaap:NotesPayableOtherPayablesMember 2021-08-01 2021-08-31 0001853816 2021-01-01 2021-01-27 0001853816 2020-10-01 2020-10-31 0001853816 2021-01-27 0001853816 drma:SeriesOneDPreferredStockMember 2021-03-15 0001853816 2020-10-31 0001853816 drma:BalanceSheetMember 2021-12-31 0001853816 drma:BalanceSheetMember 2022-09-30 0001853816 drma:CommonStockWarrantsMember 2022-01-01 2022-09-30 0001853816 us-gaap:StockOptionMember 2022-01-01 2022-09-30 0001853816 drma:CommonStockWarrantsMember 2021-01-01 2021-09-30 0001853816 us-gaap:StockOptionMember 2021-01-01 2021-09-30 0001853816 us-gaap:ConvertibleNotesPayableMember 2021-08-17 0001853816 drma:InitialPublicOfferingMember 2021-08-17 0001853816 drma:SeriesOneAPreferredStockMember 2021-08-01 2021-08-17 0001853816 us-gaap:ConvertibleNotesPayableMember 2021-08-01 2021-08-17 0001853816 drma:CommonShareMember 2021-08-01 2021-08-17 0001853816 drma:InitialPublicOfferingMember 2021-08-01 2021-08-17 0001853816 2021-01-01 2021-12-31 0001853816 2021-08-01 2021-08-17 0001853816 us-gaap:RetainedEarningsMember 2022-09-30 0001853816 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001853816 us-gaap:CommonStockMember 2022-09-30 0001853816 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001853816 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001853816 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001853816 2022-06-30 0001853816 us-gaap:RetainedEarningsMember 2022-06-30 0001853816 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001853816 us-gaap:CommonStockMember 2022-06-30 0001853816 2022-04-01 2022-06-30 0001853816 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001853816 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001853816 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001853816 2022-03-31 0001853816 us-gaap:RetainedEarningsMember 2022-03-31 0001853816 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001853816 us-gaap:CommonStockMember 2022-03-31 0001853816 2022-01-01 2022-03-31 0001853816 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001853816 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001853816 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001853816 us-gaap:RetainedEarningsMember 2021-12-31 0001853816 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001853816 us-gaap:CommonStockMember 2021-12-31 0001853816 2021-09-30 0001853816 us-gaap:RetainedEarningsMember 2021-09-30 0001853816 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001853816 drma:SeriesOnePreferredMember 2021-09-30 0001853816 drma:CommonClassesBMember 2021-09-30 0001853816 drma:CommonClassesAMember 2021-09-30 0001853816 us-gaap:CommonStockMember 2021-09-30 0001853816 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001853816 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001853816 drma:PreferredStockWarrantsMember 2021-07-01 2021-09-30 0001853816 us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0001853816 drma:SeriesOneDPreferredMember 2021-07-01 2021-09-30 0001853816 drma:SeriesOneCPreferredMember 2021-07-01 2021-09-30 0001853816 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001853816 drma:SeriesOneBPreferredMember 2021-07-01 2021-09-30 0001853816 drma:SeriesOneAWarrantsMember 2021-07-01 2021-09-30 0001853816 drma:SereiesOneAPreferredMember 2021-07-01 2021-09-30 0001853816 drma:SeriesOnePreferredMember 2021-07-01 2021-09-30 0001853816 drma:CommonClassesBMember 2021-07-01 2021-09-30 0001853816 drma:CommonClassesAMember 2021-07-01 2021-09-30 0001853816 2021-06-30 0001853816 us-gaap:RetainedEarningsMember 2021-06-30 0001853816 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001853816 drma:PreferredStockWarrantsMember 2021-06-30 0001853816 us-gaap:PreferredStockMember 2021-06-30 0001853816 drma:SeriesOneDPreferredMember 2021-06-30 0001853816 drma:SeriesOneCPreferredMember 2021-06-30 0001853816 drma:SeriesOneBPreferredMember 2021-06-30 0001853816 drma:SeriesOneAWarrantsMember 2021-06-30 0001853816 drma:SereiesOneAPreferredMember 2021-06-30 0001853816 drma:SeriesOnePreferredMember 2021-06-30 0001853816 drma:CommonClassesBMember 2021-06-30 0001853816 drma:CommonClassesAMember 2021-06-30 0001853816 us-gaap:CommonStockMember 2021-06-30 0001853816 2021-04-01 2021-06-30 0001853816 drma:PreferredStockWarrantsMember 2021-04-01 2021-06-30 0001853816 us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0001853816 drma:SeriesOneDPreferredMember 2021-04-01 2021-06-30 0001853816 drma:SeriesOneCPreferredMember 2021-04-01 2021-06-30 0001853816 drma:SeriesOneBPreferredMember 2021-04-01 2021-06-30 0001853816 drma:SeriesOneAWarrantsMember 2021-04-01 2021-06-30 0001853816 drma:SereiesOneAPreferredMember 2021-04-01 2021-06-30 0001853816 drma:SeriesOnePreferredMember 2021-04-01 2021-06-30 0001853816 drma:CommonClassesBMember 2021-04-01 2021-06-30 0001853816 drma:CommonClassesAMember 2021-04-01 2021-06-30 0001853816 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001853816 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001853816 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001853816 2021-03-31 0001853816 us-gaap:RetainedEarningsMember 2021-03-31 0001853816 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001853816 drma:PreferredStockWarrantsMember 2021-03-31 0001853816 us-gaap:PreferredStockMember 2021-03-31 0001853816 drma:SeriesOneDPreferredMember 2021-03-31 0001853816 drma:SeriesOneCPreferredMember 2021-03-31 0001853816 drma:SeriesOneBPreferredMember 2021-03-31 0001853816 drma:SeriesOneAWarrantsMember 2021-03-31 0001853816 drma:SereiesOneAPreferredMember 2021-03-31 0001853816 drma:SeriesOnePreferredMember 2021-03-31 0001853816 drma:CommonClassesBMember 2021-03-31 0001853816 drma:CommonClassesAMember 2021-03-31 0001853816 us-gaap:CommonStockMember 2021-03-31 0001853816 2021-01-01 2021-03-31 0001853816 drma:PreferredStockWarrantsMember 2021-01-01 2021-03-31 0001853816 us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001853816 drma:SeriesOneDPreferredMember 2021-01-01 2021-03-31 0001853816 drma:SeriesOneCPreferredMember 2021-01-01 2021-03-31 0001853816 drma:SeriesOneBPreferredMember 2021-01-01 2021-03-31 0001853816 drma:SeriesOneAWarrantsMember 2021-01-01 2021-03-31 0001853816 drma:SereiesOneAPreferredMember 2021-01-01 2021-03-31 0001853816 drma:SeriesOnePreferredMember 2021-01-01 2021-03-31 0001853816 drma:CommonClassesBMember 2021-01-01 2021-03-31 0001853816 drma:CommonClassesAMember 2021-01-01 2021-03-31 0001853816 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001853816 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001853816 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001853816 2020-12-31 0001853816 us-gaap:RetainedEarningsMember 2020-12-31 0001853816 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001853816 drma:PreferredStockWarrantsMember 2020-12-31 0001853816 us-gaap:PreferredStockMember 2020-12-31 0001853816 drma:SeriesOneDPreferredMember 2020-12-31 0001853816 drma:SeriesOneCPreferredMember 2020-12-31 0001853816 drma:SeriesOneBPreferredMember 2020-12-31 0001853816 drma:SeriesOneAWarrantsMember 2020-12-31 0001853816 drma:SereiesOneAPreferredMember 2020-12-31 0001853816 drma:SeriesOnePreferredMember 2020-12-31 0001853816 drma:CommonClassesBMember 2020-12-31 0001853816 drma:CommonClassesAMember 2020-12-31 0001853816 us-gaap:CommonStockMember 2020-12-31 0001853816 2021-01-01 2021-09-30 0001853816 2021-07-01 2021-09-30 0001853816 2022-07-01 2022-09-30 0001853816 2021-12-31 0001853816 2022-09-30 0001853816 2022-11-10 0001853816 drma:WarrantsMember 2022-01-01 2022-09-30 iso4217:USD shares iso4217:USD shares pure 0001853816 false --12-31 Q3 2022 false 0.0001 12102214 8328629 7.00 52100 398543 825134 225000 100000 104630 231482 2875000 5018750 46553188 90000000 65303 5.74 1.00 0.52 0.52 5.74 2300000 1200000 5221156 187978 2571428 2000000 7.00 279812 0 87 100000.0 80589 1255000 10-Q true 2022-09-30 001-40739 DERMATA THERAPEUTICS, INC. DE 86-3218736 3525 Del Mar Heights Rd 322 San Diego CA 92130 858 800-2543 Common Stock, $0.0001 Par Value DRMA NASDAQ Common Stock Purchase Warrants DRMAW NASDAQ Yes Yes Non-accelerated Filer true true true false 12102214 8066822 10798806 908067 825134 8974889 11623940 483741 515245 1020581 1001591 1504322 1516836 0.0001 250000000 12102214 90000000 8328629 1210 833 51392942 46088546 -43923585 -35982275 7470567 10107104 8974889 11623940 1553295 799779 4761686 2347564 892777 912490 3201111 2956444 2446072 1712269 7962797 5304008 -2446072 -1712269 -7962797 -5304008 -21486 651 -21486 45613 -2424586 -1712920 -7941311 -5349621 0 269038 0 269038 0 2293199 0 2293199 -2424586 -4275157 -7941311 -7911858 -0.20 -0.86 -0.75 -2.69 12276394 4980306 10622277 2945351 8328629 833 46088546 -35982275 10107104 0 531566 0 531566 0 0 -2786151 -2786151 8328629 833 46620112 -38768426 7852519 898585 90 4276275 0 4276365 875000 87 0 0 87 0 55625 0 55625 0 205947 0 205947 0 0 -2730573 -2730573 10102214 1010 51157959 -41498999 9659970 2000000 200 0 0 200 0 55625 0 55625 0 179358 0 179358 0 0 -2424586 -2424586 12102214 1210 51392942 -43923585 7470567 508777 10430 1767477 2342853 6906244 6833877 5018750 4380081 1419228 723431 6500000 4119595 0 0 0 0 -22494 0 0 0 0 0 -508777 -10430 -1744983 -2342853 0 0 0 0 0 0 -6906244 -6833877 -5018750 -4380081 0 -6500000 -4119595 0 0 0 0 -1419228 -723431 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 46553188 6491592 -28079798 -3177939 6065989 5034801 5034801 1911009 191 2353092 -46553188 -6491592 -6065989 -5034801 71044171 7104 26852842 0 0 0 1419228 142 0 723289 0 0 0 0 0 0 0 1160049 0 1160049 0 0 0 0 0 0 -2304908 -2304908 0 0 71044171 7104 1419228 142 1911009 191 31089272 -30384706 712003 0 0 0 0 0 113987 0 113987 0 0 0 0 0 0 -1331792 -1331792 0 0 71044171 7104 1419228 142 1911009 191 31203259 -31716498 -505802 0 0 -5221156 -522 0 0 -999478 0 -1000000 0 0 -65823015 -6582 0 3813973 381 6200 0 0 0 0 0 -1419228 -142 0 142 0 0 0 0 0 0 32219 3 180430 0 180434 0 0 0 0 2571428 257 15385932 0 15386189 0 0 0 0 0 142655 0 142655 0 0 0 0 0 0 -1712920 -1712920 0 0 0 0 8328629 833 45919140 -33429418 12490555 -7941311 -5349621 709435 1416691 0 14126 82933 1007393 -31504 665587 337677 371127 -7008636 -3889483 4276365 15386189 287 0 0 -1000000 0 -556482 0 1562717 0 570000 4276652 15962424 -2731984 12072941 10798806 530400 8066822 12603341 0 1420 800 1400 0 29936660 0 4464801 0 2293199 0 180434 0 6582 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1. Organization and Basis of Presentation </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Dermata Therapeutics, Inc., (the “Company”), was formed in December 2014 as a Delaware limited liability company (“LLC”) under the name Dermata Therapeutics, LLC. On March 24, 2021, the Company converted from an LLC to a Delaware C-corporation and changed its name to Dermata Therapeutics, Inc. Any references in these Notes to Financial Statements to equity securities as “units” refer to pre-conversion equity securities and any references to “shares” or “stock” in these Notes to Financial Statements refer to post-conversion equity securities. The Company is a clinical-stage biotechnology company focused on the treatment of medical and aesthetic skin conditions and diseases.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Initial Public Offering</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On August 17, 2021, the Company completed its initial public offering (“IPO”), in which it sold 2,571,428 shares of its common stock together with 2,571,428 warrants to purchase one share of common stock with an exercise price of $7.00 per share, at a combined offering price of $7.00. Additionally, the underwriters exercised their option to purchase an additional 385,714 warrants to purchase common stock with an exercise price of $7.00 per share. The Company received net cash proceeds of approximately $15.4 million from the IPO after deducting underwriters’ discounts and offering expenses of approximately $2.6 million. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Each of the following occurred in connection with the completion of the IPO in August 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">-</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The sale of 2,571,428 shares of common stock along with 2,957,142 warrants to purchase common stock.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">-</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The conversion of 65,823,015 shares of convertible preferred stock into an aggregate of 3,813,973 shares of common stock.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">-</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The conversion of $175,000 principal amount of outstanding convertible promissory notes and accrued interest of $5,434 into 32,219 shares of common stock.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">-</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The conversion of 1,419,228 Series 1a preferred warrants into 69,212 warrants exercisable into common stock.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Each purchaser in the IPO received one share of common stock and one warrant to purchase one share of common stock at a combined offering price of $7.00. Each warrant to purchase common stock entitles the holder to purchase one share of common stock, are immediately exercisable, and expire five years from the date of issuance. The Company evaluated the terms of the warrants issued and determined that they should be classified as equity instruments. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company’s shares of common stock and warrants are listed on the Nasdaq Stock Market LLC under the symbols “DRMA,” and “DRMAW,” respectively, and both began trading in August 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">After the IPO, there were no shares of preferred stock or preferred stock warrants outstanding. Prior to the IPO, the Company had 1,911,009 shares of common stock outstanding after giving effect for the Company’s reverse stock split in July 2021. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Reverse Stock Split</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On July 1, 2021, the Company effected a reverse split of shares of the Company’s common stock at a ratio of 1-for-20.5 pursuant to an amendment to the Company’s certificate of incorporation approved by the Company’s board of directors and stockholders. The par value was not adjusted as a result of the reverse split. All issued and outstanding common stock shares and per share amounts contained in the financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented, and the conversion ratios for the Company’s outstanding preferred stock was adjusted accordingly. See Note 6 – Equity Securities for additional information.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Liquidity and Going Concern Uncertainty</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Since its inception, the Company has devoted substantially all of its resources to research and development activities and has not generated any revenue or commercialized any product candidates. As of September 30, 2022, cash and cash equivalents totaled $8.1 million and the Company had an accumulated deficit of $43.9 million. For the nine months ended September 30, 2022 and the year ended December 31, 2021, the Company used cash of $7.0 million and $5.7 million, respectively, in operations. The Company’s cash balances are expected to fund operations into the third quarter of 2023. The Company anticipates that it will continue to incur net losses for the foreseeable future. These factors raise substantial doubt about the Company’s ability to continue as a going concern for the one-year period following the date that these financial statements were issued.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Historically, the Company’s principal sources of cash have included proceeds from the issuance of common and preferred equity units and proceeds from the issuance of debt. The Company’s principal uses of cash have included cash used in operations and payments for license rights. The Company expects that the principal uses of cash in the future will be for continuing operations, funding of research and development, conducting preclinical studies and clinical trials, and general working capital requirements. The Company expects that as research and development expenses continue to grow, it will need to raise additional capital to sustain operations and research and development. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Management’s Plan to Continue as a Going Concern</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">To continue as a going concern, the Company will need, among other things, to raise additional capital resources. Until the Company can generate significant cash from operations, management’s plans to obtain such resources for the Company include proceeds from offerings of the Company’s equity securities or debt, or transactions involving product development, technology licensing or collaboration. Management can provide no assurance that any sources of a sufficient amount of financing or collaboration agreements will be available to the Company on favorable terms, if at all. Additionally, the COVID-19 pandemic continues to evolve and has already disrupted global financial markets. The Company’s ability to raise additional capital may be adversely impacted by potential worsening of global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the pandemic. If the disruption persists or deepens, the Company could experience an inability to access additional capital. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company has raised additional capital through the initial public offering of its common stock and warrants and through a private placement financing; however, management’s current plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Basis of Presentation</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, the accompanying financial statements reflect all adjustments (consisting of normal recurring adjustments) that are necessary for a fair statement of the financial position, results of operations, cash flows, and stockholders’ equity for the interim periods presented. Interim results are not necessarily indicative of results for a full year. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ materially from those estimates.</p> 2571428 2571428 7.00 7.00 385714 7.00 15400000 2600000 2571428 2957142 65823015 3813973 175000 5434 32219 1419228 69212 7.00 1911009 8100000 -43900000 7000000.0 5700000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>2. Summary of Significant Accounting Policies</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Use of Estimates</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company’s financial statements are prepared in accordance with GAAP. The preparation of the Company’s financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, including those related to accrued research and development expenses, stock-based compensation, and the estimated fair values of equity instruments. Management evaluates its estimates on an ongoing basis. The Company bases its estimates on various assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Segment Information</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company’s chief operating decision maker view the Company’s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceuticals. The Company operates in only one segment.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Deferred Financing Costs</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company capitalizes certain legal, accounting, and other fees and costs that are directly attributable to in-process equity financings as deferred offering costs until such financings are completed. Upon the completion of an equity financing, these costs are recorded as a reduction of additional paid-in capital of the related offering. Upon the completion of the IPO in August 2021, approximately $2.6 million of offering costs related to the IPO were reclassified to additional paid-in capital. As of December 31, 2021, the Company had deferred financing costs of $0.06 million and as of September 30, 2022, the Company had no deferred financing costs. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Cash and Cash Equivalents</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company deposits its cash with reputable financial institutions that are insured by the Federal Deposit Insurance Corporation (“FDIC”). This cash is held in checking, cash sweep, and money market accounts. At times, deposits held may exceed the amount of insurance provided by the FDIC. The Company maintains an insured cash sweep account in which cash from its main operating checking account is invested overnight in highly liquid, short-term investments. The Company considers all highly liquid investments with a maturity date of 90 days or less at the date of purchase to be cash equivalents. The Company has not experienced any losses in its cash and cash equivalents and believes they are not exposed to significant credit risk.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Fair Value Measurement</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company believes the carrying amount of cash and cash equivalents, accounts payable, accrued expenses and debt approximate their estimated fair values due to the short-term maturities of these financial instruments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Interest Income</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Interest income consists of interest income earned on cash equivalents from interest bearing demand accounts. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Patent Costs</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">                Patent costs related to obtaining and maintaining patent protection in both the United States and other countries are expensed as incurred. Patents costs are classified as general and administrative expenses. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Research and Development</strong></em> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Research and development costs consist of expenses incurred in connection with the development of the Company’s product candidates. Such expenses include expenses incurred under agreements with contract research organizations, manufacturing and supply scale-up expenses and the cost of acquiring and manufacturing preclinical and clinical trial supply, outsourced laboratory services, including materials and supplies used to support the Company’s research and development activities, and payments made for license fees and milestones that have not been demonstrated to have commercial value. Such costs are expensed in the periods in which they are incurred. Upfront payments and milestone payments for licensed technology are expensed as research and development as incurred or when the milestone is achieved or is determined to be probable of being achieved. Advanced payments for goods or services to be received in the future for research and development activities are recorded as prepaid expenses and expensed as the related goods are received or services are performed. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Income Taxes</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">From inception until March 24, 2021, the Company operated as a limited liability company taxed as a partnership. Therefore, any income tax liability or benefit through that date accrued to the Company’s members. Since March 24, 2021, the Company has operated as a C-Corporation and accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Stock-Based Compensation</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In March 2021, the Company’s board of directors and shareholders approved the 2021 Omnibus Equity Incentive Plan (“the 2021 Plan”). For stock options granted under the 2021 Plan, the Company measures and recognizes compensation expense for all stock-based awards made to employees, directors, and non-employees, based on estimated fair values recognized using the straight-line method over the requisite service period. The fair value of options to purchase common stock granted to employees is estimated on the grant date using the Black-Scholes valuation model. The calculation of stock-based compensation expense requires that the Company make certain assumptions and judgments about variables used in the Black-Scholes model, including the expected term of the stock-based award, expected volatility of the underlying common stock, dividend yield, and the risk-free interest rate. Forfeitures are accounted for in the period they occur. Restricted stock units (“RSUs”) granted under the 2021 Plan are measured at the grant date fair value of the common stock, with corresponding compensation expense recognized ratably over the requisite service period. Refer to Note 7- Equity Incentive Plan for further discussion. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Comprehensive Loss</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Comprehensive loss includes net loss and other comprehensive income (loss) for the periods presented. The Company did not have other comprehensive income (loss) items such as unrealized gains and losses and so for the three and nine months ended September 30, 2022, and September 30, 2021, comprehensive loss was equal to the net loss.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Net Loss Per Common Unit/Share</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On March 24, 2021, the Company converted from an LLC to a C-corporation. Upon the conversion, each outstanding common unit and preferred unit was converted into one share of common stock and preferred stock, respectively. Common units had similar rights and characteristics of common stock issued upon the conversion. In calculating net loss per share, the Company retrospectively applied the effects of the conversion to the number of common units outstanding prior to the conversion. Net loss per share for periods prior to the conversion to a C-corporation refers to net loss per common unit.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Basic net loss per unit/share is calculated by dividing net loss attributable to common unitholders or shareholders by the weighted-average number of units or shares outstanding during the period, contingently issuable restricted stock units for which no future service is required as a condition to the delivery of the underlying common stock, and pre-funded warrants because their exercise requires only nominal consideration for the delivery of shares (collectively, “basic shares”), without consideration of common unit or share equivalents. Diluted net loss per unit or share is calculated by adjusting basic shares outstanding for the dilutive effect of common unit or share equivalents outstanding for the period. For purposes of the diluted net loss per unit or share calculation, preferred units or shares, profit interests, and warrants to purchase preferred units or shares are considered to be common unit or share equivalents but are excluded from the calculation of diluted net loss per common unit or share if their effect would be anti-dilutive. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">As the Company has reported a net loss for the periods presented, diluted net loss per common unit or share is the same as the basic net loss per common unit or share for the periods presented. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine Months Ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(2,424,586 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(1,712,920 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(7,941,311 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(5,349,621 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deemed dividend upon redemption of 5,221,156 shares of Series 1c convertible preferred stock </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">269,038</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">269,038</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deemed dividend upon amendment of the terms to the </p><p style="font-size:10pt;font-family:times new roman;margin:0px">Series 1d convertible preferred stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,293,199</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,293,199</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss attributable to common stockholders</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(2,424,586 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(4,275,157 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(7,941,311 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(7,911,858 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Basic and diluted net loss per common unit/share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.20 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.86 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.75 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(2.69 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted-average basic and diluted common units/shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">12,276,394</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,980,306</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">10,622,277</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,945,351</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The common unit or share equivalents that are not included in the calculation of diluted net loss per common unit or share but could potentially dilute basic earnings per share in the future are as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>As of September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Common stock options</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,056,326</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">523,199</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Common stock warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,993,813</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,091,657</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total potentially dilutive securities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,050,139</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,614,856</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Recent Accounting Pronouncements</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard-setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company’s financial statements are prepared in accordance with GAAP. The preparation of the Company’s financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, including those related to accrued research and development expenses, stock-based compensation, and the estimated fair values of equity instruments. Management evaluates its estimates on an ongoing basis. The Company bases its estimates on various assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company’s chief operating decision maker view the Company’s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceuticals. The Company operates in only one segment.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company capitalizes certain legal, accounting, and other fees and costs that are directly attributable to in-process equity financings as deferred offering costs until such financings are completed. Upon the completion of an equity financing, these costs are recorded as a reduction of additional paid-in capital of the related offering. Upon the completion of the IPO in August 2021, approximately $2.6 million of offering costs related to the IPO were reclassified to additional paid-in capital. As of December 31, 2021, the Company had deferred financing costs of $0.06 million and as of September 30, 2022, the Company had no deferred financing costs. </p> 2600000 60000.00 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company deposits its cash with reputable financial institutions that are insured by the Federal Deposit Insurance Corporation (“FDIC”). This cash is held in checking, cash sweep, and money market accounts. At times, deposits held may exceed the amount of insurance provided by the FDIC. The Company maintains an insured cash sweep account in which cash from its main operating checking account is invested overnight in highly liquid, short-term investments. The Company considers all highly liquid investments with a maturity date of 90 days or less at the date of purchase to be cash equivalents. The Company has not experienced any losses in its cash and cash equivalents and believes they are not exposed to significant credit risk.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company believes the carrying amount of cash and cash equivalents, accounts payable, accrued expenses and debt approximate their estimated fair values due to the short-term maturities of these financial instruments.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Interest income consists of interest income earned on cash equivalents from interest bearing demand accounts. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">                Patent costs related to obtaining and maintaining patent protection in both the United States and other countries are expensed as incurred. Patents costs are classified as general and administrative expenses. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Research and development costs consist of expenses incurred in connection with the development of the Company’s product candidates. Such expenses include expenses incurred under agreements with contract research organizations, manufacturing and supply scale-up expenses and the cost of acquiring and manufacturing preclinical and clinical trial supply, outsourced laboratory services, including materials and supplies used to support the Company’s research and development activities, and payments made for license fees and milestones that have not been demonstrated to have commercial value. Such costs are expensed in the periods in which they are incurred. Upfront payments and milestone payments for licensed technology are expensed as research and development as incurred or when the milestone is achieved or is determined to be probable of being achieved. Advanced payments for goods or services to be received in the future for research and development activities are recorded as prepaid expenses and expensed as the related goods are received or services are performed. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">From inception until March 24, 2021, the Company operated as a limited liability company taxed as a partnership. Therefore, any income tax liability or benefit through that date accrued to the Company’s members. Since March 24, 2021, the Company has operated as a C-Corporation and accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In March 2021, the Company’s board of directors and shareholders approved the 2021 Omnibus Equity Incentive Plan (“the 2021 Plan”). For stock options granted under the 2021 Plan, the Company measures and recognizes compensation expense for all stock-based awards made to employees, directors, and non-employees, based on estimated fair values recognized using the straight-line method over the requisite service period. The fair value of options to purchase common stock granted to employees is estimated on the grant date using the Black-Scholes valuation model. The calculation of stock-based compensation expense requires that the Company make certain assumptions and judgments about variables used in the Black-Scholes model, including the expected term of the stock-based award, expected volatility of the underlying common stock, dividend yield, and the risk-free interest rate. Forfeitures are accounted for in the period they occur. Restricted stock units (“RSUs”) granted under the 2021 Plan are measured at the grant date fair value of the common stock, with corresponding compensation expense recognized ratably over the requisite service period. Refer to Note 7- Equity Incentive Plan for further discussion. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Comprehensive loss includes net loss and other comprehensive income (loss) for the periods presented. The Company did not have other comprehensive income (loss) items such as unrealized gains and losses and so for the three and nine months ended September 30, 2022, and September 30, 2021, comprehensive loss was equal to the net loss.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On March 24, 2021, the Company converted from an LLC to a C-corporation. Upon the conversion, each outstanding common unit and preferred unit was converted into one share of common stock and preferred stock, respectively. Common units had similar rights and characteristics of common stock issued upon the conversion. In calculating net loss per share, the Company retrospectively applied the effects of the conversion to the number of common units outstanding prior to the conversion. Net loss per share for periods prior to the conversion to a C-corporation refers to net loss per common unit.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Basic net loss per unit/share is calculated by dividing net loss attributable to common unitholders or shareholders by the weighted-average number of units or shares outstanding during the period, contingently issuable restricted stock units for which no future service is required as a condition to the delivery of the underlying common stock, and pre-funded warrants because their exercise requires only nominal consideration for the delivery of shares (collectively, “basic shares”), without consideration of common unit or share equivalents. Diluted net loss per unit or share is calculated by adjusting basic shares outstanding for the dilutive effect of common unit or share equivalents outstanding for the period. For purposes of the diluted net loss per unit or share calculation, preferred units or shares, profit interests, and warrants to purchase preferred units or shares are considered to be common unit or share equivalents but are excluded from the calculation of diluted net loss per common unit or share if their effect would be anti-dilutive. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">As the Company has reported a net loss for the periods presented, diluted net loss per common unit or share is the same as the basic net loss per common unit or share for the periods presented. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine Months Ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(2,424,586 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(1,712,920 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(7,941,311 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(5,349,621 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deemed dividend upon redemption of 5,221,156 shares of Series 1c convertible preferred stock </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">269,038</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">269,038</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deemed dividend upon amendment of the terms to the </p><p style="font-size:10pt;font-family:times new roman;margin:0px">Series 1d convertible preferred stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,293,199</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,293,199</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss attributable to common stockholders</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(2,424,586 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(4,275,157 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(7,941,311 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(7,911,858 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Basic and diluted net loss per common unit/share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.20 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.86 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.75 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(2.69 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted-average basic and diluted common units/shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">12,276,394</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,980,306</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">10,622,277</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,945,351</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The common unit or share equivalents that are not included in the calculation of diluted net loss per common unit or share but could potentially dilute basic earnings per share in the future are as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>As of September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Common stock options</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,056,326</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">523,199</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Common stock warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,993,813</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,091,657</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total potentially dilutive securities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,050,139</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,614,856</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine Months Ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(2,424,586 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(1,712,920 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(7,941,311 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(5,349,621 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deemed dividend upon redemption of 5,221,156 shares of Series 1c convertible preferred stock </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">269,038</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">269,038</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deemed dividend upon amendment of the terms to the </p><p style="font-size:10pt;font-family:times new roman;margin:0px">Series 1d convertible preferred stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,293,199</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,293,199</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss attributable to common stockholders</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(2,424,586 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(4,275,157 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(7,941,311 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(7,911,858 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Basic and diluted net loss per common unit/share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.20 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.86 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.75 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(2.69 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted-average basic and diluted common units/shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">12,276,394</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,980,306</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">10,622,277</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,945,351</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> -2424586 -1712920 -7941311 -5349621 0 269038 0 269038 0 2293199 0 2293199 -2424586 -4275157 -7941311 -7911858 0.20 0.86 0.75 2.69 12276394 4980306 10622277 2945351 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>As of September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Common stock options</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,056,326</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">523,199</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Common stock warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,993,813</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,091,657</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total potentially dilutive securities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,050,139</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,614,856</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 1056326 523199 6993813 3091657 8050139 3614856 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard-setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>3. Balance Sheet Details</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The following provides certain balance sheet details:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Prepaid expenses and other current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Prepaid insurance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">806,661</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">769,416</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Prepaid research and development costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">52,100</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Prepaid other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36,413</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Interest receivable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,893</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deferred offering costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">55,718</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total prepaid expenses and other current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">908,067</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">825,134</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued and other current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued research and development costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">633,293</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">235,384</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued compensation and benefits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">317,089</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">766,207</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued legal fees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,801</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued board compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">55,625</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">773</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total accrued and other current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,020,581</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,001,591</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Prepaid expenses and other current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Prepaid insurance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">806,661</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">769,416</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Prepaid research and development costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">52,100</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Prepaid other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36,413</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Interest receivable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,893</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deferred offering costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">55,718</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total prepaid expenses and other current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">908,067</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">825,134</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued and other current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued research and development costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">633,293</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">235,384</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued compensation and benefits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">317,089</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">766,207</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued legal fees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,801</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued board compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">55,625</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">773</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total accrued and other current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,020,581</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,001,591</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 806661 769416 52100 0 36413 0 12893 0 0 5571800000 908067 825134 633293 235384 317089 766207 13801 0 55625 0 773 0 1020581 1001591 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>4. Subordinated Convertible Promissory Notes</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In July and October 2020, the Company issued an aggregate of $3,000,000 of subordinated convertible promissory notes (the “Notes”). Notes in the amount of $1,145,000 were issued to existing investors who are also related parties (See Note 11 - Related Parties), $1,730,000 were issued to existing investors who are not related parties and notes in the amount of $125,000 were issued to new investors. The Notes bore interest at 4% per annum and were to mature on July 17, 2021. The Notes were subordinated to the Company’s long-term debt and were convertible into a qualified Series A financing of at least $10 million at a 20% discount to the lowest price per unit paid by investors for that financing. Under authoritative accounting guidance, this contingent beneficial conversion feature was to be measured and recognized when the contingency is resolved. The Notes were recorded upon issuance net of debt discount costs of $28,301. The Company recognized $14,126 of amortized debt discount costs during the nine months ended September 30, 2021. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On January 27, 2021, the Company amended the terms of the Notes to increase the maximum amount of convertible promissory notes to be issued from $3,000,000 to $5,000,000, to allow for the conversion of the convertible promissory notes into shares of common stock upon a Qualified Initial Public Offering with aggregate gross proceeds to the Company of at least $10,000,000 at a 20% discount to the lowest price per share paid by investors for that financing and to extend the maturity date to December 31, 2021. In connection with this amendment, Notes in the amount of $1,255,000 were issued to existing investors who are also related parties (See Note 11 - Related Parties) and $311,000 were issued to existing investors who are not related parties.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In March 2021, the Company further amended the terms of the Notes to allow for the conversion of the Notes into Series 1d Preferred Units at the same price as purchasers of Series 1d Preferred Units. As of March 15, 2021, $4,391,000 of the Notes, along with related interest of $73,801, were converted to 5,379,247 Series 1d Preferred Units. Since the Notes did not convert at a discount, there was no beneficial conversion feature.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company considers the above modification of the Notes in March 2021 to be a substantial modification requiring extinguishment accounting under Accounting Standards Codification (“ASC”) 470-50-40-10. Based upon an independent valuation of the reacquisition price of the Notes, the difference between the reacquisition price and the net carrying amount of the Notes immediately prior to the modification is not material to the financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In connection with the Company’s IPO in August 2021, the outstanding principal of the Notes and accrued interest totaling $180,434 converted into 32,219 shares of common stock. Upon this conversion, since the conversion contained a 20% discount, the Company measured the beneficial conversion feature and determined that it was not material to the financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">As of December 31, 2021, and September 30, 2022, the Company had no promissory notes outstanding. </p> 3000000 1145000 1730000 125000 0.04 2021-07-17 10000000 0.20 28301 14126 3000000 5000000 10000000 0.20 2021-12-31 1255000 311000 4391000 73801 5379247 180434 32219 0.20 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>5. Long-Term Debt</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In February 2017, the Company entered into a Loan and Security Agreement with Silicon Valley Bank (“SVB”) whereas SVB agreed to provide term loans to the Company in two tranches. The first tranche of $2,500,000 was drawn in February 2017 and bore interest at a rate of 1.5% above the prime rate, which was 3.25% as of December 31, 2020, with principal and interest payable monthly through February 9, 2021. The second tranche was not utilized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In connection with the Loan and Security Agreement, SVB also received warrant units to purchase, at any time after February 9, 2017 and prior to February 9, 2027, 187,978 Series 1a Preferred Units or the equivalent Series A Preferred Units had they purchased Series 1a Preferred Units, if Series A Preferred Units are issued, at a price of $1.00 per unit. The estimated fair value of these warrant units of $104,630 (See Note 6 – Equity Securities), as well as costs associated with the term loan, including provision for a final payment of $225,000, were recorded as a discount to outstanding debt and amortized to interest expense utilizing the effective interest method over the underlying term of the loan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In June 2019, the Company and SVB entered into a First Amendment to the Loan and Security Agreement whereby if the Company did not achieve certain capital milestones by December 1, 2019, term loan principal payments would be deferred from December 21, 2019 through May 1, 2020 with the deferred principal payments being payable in equal monthly installments, in addition to those principal payments already scheduled to be paid, starting on June 1, 2020 and extending through the February 9, 2021 maturity date of the term loan. In addition, if those principal payments were deferred for that six-month period, a non-refundable amendment fee of $100,000 would be due and payable on the earliest to occur of the maturity date, the prepayment of the term loan or the occurrence of an event of default. The capital milestones were not achieved by December 1, 2019 and, therefore, the defined principal repayments were deferred.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The non-refundable amendment fee of $100,000, as well as $12,280 of costs associated with the amendment, were recorded as a discount to outstanding debt and were amortized to interest expense utilizing the effective interest method over the remaining underlying term of the loan. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In January and February 2021, the Company paid the final principal payments of $231,482 under the SVB Loan and Security Agreement. The Company also paid the final payment fee of $225,000 in February 2021 and the amendment fee of $100,000 in March 2021. For the nine months ended September 30, 2021, the Company paid a total of $556,482 to SVB as final payments for its long-term debt. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">As of December 31, 2021, and September 30, 2022, the Company had no long-term debt outstanding.</p> 2500000 0.015 0.0325 187978 1.00 104630 225000 100000 100000 12280 231482 225000 100000 556482 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>6. Equity Securities </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Common Stock and Preferred Stock</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On March 24, 2021, the Company entered into a Plan of Conversion (“Conversion”) whereby the Company converted from an LLC under the laws of the State of Delaware to a Delaware C-corporation with the name Dermata Therapeutics, Inc. In connection with the Conversion, each fully paid preferred and common unit in the LLC was converted into a like number of shares of preferred and common stock of the Company with a par value of $0.0001 per share. The Shares issued had the same rights, preferences and privileges that had accrued to the pre-converted Units. Any references in these Notes to Financial Statements to equity securities as “units” refer to pre-conversion equity securities and any references to “shares” or “stock” in these Notes to Financial Statements refer to post-conversion equity securities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On July 1, 2021, the Company effected a reverse split of shares of the Company’s common stock at a ratio of 1-for-20.5 pursuant to an amendment to the Company’s certificate of incorporation approved by the Company’s board of directors and stockholders. The par value was not adjusted as a result of the reverse split. All issued and outstanding common stock share and per share amounts contained in the financial statements have been retroactively adjusted to reflect this reverse split for all periods presented.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On August 17, 2021, the Company completed its IPO, in which it sold 2,571,428 shares of its common stock together with 2,571,428 warrants to purchase one share of common stock with an exercise price of $7.00 per share at a combined offering price of $7.00. Additionally, the underwriters exercised their option to purchase an additional 385,714 warrants with an exercise price of $7.00 per warrant. The Company received net cash proceeds of approximately $15.4 million from the IPO after deducting underwriters’ discounts and offering expenses of approximately $2.6 million. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Each of the following occurred in connection with the completion of the IPO in August 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">-</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The sale of 2,571,428 shares of common stock along with 2,957,142 warrants to purchase common stock.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">-</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The conversion of 65,823,015 shares of convertible preferred stock into an aggregate of 3,813,973 shares of common stock.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">-</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The conversion of $175,000 principal amount of outstanding convertible promissory notes and accrued interest of $5,434 into 32,219 shares of common stock.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">-</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The conversion of 1,419,228 Series 1a preferred warrants into 69,212 warrant shares exercisable into common stock.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">After the IPO, there were no shares of preferred stock or preferred stock warrants outstanding. Prior to the IPO, the Company had 1,911,009 shares of common stock outstanding after giving effect for the Company’s reverse stock split in July 2021. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On April 25, 2022, the Company closed a private placement (“PIPE”), in which it sold 898,585 shares of its common stock together with 2,875,000 pre-funded warrants to purchase one share of common stock with an exercise price of $0.0001 per share (“Pre-funded Warrant”), and 3,773,585 warrants to purchase one share of common stock with an exercise price of $1.325 per share (“PIPE Common Warrant”) at a combined offering price of $1.325. The Company received net cash proceeds of approximately $4.3 million from the PIPE after deducting underwriters’ discounts and offering expenses of approximately $0.7 million. The PIPE Common Warrant related to this private placement will expire on May 12, 2027. During the quarter ended June 30, 2022, 875,000 of the Pre-funded Warrants were exercised. Further, during the quarter ended September 30, 2022, 2,000,000 of the Pre-funded Warrants were exercised. No Pre-Funded Warrants were outstanding as of September 30, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company’s total common stock issued and outstanding was 12,102,214 and 8,328,629 shares as of September 30, 2022, and December 31, 2021, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Series 1 Preferred Units</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">From the Company’s formation on December 8, 2014 through 2016, the Company issued 6,906,244 Series 1 Preferred Units for net consideration of $6,833,877. The Company’s Series 1 Preferred Units were converted to preferred stock during the first quarter of 2021. Additionally, in August 2021, the Company converted all preferred stock into common stock. No Series 1 Preferred Units were outstanding as of December 31, 2021 and September 30, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Series 1a Preferred Units</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In 2016, the Company issued 5,000,000 Series 1a Preferred Units in exchange for cash of $5,000,000 and net of issuance costs of $19,868. Purchasers of the Series 1a Preferred Units also received 1,250,000 Warrant Units to purchase an additional amount of Series 1a Preferred Units. The estimated fair value of the warrant units was recorded as a separate component of members’ equity (deficit) in the accompanying balance sheet as of December 31, 2020 with an offset to the Series 1a proceeds. In June 2020, 18,750 of the warrants were exercised for consideration of $18,750, which consideration was received in July 2020. The Company’s Series 1a Preferred Units were converted to preferred stock during the first quarter of 2021. Additionally, in August 2021, the Company converted all preferred stock into common stock. No Series 1a Preferred Units were outstanding as of December 31, 2021 and September 30, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Series 1b Preferred Units</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In 2018, the Company issued 6,500,000 Series 1b Preferred Units in exchange for cash of $6,500,000 and net of issuance costs of $40,405. Purchasers of the Series 1b Preferred Units also received 1,268,279 Class B Common Units. The estimated fair value of the Class B Common units has been recorded as a component of members’ equity (deficit) in the accompanying balance sheet as of December 31, 2020 with an offset to the Series 1b proceeds. The Company’s Series 1b Preferred Units were converted to preferred stock during the first quarter of 2021. Additionally, in August 2021, the Company converted all preferred stock into common stock. No Series 1b Preferred Units were outstanding as of December 31, 2021 and September 30, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Series 1c Preferred Units</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On June 14, 2019, the Company closed participation in a $5,785,000 Series 1c financing from current and new investors. As of December 31, 2019, cash of $5,535,000, including $150,000 from the conversion of a convertible note issued to a Managing Member of the Company for a loan made to the Company, net of issuance costs of $25,857, had been received. The accrued interest on the convertible note in the amount of $1,487 was also converted into Series 1c Preferred Units. The remaining balance of $250,000 committed to the financing was paid in the amounts of $125,000 in May 2020 and $125,000 in June 2020. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In June 2019, 5,221,156 Series 1c Preferred Units were issued in connection with the settlement and license agreement, and in July 2021, the Company redeemed these units/shares in connection with an amendment to the settlement and license agreement. See Note 9 – License Agreements for more information.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company’s Series 1c Preferred Units were converted to preferred stock during the first quarter of 2021. Additionally, in August 2021, the Company converted all preferred stock into common stock. No Series 1c Preferred Units were outstanding as of December 31, 2021 and September 30, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Series 1d Preferred Units</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In March 2021, the Company issued 686,742 Series 1d Preferred Units at a cost of $0.83 per unit for total proceeds of $570,000. In addition, as described in Note 4 – Subordinated Convertible Promissory Notes, as of March 15, 2021, $4,391,000 of convertible promissory notes, along with related interest of $73,801, were converted into 5,379,247 Series 1d Preferred Units. The outstanding Series 1d Preferred Units were converted to preferred stock during the first quarter of 2021. Additionally, in August 2021, the Company converted all preferred stock into common stock. No Series 1d Preferred Units were outstanding as of December 31, 2021 and September 30, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Class A Common Units</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">During 2014 and 2015, the Company issued 508,777 Class A Common Units in exchange for consideration of $10,430. The Class A Common Units outstanding converted to common stock during the first quarter of 2021. No Class A Common Units were outstanding as of December 31, 2021 and September 30, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Class B Common Units</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company had 1,767,477 Class B Common Units outstanding as of December 31, 2020. This includes 133,953 Class B Common Units issued for consideration of $2,853 and 1,268,279 Class B Common Units issued in connection with the issuance of the Series 1b Preferred Units, which were assigned an estimated fair value of $2,340,000. The remaining 365,245 Class B Common Units were issued as a profits interest as that term is defined by Revenue Procedure 93-27, 1993-2 C.B. 343, as clarified by Revenue Procedure 2001-43, 2001-2 C.B. 191, with participation thresholds from $0.001 to $0.36. During the first quarter 2020, the Company issued 2,439 Class B Common Units, all of which represented a profits interest. During the first quarter of 2021, 22,494 Class B Common Units were forfeited as a result of employee resignations. The remaining Class B Common Units outstanding converted to common stock during the first quarter of 2021. No Class B Common Units were outstanding as of December 31, 2021 and September 30, 2022.  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Liquidation Preference</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Prior to the Company’s IPO in August 2021, the Company’s preferred units were subject to liquidation preferences contained herein. So long as there were no Series A Preferred Units outstanding at the time of a liquidity event, any liquidity event proceeds would have been distributed as follows: First, the Series 1d Preferred Units had a two times preference in liquidation over the Series 1c Preferred Units and then participated with the Series 1c, 1b and 1a Preferred Units once the Series 1c Preferred Unit preferences had been satisfied. Second, proceeds to Series 1c Preferred Unit holders sufficient to cover two times their Series 1c investment; third, proceeds to Series 1, Series 1a, Series 1b, Series 1c, and Series 1d Preferred Unit holders sufficient to cover interest at the rate of 8% per annum on the Series 1 Preferred Units, the Series 1a Preferred Units, the Series 1b Preferred Units, the Series 1c Preferred Units, and Series 1d Preferred Units; fourth, proceeds to the Series 1, Series 1a, Series 1b and Series 1c Preferred Unit holders sufficient to cover the unit value of Series 1 Preferred Units, Series 1a Preferred Units, Series 1b Preferred Units, Series 1c Preferred Units, and Series 1d Preferred Units; fifth, to Class A and Class B Common holders proceeds sufficient to cover their pro-rata portion of distributions made to Series 1, Series 1a, Series 1b, Series 1c, and Series 1d Preferred Unit holders, provided that no Class B Common Units would share in any distribution until after the point at which the amount per Class A Common Unit exceeds the amount of such Class B Common Unit’s Participation Threshold; and sixth, a pro-rata distribution of the remaining proceeds to all equity holders. Upon the issuance of Series A Preferred Units, each Series 1 Preferred Unit, each Series 1a Preferred Unit, each Series 1b Preferred Unit, each Series 1c Preferred Unit and each Series 1d Preferred Unit would have automatically converted into the number of Series A Preferred Units equal to the sum of the unit value of the Series 1, Series 1a, Series 1b, Series 1c or Series 1d Preferred Units plus all accumulated preferred return as of the conversion date that would have been due with respect to such Series 1, Series 1a, Series 1b, Series 1c or Series 1d Preferred Units in the case of a liquidity event. As of December 31, 2021 and September 30, 2022, no Series A Preferred Units had been issued, and no preferred stock remained outstanding.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Conversion Rights</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Prior to the Company’s IPO in August 2021, the Company’s preferred units were subject to conversion rights contained herein. Upon the first issuance by the Company of any Series A Preferred Units, each Series 1 Preferred Unit and each Series 1a Preferred Unit and each Series 1b Preferred Unit and each Series 1c Preferred Unit and each Series 1d Preferred Unit would have automatically been converted into the number of Series A Preferred Units equal to the sum of the Unit Value with respect to such Series 1 Preferred Unit or Series 1a Preferred Unit or Series 1b Preferred Unit or Series 1c Preferred Unit or Series 1d Preferred Unit as of the conversion date divided by the product of 0.80 multiplied by the Unit Value of the Series 1 Preferred Units or Series 1a Preferred Units or Series 1b Preferred Units or Series 1c Preferred Units or Series 1d Preferred Unit issued on the conversion date. The Series A Preferred Units issued to the Series 1 Preferred Members and Series 1a Preferred Members and Series 1b Preferred Members and Series 1c Preferred Members and Series 1d Preferred Members upon conversion of such Series 1 Preferred Units and Series 1a Preferred Units and such Series 1b Preferred Units and Series 1c Preferred Units and Series 1d Preferred Units would have had the same rights, privileges and preferences as the other Series A Preferred Units issued by the Company on the conversion date. The Company considered the classification of the Preferred Units and concluded that they were appropriately included as a component of equity since each class of Preferred Units participates in the same form of consideration received upon a change in control. As of December 31, 2021 and September 30, 2022, no preferred units or stock remained outstanding.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Stockholders’ Agreements</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On March 24, 2021, in connection with the conversion of Dermata Therapeutics, LLC into a Delaware corporation, the Company entered into a Stockholders’ Agreement (as amended, the Stockholders’ Agreement) with all of its then-existing stockholders, including Proehl Investment Ventures, LLC and Hale Biopharma Ventures, LLC. The Stockholders’ Agreement among other things, provided for certain restrictions on transfer of the Company’s shares of capital stock, set forth agreements and understandings with respect to how shares of its capital stock held by the stockholders party thereto will have been voted on, or tendered in connection with, an acquisition of the Company and provided for certain voting rights with respect to the election of directors. In addition, pursuant to the Stockholders’ Agreement, holders of the Company’s Series 1a Preferred Stock were entitled to purchase, at any time prior to March 14, 2026, such number of shares of the Company’s Series 1a Preferred Stock as such Series 1a Stockholder shall request, up to an aggregate number of shares of Series 1a Preferred Stock not to exceed the product of 25% and the aggregate number of shares Series 1a Preferred Stock then held by such Series 1a Stockholder (or the Series 1a Preferred Warrant Rights). The shares of Series 1a Preferred Stock purchased pursuant to any Series 1a Preferred Warrant Right had a per share purchase price of $20.50 (subject to appropriate adjustment in the event of any stock dividend, stock split, combination, or other similar recapitalization). Upon the consummation of the Company’s IPO of common stock, each Series 1a Preferred Stock Warrant became exercisable for the same number of shares of Common Stock with the same per share exercise price of $20.50 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination, or other similar recapitalization). The Stockholders’ Agreement would have automatically terminated upon the earliest of (a) immediately prior to the consummation of the Company’s initial public offering of common stock, and (b) the consummation of a sale of the Company, subject to certain conditions. The Company completed the IPO of common stock in August 2021, thereby terminating the Stockholders’ Agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On June 29, 2021, with effectiveness on July 1, 2021, the Company’s board of directors amended its Certificate of Incorporation to adjust the conversion price and certain conversion mechanics of the Company’s issued and outstanding Series 1d Preferred Stock, whereby each share of Series 1d Preferred stock would convert into such number of Common Stock as determined by dividing (i) the product of (a) the Original Issue Price for the Series 1d Preferred Stock, multiplied by (b) 1.2, rounded to the nearest whole cent, by (ii) the 80% of the initial public per share offering price in the IPO. The Series 1d conversion shall not be subject to further adjustment for any stock split.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On June 29, 2021, with effectiveness on July 1, 2021, the Company’s board of directors approved an amendment to the 2021 Plan to increase the number of shares of Common Stock available for issuances from 593,340 to 1,648,213 shares. Effective January 1, 2022, an evergreen provision contained in the Company's 2021 Omnibus Equity Incentive Plan, or the 2021 Plan, added one percent of common shares outstanding as of December 31, 2021 to the 2021 Plan. This evergreen provision resulted in an increase of 83,286 shares to the 2021 Plan, increasing shares authorized for issuance under the 2021 Plan to 1,731,499 as of January 1, 2022. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On June 29, 2021, the Company’s board of directors approved a 1-for-20.5 reverse split of all outstanding shares of common stock, effected on July 1, 2021 (no fractional shares were issued). Except as otherwise noted, all references to share and per share amounts related to common stock and common units have been restated to reflect the reverse stock split.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On July 12, 2021, the Company’s board of directors amended its Certificate of Incorporation to further adjust the conversion price and certain conversion mechanics of the Company’s issued and outstanding Series 1d Preferred Stock. The two amendments to the Series 1d Preferred Stock conversion terms were combined for purposes of accounting for the amendments. In order to determine if these amendments resulted in a modification or extinguishment of the Series 1d Preferred Stock, pursuant to the related authoritative guidance, the Company engaged an independent third-party valuation firm to assist with determining the fair value of the Series 1d Preferred Stock immediately before the change in conversion terms, as well as immediately after the change in conversion terms. This resulted in a substantive increase in fair value, and as such, the Company determined the amendments resulted in extinguishment accounting. Accordingly, the Company applied ASC 260, Earnings per Share, and ASC 470, Debt, by analogy to determine the appropriate measurement and presentation. The Company compared the fair value of the Series 1d Preferred Stock, as amended, to its carrying value and recorded the resulting difference of approximately $2.3 million as a deemed dividend for the Series 1d preferred shareholders. The Company recorded the deemed dividend to additional paid-in capital during the quarter ended September 30, 2021. Because the Company is in an accumulated deficit position, the deemed dividend increased the net loss attributable to the common shareholders for the three and nine months ended September 30, 2021. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On July 30, 2021, the Company entered into a Second Amendment to the License and Settlement Agreement (or, the Second License Amendment), whereby, for the settlement of certain disputes arising under the License Agreement, the Company agreed to exchange the shares of Series 1c Preferred Stock owned by Villani, Inc. (“Villani”) for an increase of milestone payments and royalty rates due to Villani under the License Agreement. On July 30, 2021, Villani surrendered 5,221,156 shares of Series 1c Preferred Stock to the Company and on August 17, 2021, the Company paid to Villani $1.0 million upon the close of the Company’s initial public offering for the redemption of the Series 1c shares. The Company determined that the deemed dividend to Villani for the Series 1c preferred share redemption was the difference between the $1.0 million paid for the shares and the carrying value of the shares of $730,962, resulting in a deemed dividend of $269,038. This deemed dividend of $269,038 was recorded to additional paid-in capital during the quarter ended September 30, 2021. Because the Company is in an accumulated deficit position, the deemed dividend increased the net loss attributable to common shareholders for the three and nine months ended September 30, 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On August 14, 2021, the Company’s board of directors approved an amendment to the Company’s Certificate of Incorporation to increase the number of shares of Common Stock authorized to 90,000,000. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On July 11, 2022, the Company filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to increase the number of authorized shares of the Company’s common stock from 90,000,000 shares to 250,000,000 shares. The increase in the number of authorized shares was approved by the holders of a majority of the outstanding shares of common stock of the Company at its annual meeting on July 11, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Warrants</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Warrants issued at IPO</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On August 17, 2021, the Company completed its IPO, in which it sold 2,571,428 shares of its common stock together with 2,571,428 warrants to purchase one share of common stock with an exercise price of $7.00 per share at a combined offering price of $7.00. The underwriters exercised their option to purchase an additional 385,714 warrants with an exercise price of $7.00, increasing the number of warrants issued at IPO to 2,957,142. Each warrant is immediately exercisable at the option of the holder and expires five years from the date of issuance. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company evaluated the terms of the warrants issued at the IPO and determined that they should be classified as equity instruments based upon accounting guidance provided in ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging. Since the Company determined that the warrants were equity classified, the Company recorded the proceeds from the IPO, net of issuance costs, within common stock at par value and the balance of proceeds to additional paid in capital. The fair value of each warrant on August 17, 2021 was $0.9995 based on the closing trading price on that day. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">As of September 30, 2022, the Company had 2,957,142 warrants outstanding resulting from the IPO with an exercise price of $7.00 and which expire August 17, 2026. As of September 30, 2022, the outstanding warrants are exercisable into 2,957,142 shares of common stock whose fair value was $0.52 per share, based on the closing trading price on that day.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Underwriter IPO Warrants</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Upon the closing of the Company's IPO in August 2021, the Company issued to the underwriters warrants to purchase 128,571 of shares of common stock at an exercise price equal to 115% of the public offering price, or $8.05 per share, exercisable for a period of five years, or until August 2026. As of September 30, 2022, the Company had 128,571 warrants outstanding resulting from the underwriter IPO warrants with an exercise price of $8.05 and which expire August 17, 2026. As of September 30, 2022, the outstanding warrants are exercisable for 128,571 shares of common stock whose fair value was $0.52 per share, based on the closing trading price on that day.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Warrants issued with Class B Common Units</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In March 2021, the Company granted Class B Common Units Profits interests to certain former employees and consultants. In connection with the conversion from an LLC to a C-Corporation, the Company converted 65,303 of vested Units to fully vested Common Stock Warrants with an exercise price of $5.74. These Common Stock Warrants issuances were considered a modification under ASC 718, Stock Compensation, in which the fair value of the Class B Common Units profits interests were measured at the modification date and compared to the fair value of the common stock warrants, with the difference of $279,812 recorded as stock-based compensation expense in the first quarter of 2021. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">As of September 30, 2022, the Company had 65,303 common warrants outstanding related to the prior Class B Common Units with an exercise price of $5.74 and which expire December 31, 2024. As of September 30, 2022, the outstanding warrants are exercisable into 65,303 shares of common stock whose fair value was $0.52 per share, based on the closing trading price on that day.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Warrants issued with Series 1a Preferred Units</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In connection with the issuance of 5,000,000 Series 1a Preferred Units in November 2016, each Series 1a Preferred Member received Warrant Units to purchase from the Company, at any time after November 15, 2016 and on or prior to November 15, 2021, such number of Series 1a Preferred Units as such Series 1a Preferred Member shall request, up to an aggregate number of Series 1a Preferred Units not to exceed the product of 25% and the aggregate number of Series 1a Preferred Units then held by such Series 1a Preferred Member, which was 1,231,250 units at December 31, 2020. The exercise price for each Warrant Unit was $1.00, subject to adjustment for unit splits and combinations. The warrants had a 5-year term. The Company received total proceeds of $5,000,000 for the Series 1a Preferred Units and warrants which were allocated on a relative fair value basis to the Units and warrants resulting in a relative fair value of $4,381,199 and $618,801, respectively. The estimated fair value of the Series 1a Warrant Units was recorded as a separate component of members’ equity (deficit) in the accompanying financial statements as of December 31, 2020. In June 2020, 18,750 of the warrants were exercised for consideration of $18,750, which consideration was received in July 2020.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In connection with the Loan and Security Agreement, SVB also received Warrant Units to purchase, at any time after February 9, 2017 and prior to February 9, 2027, 187,978 Series 1a Preferred Units or the equivalent Series A Preferred Units had they purchased Series 1a Preferred Units, if Series A Preferred Units are issued, at an exercise price of $1.00 per unit. On March 24, 2021, in connection with the conversion from an LLC to a C-Corporation, each warrant to purchase Series 1a Preferred Units in the LLC was automatically converted into a warrant to purchase, upon the same terms and conditions, shares of Series 1a Preferred Stock of the Company. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In July 2021, the Company effected a reverse split of shares of the Company’s common stock at a ratio of 1-for-20.5, and the conversion ratio of the preferred stock was adjusted accordingly. In August 2021, in connection with the Company’s IPO, the outstanding Series 1a preferred warrants were converted into 69,212 common warrants.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">As of September 30, 2022, the Company had 69,212 common warrants outstanding related to the prior Series 1a preferred warrants with an exercise price of $20.50 and which expire November 15, 2026. As of September 30, 2022, the outstanding warrants are exercisable into 69,212 shares of common stock whose fair value was $0.52 per share, based on the closing trading price on that day.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Common and Pre-Funded Warrants issued with PIPE</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In April 2022, the Company completed the PIPE, in which it sold 898,585 shares of its common stock together with 2,875,000 Pre-funded Warrants to purchase one share of common stock with an exercise price of $0.0001 per share, and 3,773,585 PIPE Common Warrants to purchase one share of common stock with an exercise price of $1.325 per share, at a combined offering price of $1.325. Each PIPE Common Warrant is immediately exercisable at the option of the holder and expires May 13, 2027.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">During the quarter ended June 30, 2022, 875,000 of the Pre-funded Warrants were exercised. During the quarter ended September 30, 2022, the remaining 2,000,000 Pre-funded Warrants were exercised. No additional Pre-funded Warrants are outstanding as of September 30, 2022. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">As of September 30, 2022, the Company had 3,773,585 PIPE Common Warrants outstanding with an exercise price of $1.325 and which expire May 13, 2027. As of September 30, 2022, the outstanding PIPE Common Warrants are exercisable into 3,773,585 shares of common stock whose fair value was $0.52 per share, based on the closing trading price on that day.</p> 0.0001 2571428 2571428 7.00 7.00 7.00 15400000 2600000 2957142 65823015 3813973 175000 5434 32219 1419228 69212 1911009 898585 0.0001 3773585 1.325 1.325 4300000 700000 2000000 12102214 8328629 6906244 6833877 5000000 5000000 19868 1250000 18750 18750 6500000 6500000 40405 1268279 5785000 5535000 150000 25857 1487 250000 125000 125000 5221156 686742 0.83 570000 4391000 73801 5379247 508777 10430 1767477 133953 2853 1268279 2340000 365245 0.001 0.36 2439 22494 8 0.80 20.50 20.50 0.80 593340 1648213 83286 1731499 1-for-20.5 reverse split The Company compared the fair value of the Series 1d Preferred Stock, as amended, to its carrying value and recorded the resulting difference of approximately $2.3 million as a deemed dividend for the Series 1d preferred shareholders. 5221156 1.0 730962 269038 269038 90000000 90000000 250000000 2571428 2571428 7.00 7.00 385714 7.00 2957142 0.9995 2957142 7.00 August 17, 2026 2957142 0.52 128571 1.15 8.05 128571 8.05 August 17, 2026 128571 0.52 65303 5.74 279812 65303 5.74 65303 0.52 5000000 up to an aggregate number of Series 1a Preferred Units not to exceed the product of 25% and the aggregate number of Series 1a Preferred Units then held by such Series 1a Preferred Member, which was 1,231,250 units at December 31, 2020. The exercise price for each Warrant Unit was $1.00, subject to adjustment for unit splits and combinations. The warrants had a 5-year term. 5000000 4381199 618801 18750 18750 187978 1.00 69212 69212 20.50 69212 0.52 898585 2875000 0.0001 3773585 1.325 1.325 875000 2000000 3773585 1.325 3773585 0.52 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>7. Equity Incentive Plan</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Under the Company’s 2021 Omnibus Equity Incentive Plan (the “2021 Plan”), the Company may grant options to purchase common stock, restricted stock awards, performance stock awards, incentive bonus awards, other cash-based awards or directly issue shares of common stock to employees, directors, and consultants of the Company. Effective January 1, 2022, an evergreen provision contained in the Company’s 2021 Plan increased the total number of shares of common shares issuable under the 2021 Plan in an amount equal to one percent of the Company’s common shares outstanding as of December 31, 2021. This evergreen provision resulted in an additional 83,286 common shares issuable pursuant to the 2021 Plan, increasing the total authorized shares available for issuance under the 2021 Plan to 1,731,499 as of January 1, 2022. Stock awards may be granted at an exercise price per share of not less than 100% of the fair market value at the date of grant. Stock awards granted are exercisable over a maximum term of 10 years from the date of grant and generally vest over a period of four years for employees and one year for directors of the Company’s board and consultants. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">As of September 30, 2022, there remain an additional 547,447 shares reserved for issuance under the 2021 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Fair Value Measurement</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company uses the Black-Scholes option valuation model, which requires the use of highly subjective assumptions, to determine the fair value of stock-based awards. The fair value of each employee stock option is estimated on the grant date under the fair value method using the Black-Scholes model. The estimated fair value of each stock option is then expensed over the requisite service period, which is generally the vesting period. The assumptions and estimates that the Company uses in the Black-Scholes model are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Fair Value of Common Stock.</em> The estimated fair value of the common stock underlying the Company’s stock option plan was determined by management by considering various factors as discussed below. All options to purchase shares of the Company’s common stock are intended to be exercisable at a price per share not less than the per-share fair value of the Company’s common stock underlying those options on the date of grant. In the absence of a public trading market for the Company’s common stock, before the initial public offering, on each grant date, the Company developed an estimate of the fair value of its common stock based on the information known to the Company on the date of grant, upon a review of any recent events and their potential impact on the estimated fair value per share of the common stock and in part on input from an independent third-party valuation firm. After the Company’s initial public offering, the fair value of common stock is measured as the Company’s closing price of common stock on the date of grant.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Risk-Free Interest Rate.</em> The Company bases the risk-free interest rate used in the Black-Scholes valuation model on the implied yield available on U.S. Treasury zero-coupon issues with a term equivalent to that of the expected term of the options. </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Expected Term.</em> The expected term represents the period that the Company’s stock-based awards are expected to be outstanding. Because of the limitations on the sale or transfer of the Company’s common stock as a privately held company, the Company does not believe its historical exercise pattern is indicative of the pattern it will experience as a publicly traded company. The Company plans to continue to use the SAB 110 simplified method until it has sufficient trading history as a publicly traded company. </p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Volatility.</em> The Company determines the price volatility based on the historical volatilities of industry peers as it has limited trading history for its common stock price. Industry peers consist of several public companies in the biotechnology industry with comparable characteristics, including clinical trials progress and therapeutic indications. </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Dividend Yield.</em> The expected dividend assumption is based on the Company’s current expectations about its anticipated dividend policy. To date, the Company has not declared any dividends to common shareholders, and therefore the Company has used an expected dividend yield of zero.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The following table presents the weighted-average assumptions used for the stock option grants: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine Months Ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Grant date fair value</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.45</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.54</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.46</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.87</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Risk-free rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.9</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.98</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.5</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.92</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected life in years</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.1</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.8</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.4</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.7</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">132</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">125</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">123</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">122</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Stock-based Compensation Expense</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In general, stock-based compensation is allocated to research and development expense or general and administrative expense according to the classification of cash compensation paid to the employee, director, or consultant to whom the stock award was granted. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On March 24, 2021, in connection with the conversion from an LLC to a C-Corporation, the Company converted 277,448 of Class B Common Units profits interests, for which no consideration had been received, into 277,448 options to purchase common stock at an exercise price of $5.74 to $6.314 per share. The fair value of common stock prior to IPO was determined in part based upon input from an independent third-party valuation firm. The Company considered the conversion of these Class B Common Units profits interests as a modification under ASC 718, Stock Compensation, in which the fair value of the Class B Common Units profits interests was measured at the modification date and compared to the fair value of the common stock options, with the difference of $1,339,993 resulting in incremental stock-based compensation expense. Related to the options, the Company recorded $849,564 of stock-based compensation expense recorded in the first quarter of 2021. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In December 2021, the Company’s board of directors authorized a stock option grant in lieu of a cash bonus for the Company’s Chairman and Chief Executive Officer. The stock-based compensation expense of $0.4 million related to the stock option grant was booked to the fiscal year ended December 31, 2021; however, the impact to additional paid-in capital was not booked until the first quarter of 2022, when the stock option award was granted. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The following table summarizes the total stock-based compensation expense related to stock options and RSUs included in the Company’s statements of operations:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine Months Ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">54,907</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,075</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">163,417</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">310,046</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">180,076</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">112,580</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">546,018</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,106,645</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">234,983</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">142,655</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">709,435</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,416,691</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Stock Option Award Activity </strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">A summary of the Company’s Equity Plan stock option activity is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Options</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Outstanding</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted-</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercise</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted-</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Remaining</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Contractual</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Term (in</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">523,199</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">5.84</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">8.8</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">533,127</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,056,326</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.77</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8.5</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercisable at September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">586,100</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.32</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.6</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The aggregate intrinsic value of options exercisable as of September 30, 2022 is calculated as the difference between the exercise price of the underlying options and the closing market price of the Company’s common stock on that date, which was $0.52 per share. The intrinsic value of options outstanding and exercisable as of September 30, 2022 was $385. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">As of September 30, 2022, total unrecognized compensation cost related to stock options was approximately $1.1 million and the weighted average period over which this cost is expected to be recognized is 2.5 years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> <em><strong>Restricted Stock Unit Award Activity</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">A summary of the Company’s Equity Plan restricted stock unit, or RSU, award activity is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>RSU’s outstanding</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">RSUs granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">127,726</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">RSUs settled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">RSUs cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">127,726</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">During the three and nine months ended September 30, 2022, the Company issued to certain of the Company’s directors 80,589 and 127,726 RSUs, respectively, as partial compensation for their services during 2022. The Company recognized stock-based compensation expense of approximately $0.1 million during the three and nine months ended September 30, 2022 related to the restricted stock unit awards. There were no RSUs outstanding during 2021 and there is no unrecognized compensation expense related to outstanding RSUs as of September 30, 2022.  </p> 1731499 1 P10Y four years for employees and one year for directors of the Company’s board and consultants 547447 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine Months Ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Grant date fair value</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.45</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.54</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.46</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.87</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Risk-free rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.9</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.98</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.5</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.92</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected life in years</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.1</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.8</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.4</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.7</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">132</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">125</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">123</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">122</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table> 0.45 4.54 1.46 4.87 0.029 0.0098 0.015 0.0092 0.0000 0.0000 0.000 0.0000 6.1 5.8 5.4 5.7 1.32 1.25 1.23 1.22 277448 277448 5.74 6.314 1339993 849564 400000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine Months Ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">54,907</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,075</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">163,417</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">310,046</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">180,076</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">112,580</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">546,018</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,106,645</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">234,983</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">142,655</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">709,435</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,416,691</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 54907 30075 163417 310046 180076 112580 546018 1106645 234983 142655 709435 1416691 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Options</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Outstanding</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted-</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercise</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted-</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Remaining</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Contractual</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Term (in</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">523,199</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">5.84</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">8.8</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">533,127</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,056,326</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.77</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8.5</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercisable at September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">586,100</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.32</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.6</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 523199 5.84 P8Y9M18D 533127 1.75 0 0 1056326 3.77 P8Y6M 586100 4.32 P8Y7M6D 0.52 385 1100000 P2Y6M <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>RSU’s outstanding</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">RSUs granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">127,726</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">RSUs settled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">RSUs cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">127,726</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 127726 127726 80589 127726 100000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>8. 401(k) Plan</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company sponsors a 401(k) savings plan for all eligible employees. The Company may make discretionary matching contributions to the plan to be allocated to employee accounts based upon employee deferrals and compensation. To date, the Company has not made any matching contributions into the savings plan.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>9. License Agreements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On March 31, 2017, the Company entered into a license agreement, as amended (the “License Agreement”) with Villani, Inc. whereby Villani has granted the Company an exclusive, sub-licensable, royalty-bearing license (the “License”) under the Licensed Patents (as defined in the License Agreement), to formulate, develop, seek regulatory approval for, make or sell products that contain <em>Spongilla lacustris</em> (alone or in combination with other active or inactive ingredients) for the treatment of diseases, disorders and conditions of the skin, including but not limited to acne, rosacea, psoriasis, atopic dermatitis, seborrheic dermatitis, actinic keratosis and eczema that were developed using certain licensed know-how (“Licensed Products”). The Company is responsible for the development (including manufacturing, packaging, non-clinical studies, clinical trials and obtaining regulatory approval and commercialization (including marketing, promotion, distribution, etc.)) for all Licensed Products. In partial consideration of the License, the Company forgave its previous outstanding loan to Villani in the amount of $400,000. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The original License Agreement was amended in 2019 and, in consideration of the receipt of certain know-how and patents, the Company issued to Villani 5,221,156 Series 1c Preferred Units equal to 5% of the Company’s fully diluted capitalization, valued at $730,962. Pursuant to the amended License Agreement, the Company was required to make future milestone payments to Villani in an aggregate amount of up to $20.25 million upon the achievement of specified development and sales milestones, payable in cash or in equity, at the option of Villani, as well as single-digit royalty payments on net sales. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On July 30, 2021, the Company further amended the License Agreement in the Second Amendment to the License and Settlement Agreement (the “Second Amendment”). In consideration of the Second Amendment, Villani exchanged the 5,221,156 Series 1c Preferred Shares issued to Villani in 2019 for an increase in milestone payments and royalty rates payable pursuant to the License Agreement and the Company paid Villani $1 million after the close of the IPO. Pursuant to the Second Amendment, the Company is required to make future milestone payments to Villani in an aggregate amount of up to $40.5 million upon the achievement of specified development and sales milestones, payable in cash or in equity, at the option of Villani, as well as single-digit royalty payments on net sales. The Second Amendment includes customary terms relating to, among others, indemnification, intellectual property protection, confidentiality, remedies, and warranties. See Note 6 – Equity Securities for additional information regarding the Company’s redemption of the Series 1c Preferred Shares from Villani. </p> 400000 5221156 0.05 730962 202500 5221156 1000000 4050000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>10. Commitments and Contingencies</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Clinical Trials</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">During 2021, the Company initiated a clinical trial which completed patient enrollment in June 2022; however, the Company had not completed data analysis for the clinical trial by September 30, 2022. Accordingly, the Company anticipates additional research and development expense of $0.1 to $0.2 million to be incurred during the fourth quarter of fiscal year 2022 related to this ongoing clinical trial.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Coronavirus Pandemic</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On March 11, 2020, the World Health Organization declared the outbreak of a coronavirus (COVID-19) pandemic. Significant uncertainties may arise with respect to potential shutdowns of operations or government orders to cease activities due to emergency declarations, inability to operate, employee shortages, or claims for business interruption insurance, etc. Each of these matters may have a significant impact on the future results of the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Supplier Agreement</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">As a result of Russia’s invasion of Ukraine, the United States, the United Kingdom, and the European Union governments, among others, have developed coordinated sanctions and export-control measure packages against Russian individuals and entities. The Company is currently a party to an exclusive supply agreement for the supply of the <em>Spongilla </em>raw material used in DMT310 and DMT410. The counterparty to this supply agreement is a Russian entity. The imposition of enhanced export controls and economic sanctions on transactions with Russia and Russian entities by the United States, the United Kingdom, and/or the European Union could prevent the Company from performing under this existing contract or any future contract it may enter or may prevent the Company from remitting payment for raw material purchased from the Company’s supplier. The Company has received two shipments of raw material from its supplier during fiscal year 2022 containing additional quantities of <em>Spongilla</em> raw material which will provide the Company with sufficient quantities of <em>Spongilla</em> to initiate and complete two Phase 3 studies in moderate-to-severe acne and support filing a new drug application for DMT310 in acne upon the successful completion of two Phase 3 studies. Depending on the extent and breadth of new sanctions or export controls that may be imposed against Russia, otherwise or as a result of the impact of the war in Ukraine, it is possible that the Company’s ability to obtain additional supply of the <em>Spongilla</em> raw material used in DMT310 and DMT410 could be negatively impacted, which could adversely affect its business, results of operations, and financial condition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Legal Proceedings</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In the normal course of business, the Company may be involved in legal proceedings or threatened legal proceedings. The Company is not a party to any legal proceedings or aware of any threatened legal proceedings which are expected to have a material adverse effect on its financial condition, results of operations or liquidity. </p> 10000 20000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>11. Related Parties</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Prior to the Company converting from an LLC to a C-corporation in March 2021, the Company had two Managing Members. One of the Managing Members remained the Company’s majority stockholder upon the close of the Company’s IPO and serves as the Company’s President, Chief Executive Officer, and Chairman of the Board of Directors. The other Managing Member remained a beneficial owner upon the close of the Company’s IPO and serves as the Company’s Lead Director of the Board of Directors. Hereinafter these two Managing Members, and their affiliates, are referred to collectively as the Principal Stockholders after the completion of the IPO. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">During 2020, the Managing Members and other related parties loaned the Company $1,145,000 as subordinated convertible promissory notes. Additionally, during the first quarter of 2021, the Managing Members and other related parties loaned the Company $1,255,000 as subordinated convertible promissory notes. Refer to Note 4 – Subordinated Convertible Promissory Notes for further discussion. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">During the third quarter of 2021, the Company amended the conversion terms of its Series 1d preferred stock, as described in Note 6 – Equity Securities. As a result of the Series 1d preferred stock amendments, the Company presented a deemed dividend of approximately $2.3 million for the year ended December 31, 2021, approximately $1.2 million of which related to Series 1d preferred shares owned by the Company’s Principal Stockholders and their affiliates. </p> 1145000 1255000 230000 120000 EXCEL 48 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 49 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 50 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 259 317 1 false 49 0 false 4 false false R1.htm 000001 - Document - Cover Sheet http://drma.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - Balance Sheets Sheet http://drma.com/role/BalanceSheets Balance Sheets Statements 2 false false R3.htm 000003 - Statement - Balance Sheets (Parenthetical) Sheet http://drma.com/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - Statements of Operations (unaudited) Sheet http://drma.com/role/StatementsOfOperationsUnaudited Statements of Operations (unaudited) Statements 4 false false R5.htm 000005 - Statement - Statements of Stockholder's Equity (Unaudited) Sheet http://drma.com/role/StatementsOfStockholdersEquityUnaudited Statements of Stockholder's Equity (Unaudited) Statements 5 false false R6.htm 000006 - Statement - Statements of Cash Flows (unaudited) Sheet http://drma.com/role/StatementsOfCashFlowsUnaudited Statements of Cash Flows (unaudited) Statements 6 false false R7.htm 000007 - Disclosure - Organization and Basis of Presentation Sheet http://drma.com/role/OrganizationAndBasisOfPresentation Organization and Basis of Presentation Notes 7 false false R8.htm 000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://drma.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 000009 - Disclosure - Balance Sheet Details Sheet http://drma.com/role/BalanceSheetDetails Balance Sheet Details Notes 9 false false R10.htm 000010 - Disclosure - Subordinated Convertible Promissory Notes Notes http://drma.com/role/SubordinatedConvertiblePromissoryNotes Subordinated Convertible Promissory Notes Notes 10 false false R11.htm 000011 - Disclosure - LongTerm Debt Sheet http://drma.com/role/LongtermDebt LongTerm Debt Notes 11 false false R12.htm 000012 - Disclosure - Equity Securities Sheet http://drma.com/role/EquitySecurities Equity Securities Notes 12 false false R13.htm 000013 - Disclosure - Equity Incentive Plan Sheet http://drma.com/role/EquityIncentivePlan Equity Incentive Plan Notes 13 false false R14.htm 000014 - Disclosure - 401(k) Plan Sheet http://drma.com/role/KPlan 401(k) Plan Notes 14 false false R15.htm 000015 - Disclosure - License Agreements Sheet http://drma.com/role/LicenseAgreements License Agreements Notes 15 false false R16.htm 000016 - Disclosure - Commitments and Contingencies Sheet http://drma.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 000017 - Disclosure - Related Parties Sheet http://drma.com/role/RelatedParties Related Parties Notes 17 false false R18.htm 000018 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://drma.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://drma.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 000019 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://drma.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://drma.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 000020 - Disclosure - Balance Sheet Details (Tables) Sheet http://drma.com/role/BalanceSheetDetailsTables Balance Sheet Details (Tables) Tables http://drma.com/role/BalanceSheetDetails 20 false false R21.htm 000021 - Disclosure - Equity Incentive Plan (Tables) Sheet http://drma.com/role/EquityIncentivePlanTables Equity Incentive Plan (Tables) Tables http://drma.com/role/EquityIncentivePlan 21 false false R22.htm 000022 - Disclosure - Organization and Basis of Presentation (Details Narrative) Sheet http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative Organization and Basis of Presentation (Details Narrative) Details http://drma.com/role/OrganizationAndBasisOfPresentation 22 false false R23.htm 000023 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://drma.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://drma.com/role/SummaryOfSignificantAccountingPoliciesTables 23 false false R24.htm 000024 - Disclosure - Summary of Significant Accounting Policies (Details 1) Sheet http://drma.com/role/SummaryOfSignificantAccountingPoliciesDetails1 Summary of Significant Accounting Policies (Details 1) Details http://drma.com/role/SummaryOfSignificantAccountingPoliciesTables 24 false false R25.htm 000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://drma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://drma.com/role/SummaryOfSignificantAccountingPoliciesTables 25 false false R26.htm 000026 - Disclosure - Balance Sheet Details (Details) Sheet http://drma.com/role/BalanceSheetDetailsDetails Balance Sheet Details (Details) Details http://drma.com/role/BalanceSheetDetailsTables 26 false false R27.htm 000027 - Disclosure - Subordinated Convertible Promissory Notes (Details Narrative) Notes http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative Subordinated Convertible Promissory Notes (Details Narrative) Details http://drma.com/role/SubordinatedConvertiblePromissoryNotes 27 false false R28.htm 000028 - Disclosure - LongTerm Debt (Details Narrative) Sheet http://drma.com/role/LongtermDebtDetailsNarrative LongTerm Debt (Details Narrative) Details http://drma.com/role/LongtermDebt 28 false false R29.htm 000029 - Disclosure - Equity Securities (Details Narrative) Sheet http://drma.com/role/EquitySecuritiesDetailsNarrative Equity Securities (Details Narrative) Details http://drma.com/role/EquitySecurities 29 false false R30.htm 000030 - Disclosure - Equity Incentive Plan (Details) Sheet http://drma.com/role/EquityIncentivePlanDetails Equity Incentive Plan (Details) Details http://drma.com/role/EquityIncentivePlanTables 30 false false R31.htm 000031 - Disclosure - Equity Incentive Plan (Details 1) Sheet http://drma.com/role/EquityIncentivePlanDetails1 Equity Incentive Plan (Details 1) Details http://drma.com/role/EquityIncentivePlanTables 31 false false R32.htm 000032 - Disclosure - Equity Incentive Plan (Details 2) Sheet http://drma.com/role/EquityIncentivePlanDetails2 Equity Incentive Plan (Details 2) Details http://drma.com/role/EquityIncentivePlanTables 32 false false R33.htm 000033 - Disclosure - Equity Incentive Plan (Details 3) Sheet http://drma.com/role/EquityIncentivePlanDetails3 Equity Incentive Plan (Details 3) Details http://drma.com/role/EquityIncentivePlanTables 33 false false R34.htm 000034 - Disclosure - Equity Incentive Plan (Details Narrative) Sheet http://drma.com/role/EquityIncentivePlanDetailsNarrative Equity Incentive Plan (Details Narrative) Details http://drma.com/role/EquityIncentivePlanTables 34 false false R35.htm 000035 - Disclosure - License Agreements (Details Narrative) Sheet http://drma.com/role/LicenseAgreementsDetailsNarrative License Agreements (Details Narrative) Details http://drma.com/role/LicenseAgreements 35 false false R36.htm 000036 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://drma.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://drma.com/role/CommitmentsAndContingencies 36 false false R37.htm 000037 - Disclosure - Related Parties (Details Narrative) Sheet http://drma.com/role/RelatedPartiesDetailsNarrative Related Parties (Details Narrative) Details http://drma.com/role/RelatedParties 37 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 35 fact(s) appearing in ix:hidden were eligible for transformation: dei:DocumentTransitionReport, drma:AuthorizedCommonStockShares, drma:CommonStockSharesSold, drma:DividendPreferredStock, drma:FairValueExercisePricePerShare, drma:OptionsExercisedToPurchaseAdditionalWarrantsExercisePrice, drma:PreFundedWarrantOutstanding, drma:PreFundedWarrantsToPurchaseCommonShare, drma:StockBasedCompensationExpense, us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1, us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight, us-gaap:ClassOfWarrantOrRightOutstanding, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesOutstanding, us-gaap:ConvertiblePreferredStockConvertedToOtherSecurities, us-gaap:DebtInstrumentFeeAmount, us-gaap:DebtInstrumentPeriodicPaymentPrincipal, us-gaap:FairValueAdjustmentOfWarrants, us-gaap:OptionIndexedToIssuersEquityStrikePrice1, us-gaap:PaymentForManagementFee, us-gaap:PreferredUnitsIssued, us-gaap:PrepaidExpenseAndOtherAssets, us-gaap:PrepaidExpenseCurrent, us-gaap:ProceedsFromIssuanceOfWarrants, us-gaap:ShareBasedCompensation, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod - drma_10q.htm 1 drma_10q.htm drma-20220930.xsd drma-20220930_cal.xml drma-20220930_def.xml drma-20220930_lab.xml drma-20220930_pre.xml drma_ex311.htm drma_ex312.htm drma_ex321.htm http://fasb.org/srt/2022 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 54 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "drma_10q.htm": { "axisCustom": 0, "axisStandard": 14, "contextCount": 259, "dts": { "calculationLink": { "local": [ "drma-20220930_cal.xml" ] }, "definitionLink": { "local": [ "drma-20220930_def.xml" ] }, "inline": { "local": [ "drma_10q.htm" ] }, "labelLink": { "local": [ "drma-20220930_lab.xml" ] }, "presentationLink": { "local": [ "drma-20220930_pre.xml" ] }, "schema": { "local": [ "drma-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 435, "entityCount": 1, "hidden": { "http://drma.com/20220930": 9, "http://fasb.org/us-gaap/2022": 25, "http://xbrl.sec.gov/dei/2022": 6, "total": 40 }, "keyCustom": 135, "keyStandard": 182, "memberCustom": 38, "memberStandard": 11, "nsprefix": "drma", "nsuri": "http://drma.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "role": "http://drma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "drma:SubordinatedConvertiblePromissoryNotes", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - Subordinated Convertible Promissory Notes", "role": "http://drma.com/role/SubordinatedConvertiblePromissoryNotes", "shortName": "Subordinated Convertible Promissory Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "drma:SubordinatedConvertiblePromissoryNotes", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - LongTerm Debt", "role": "http://drma.com/role/LongtermDebt", "shortName": "LongTerm Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - Equity Securities", "role": "http://drma.com/role/EquitySecurities", "shortName": "Equity Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - Equity Incentive Plan", "role": "http://drma.com/role/EquityIncentivePlan", "shortName": "Equity Incentive Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - 401(k) Plan", "role": "http://drma.com/role/KPlan", "shortName": "401(k) Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InsuranceDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - License Agreements", "role": "http://drma.com/role/LicenseAgreements", "shortName": "License Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InsuranceDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - Commitments and Contingencies", "role": "http://drma.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - Related Parties", "role": "http://drma.com/role/RelatedParties", "shortName": "Related Parties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://drma.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://drma.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - Balance Sheets", "role": "http://drma.com/role/BalanceSheets", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - Balance Sheet Details (Tables)", "role": "http://drma.com/role/BalanceSheetDetailsTables", "shortName": "Balance Sheet Details (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - Equity Incentive Plan (Tables)", "role": "http://drma.com/role/EquityIncentivePlanTables", "shortName": "Equity Incentive Plan (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "AsOf2022-09-30", "decimals": "-5", "first": true, "lang": null, "name": "drma:AccumulatedDeficit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - Organization and Basis of Presentation (Details Narrative)", "role": "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative", "shortName": "Organization and Basis of Presentation (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "AsOf2022-09-30", "decimals": "-5", "first": true, "lang": null, "name": "drma:AccumulatedDeficit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://drma.com/role/SummaryOfSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": "0", "lang": null, "name": "drma:DeemedDividendUponRedemptionOf5221156SharesOfSeries1CConvertiblePreferredStock", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - Summary of Significant Accounting Policies (Details 1)", "role": "http://drma.com/role/SummaryOfSignificantAccountingPoliciesDetails1", "shortName": "Summary of Significant Accounting Policies (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "AsOf2022-09-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredOfferingCosts", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "role": "http://drma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "-4", "lang": null, "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "AsOf2022-09-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredOfferingCosts", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - Balance Sheet Details (Details)", "role": "http://drma.com/role/BalanceSheetDetailsDetails", "shortName": "Balance Sheet Details (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "AsOf2022-09-30_drma_BalanceSheetMember", "decimals": "0", "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "drma:SubordinatedConvertiblePromissoryNotes", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "AsOf2020-10-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConvertibleSubordinatedDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - Subordinated Convertible Promissory Notes (Details Narrative)", "role": "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative", "shortName": "Subordinated Convertible Promissory Notes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "drma:SubordinatedConvertiblePromissoryNotes", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "AsOf2020-10-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConvertibleSubordinatedDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "AsOf2021-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFeeAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - LongTerm Debt (Details Narrative)", "role": "http://drma.com/role/LongtermDebtDetailsNarrative", "shortName": "LongTerm Debt (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "AsOf2021-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFeeAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "AsOf2021-06-29", "decimals": "0", "first": true, "lang": null, "name": "drma:CommonStockSharesAvailableForIssuances", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - Equity Securities (Details Narrative)", "role": "http://drma.com/role/EquitySecuritiesDetailsNarrative", "shortName": "Equity Securities (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "AsOf2021-06-29", "decimals": "0", "first": true, "lang": null, "name": "drma:CommonStockSharesAvailableForIssuances", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "AsOf2022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - Balance Sheets (Parenthetical)", "role": "http://drma.com/role/BalanceSheetsParenthetical", "shortName": "Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "AsOf2022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-07-01to2022-09-30_us-gaap_StockOptionMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - Equity Incentive Plan (Details)", "role": "http://drma.com/role/EquityIncentivePlanDetails", "shortName": "Equity Incentive Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-07-01to2022-09-30_us-gaap_StockOptionMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2021-03-01to2021-03-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - Equity Incentive Plan (Details 1)", "role": "http://drma.com/role/EquityIncentivePlanDetails1", "shortName": "Equity Incentive Plan (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-07-01to2022-09-30_drma_ResearchanddevelopmentMember", "decimals": "0", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "AsOf2021-12-31_us-gaap_StockOptionMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000032 - Disclosure - Equity Incentive Plan (Details 2)", "role": "http://drma.com/role/EquityIncentivePlanDetails2", "shortName": "Equity Incentive Plan (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30_us-gaap_StockOptionMember", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "0", "first": true, "lang": null, "name": "drma:RestrictedStockUnitGranted", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000033 - Disclosure - Equity Incentive Plan (Details 3)", "role": "http://drma.com/role/EquityIncentivePlanDetails3", "shortName": "Equity Incentive Plan (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "0", "first": true, "lang": null, "name": "drma:RestrictedStockUnitGranted", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000034 - Disclosure - Equity Incentive Plan (Details Narrative)", "role": "http://drma.com/role/EquityIncentivePlanDetailsNarrative", "shortName": "Equity Incentive Plan (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2021-03-01to2021-03-24", "decimals": "0", "lang": null, "name": "drma:ClassBCommonUnitsProfitsInterestsConvertedDueToTheConversionFromAnLlcToACCorporation", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InsuranceDisclosureTextBlock", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "AsOf2021-07-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PreferredUnitsIssued", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000035 - Disclosure - License Agreements (Details Narrative)", "role": "http://drma.com/role/LicenseAgreementsDetailsNarrative", "shortName": "License Agreements (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InsuranceDisclosureTextBlock", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2021-07-07to2021-07-30_drma_LicenseAgreementSecondAmendmentMember_drma_VillaniIncMember", "decimals": "-6", "lang": null, "name": "drma:PaymentsMadeToRelatedPartyAfterIpoClosed", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30_srt_MinimumMember", "decimals": "-4", "first": true, "lang": null, "name": "drma:AdditionalResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000036 - Disclosure - Commitments and Contingencies (Details Narrative)", "role": "http://drma.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "Commitments and Contingencies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30_srt_MinimumMember", "decimals": "-4", "first": true, "lang": null, "name": "drma:AdditionalResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2020-10-01to2020-10-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentAmount1", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000037 - Disclosure - Related Parties (Details Narrative)", "role": "http://drma.com/role/RelatedPartiesDetailsNarrative", "shortName": "Related Parties (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-4", "lang": null, "name": "us-gaap:DividendsPreferredStock", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - Statements of Operations (unaudited)", "role": "http://drma.com/role/StatementsOfOperationsUnaudited", "shortName": "Statements of Operations (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "AsOf2020-12-31_drma_CommonClassesAMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - Statements of Stockholder's Equity (Unaudited)", "role": "http://drma.com/role/StatementsOfStockholdersEquityUnaudited", "shortName": "Statements of Stockholder's Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2021-01-01to2021-03-31", "decimals": "0", "lang": null, "name": "drma:Series1DPreferredUnitsIssuedAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - Statements of Cash Flows (unaudited)", "role": "http://drma.com/role/StatementsOfCashFlowsUnaudited", "shortName": "Statements of Cash Flows (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "lang": null, "name": "us-gaap:AmortizationOfDebtDiscountPremium", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000007 - Disclosure - Organization and Basis of Presentation", "role": "http://drma.com/role/OrganizationAndBasisOfPresentation", "shortName": "Organization and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - Summary of Significant Accounting Policies", "role": "http://drma.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - Balance Sheet Details", "role": "http://drma.com/role/BalanceSheetDetails", "shortName": "Balance Sheet Details", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "drma_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 49, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://drma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "drma_AccruedBoardCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued board compensation" } } }, "localname": "AccruedBoardCompensation", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/BalanceSheetDetailsDetails" ], "xbrltype": "monetaryItemType" }, "drma_AccruedInterestOnTheConvertibleNote": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued interest on the convertible note" } } }, "localname": "AccruedInterestOnTheConvertibleNote", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_AccumulatedDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Accumulated deficit]", "verboseLabel": "Accumulated deficit" } } }, "localname": "AccumulatedDeficit", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_AdditionalResearchAndDevelopmentExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Additional Research And Development Expense" } } }, "localname": "AdditionalResearchAndDevelopmentExpense", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_AdditionalSharesOfWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Additional shares of warrant" } } }, "localname": "AdditionalSharesOfWarrant", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_AmendmentFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Amendment fee" } } }, "localname": "AmendmentFee", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_AmortizedDebtDiscountCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Amortized debt discount costs" } } }, "localname": "AmortizedDebtDiscountCosts", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_AuthorizedCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stocks, authorized" } } }, "localname": "AuthorizedCommonStockShares", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_BalanceAtSeptember302022EndingBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance at September 30, 2022, Ending balance" } } }, "localname": "BalanceAtSeptember302022EndingBalance", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails3" ], "xbrltype": "sharesItemType" }, "drma_BalanceSheetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet [Member]" } } }, "localname": "BalanceSheetMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/BalanceSheetDetailsDetails" ], "xbrltype": "domainItemType" }, "drma_BoardOfDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Board of Directors" } } }, "localname": "BoardOfDirectorsMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "drma_CashProceeds": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Cash proceeds" } } }, "localname": "CashProceeds", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_CashTotal": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Total cash" } } }, "localname": "CashTotal", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_ClassACommonUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class A Common Units" } } }, "localname": "ClassACommonUnitsMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "drma_ClassBCommonUnitIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class B common unit issued" } } }, "localname": "ClassBCommonUnitIssued", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_ClassBCommonUnitsForfeitedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Class B Common Units forfeited" } } }, "localname": "ClassBCommonUnitsForfeitedAmount", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "drma_ClassBCommonUnitsForfeitedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class B Common Units forfeited, shares" } } }, "localname": "ClassBCommonUnitsForfeitedShares", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "drma_ClassBCommonUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class B Common Units" } } }, "localname": "ClassBCommonUnitsMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "drma_ClassBCommonUnitsProfitsInterestsConvertedDueToTheConversionFromAnLlcToACCorporation": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class B Common Units profits interests converted due to the conversion from an LLC to a C-Corporation" } } }, "localname": "ClassBCommonUnitsProfitsInterestsConvertedDueToTheConversionFromAnLlcToACCorporation", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_ClassBCommonUnitsProfitsInterestsConvertedIntoOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class B Common Units profits interests converted into options" } } }, "localname": "ClassBCommonUnitsProfitsInterestsConvertedIntoOptions", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_ClassBCommonUnitsProfitsInterestsConvertedIntoOptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class B Common Units profits interests converted into options, exercise price" } } }, "localname": "ClassBCommonUnitsProfitsInterestsConvertedIntoOptionsExercisePrice", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetailsNarrative" ], "xbrltype": "perShareItemType" }, "drma_ClosingTradingPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Closing trading price" } } }, "localname": "ClosingTradingPrice", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "drma_CombinedOfferingPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Combined Offering Price" } } }, "localname": "CombinedOfferingPrice", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "drma_CommitmentsAndContingenciesSeeNote10Abstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (see Note 10)" } } }, "localname": "CommitmentsAndContingenciesSeeNote10Abstract", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "drma_CommonClassesAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Classes A Member" } } }, "localname": "CommonClassesAMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "drma_CommonClassesBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Classes B Member" } } }, "localname": "CommonClassesBMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "drma_CommonShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonShareMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "domainItemType" }, "drma_CommonStockAndPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock and Preferred Stock" } } }, "localname": "CommonStockAndPreferredStockMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "drma_CommonStockAtAnExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Exercise Price" } } }, "localname": "CommonStockAtAnExercisePrice", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "drma_CommonStockAuthorized1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common share, authorized" } } }, "localname": "CommonStockAuthorized1", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_CommonStockConversionOfStockWarrantExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock, Conversion of Stock, Warrant Exercisable" } } }, "localname": "CommonStockConversionOfStockWarrantExercisable", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_CommonStockShareIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Common stock, shares issued]", "verboseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockShareIssued", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_CommonStockSharesAvailableForIssuances": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock, shares available for issuances" } } }, "localname": "CommonStockSharesAvailableForIssuances", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_CommonStockSharesSold": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock, shares sold" } } }, "localname": "CommonStockSharesSold", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_CommonStockTradedPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock traded price" } } }, "localname": "CommonStockTradedPrice", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetailsNarrative" ], "xbrltype": "perShareItemType" }, "drma_CommonStockWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Warrants [Member]" } } }, "localname": "CommonStockWarrantsMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "domainItemType" }, "drma_CommonUnitsIssuedAsProfitsInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common units issued as profits interest" } } }, "localname": "CommonUnitsIssuedAsProfitsInterest", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_CommonUnitsIssuedConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common units issued consideration" } } }, "localname": "CommonUnitsIssuedConsideration", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_CommonWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Warrants" } } }, "localname": "CommonWarrantsMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "drma_CommonandPreFundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common and Pre-Funded Warrants [Member]" } } }, "localname": "CommonandPreFundedWarrantsMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "drma_ConsiderationOfWarrantsExercised": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Consideration of warrants exercised" } } }, "localname": "ConsiderationOfWarrantsExercised", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_ConversionOfCommonAndPreferredUnitsAndWarrantsToCommonAndPreferredStockAndWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Conversion of common and preferred units and warrants to common and preferred stock and warrants" } } }, "localname": "ConversionOfCommonAndPreferredUnitsAndWarrantsToCommonAndPreferredStockAndWarrants", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "drma_ConversionOfCommonUnitsToCommonStockAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of Common Units to Common Stock, amount" } } }, "localname": "ConversionOfCommonUnitsToCommonStockAmount", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "drma_ConversionOfCommonUnitsToCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Conversion of Common Units to Common Stock, shares" } } }, "localname": "ConversionOfCommonUnitsToCommonStockShares", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "drma_ConversionOfConvertibleDebtToCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of Convertible Debt to Common Stock" } } }, "localname": "ConversionOfConvertibleDebtToCommonStock", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "drma_ConversionOfConvertibleDebtToCommonStockAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of Convertible Debt to Common Stock, amount" } } }, "localname": "ConversionOfConvertibleDebtToCommonStockAmount", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "drma_ConversionOfConvertibleDebtToCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Conversion of Convertible Debt to Common Stock, shares" } } }, "localname": "ConversionOfConvertibleDebtToCommonStockShares", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "drma_ConversionOfConvertibleSubordinatedPromissoryNotesAndAccruedInterestToCommonSharesAtIpo": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Conversion of convertible subordinated promissory notes and accrued interest to common shares at IPO" } } }, "localname": "ConversionOfConvertibleSubordinatedPromissoryNotesAndAccruedInterestToCommonSharesAtIpo", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "drma_ConversionOfConvertibleSubordinatedPromissoryNotesToSeries1DPreferredUnits": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Conversion of convertible subordinated promissory notes to Series 1d preferred units" } } }, "localname": "ConversionOfConvertibleSubordinatedPromissoryNotesToSeries1DPreferredUnits", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "drma_ConversionOfPreferredStockToCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of Preferred Stock to Common Stock" } } }, "localname": "ConversionOfPreferredStockToCommonStock", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "drma_ConversionOfPreferredStockToCommonStockAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of Preferred Stock to Common Stock, amount" } } }, "localname": "ConversionOfPreferredStockToCommonStockAmount", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "drma_ConversionOfPreferredStockToCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Conversion of Preferred Stock to Common Stock, shares" } } }, "localname": "ConversionOfPreferredStockToCommonStockShares", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "drma_ConversionOfPreferredStockWarrantsToCommonStockWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of Preferred Stock Warrants to Common Stock Warrants" } } }, "localname": "ConversionOfPreferredStockWarrantsToCommonStockWarrants", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "drma_ConversionOfPreferredStockWarrantsToCommonStockWarrantsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of Preferred Stock Warrants to Common Stock Warrants, amount" } } }, "localname": "ConversionOfPreferredStockWarrantsToCommonStockWarrantsAmount", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "drma_ConversionOfPreferredStockWarrantsToCommonStockWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Conversion of Preferred Stock Warrants to Common Stock Warrants, shares" } } }, "localname": "ConversionOfPreferredStockWarrantsToCommonStockWarrantsShares", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "drma_ConversionOfPreferredUnitsToPreferredStockAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Conversion of Preferred Units to Preferred Stock, amount" } } }, "localname": "ConversionOfPreferredUnitsToPreferredStockAmount", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "drma_ConversionOfPreferredUnitsToPreferredStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Conversion of Preferred Units to Preferred Stock, shares" } } }, "localname": "ConversionOfPreferredUnitsToPreferredStockShares", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "drma_ConversionOfStockUnitsIntoWarrantsSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Conversion of stock units into warrants, shares issued" } } }, "localname": "ConversionOfStockUnitsIntoWarrantsSharesIssued", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_ConversionOfWarrantUnitsToPreferredStockWarrantsAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Conversion of Warrant Units to Preferred Stock Warrants, amount" } } }, "localname": "ConversionOfWarrantUnitsToPreferredStockWarrantsAmount", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "drma_ConversionOfWarrantUnitsToPreferredStockWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Conversion of Warrant Units to Preferred Stock Warrants, shares" } } }, "localname": "ConversionOfWarrantUnitsToPreferredStockWarrantsShares", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "drma_ConvertiblePromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Promissory Notes" } } }, "localname": "ConvertiblePromissoryNotesMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "drma_DebtConversionConvertedInstrumentAmount2": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Debt conversion amount converted" } } }, "localname": "DebtConversionConvertedInstrumentAmount2", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_DebtConversionConvertedInstrumentSharesIssued2": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt conversion converted instrument shares issued" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued2", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_DebtInstrumentPeriodicPaymentTermBalloonPaymentToBePaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Provision for final payment" } } }, "localname": "DebtInstrumentPeriodicPaymentTermBalloonPaymentToBePaid", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_DeemedDividendUponAmendmentOfTheTermsToTheSeries1DConvertiblePreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Deemed dividend upon amendment of the terms to the Series 1d convertible preferred stock" } } }, "localname": "DeemedDividendUponAmendmentOfTheTermsToTheSeries1DConvertiblePreferredStock", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "drma_DeemedDividendUponRedemptionOf5221156SharesOfSeries1CConvertiblePreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Deemed dividend upon redemption of 5,221,156 shares of Series 1c convertible preferred stock" } } }, "localname": "DeemedDividendUponRedemptionOf5221156SharesOfSeries1CConvertiblePreferredStock", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "drma_DeemedDividendUponTheAmendmentOfTermsOfTheSeries1DConvertiblePreferredStockSeeNote6": { "auth_ref": [], "calculation": { "http://drma.com/role/StatementsOfOperationsUnaudited": { "order": 9.0, "parentTag": "drma_NetLossAttributableToCommonStockholders", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Deemed dividend upon the amendment of terms of the Series 1d convertible preferred stock (see Note 6)" } } }, "localname": "DeemedDividendUponTheAmendmentOfTermsOfTheSeries1DConvertiblePreferredStockSeeNote6", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "drma_DeemedDividendUponTheRedemptionOf5221156SharesOfSeries1CPreferredStockSeeNote6": { "auth_ref": [], "calculation": { "http://drma.com/role/StatementsOfOperationsUnaudited": { "order": 8.0, "parentTag": "drma_NetLossAttributableToCommonStockholders", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Deemed dividend upon the redemption of 5,221,156 shares of Series 1c preferred stock (see Note 6)" } } }, "localname": "DeemedDividendUponTheRedemptionOf5221156SharesOfSeries1CPreferredStockSeeNote6", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "drma_DescriptionOfWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of warrant" } } }, "localname": "DescriptionOfWarrant", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "drma_DifferenceInShareDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of difference" } } }, "localname": "DifferenceInShareDescription", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "drma_DirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "localname": "DirectorsMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetailsNarrative" ], "xbrltype": "domainItemType" }, "drma_Discount": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discount" } } }, "localname": "Discount", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "percentItemType" }, "drma_DiscountRateForPreferredShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "20% Discount rate for preferred shares" } } }, "localname": "DiscountRateForPreferredShares", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_DividendPreferredStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Deemed dividend" } } }, "localname": "DividendPreferredStock", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_EarningsPerShareBasicsAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Basic and diluted net loss per common unit/share]", "negatedLabel": "Basic and diluted net loss per common unit/share" } } }, "localname": "EarningsPerShareBasicsAndDiluted", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "perShareItemType" }, "drma_EstimatedFairValueOfCommonStockIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Estimated fair value of common stock issued" } } }, "localname": "EstimatedFairValueOfCommonStockIssued", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_EvergreenProvisionResultedInIncrease": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Evergreen provision resulted in increase" } } }, "localname": "EvergreenProvisionResultedInIncrease", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_ExercisableWarrantOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercisable warrant outstanding" } } }, "localname": "ExercisableWarrantOutstanding", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_ExercisePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Exercise price]", "verboseLabel": "Exercise price" } } }, "localname": "ExercisePricePerShare", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "drma_FairMarketValue": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "fair market value" } } }, "localname": "FairMarketValue", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetailsNarrative" ], "xbrltype": "percentItemType" }, "drma_FairValueExercisePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair value Exercise price per share" } } }, "localname": "FairValueExercisePricePerShare", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "drma_FairValuePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair value price per share" } } }, "localname": "FairValuePricePerShare", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "drma_FinancingFromCurrentAndNewInvestors": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Financing from current and new investors" } } }, "localname": "FinancingFromCurrentAndNewInvestors", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_FutureMilestonePaymentsPayableUponTheAchievementOfSpecifiedDevelopmentAndSalesMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Future milestone payments payable upon the achievement of specified development and sales milestones" } } }, "localname": "FutureMilestonePaymentsPayableUponTheAchievementOfSpecifiedDevelopmentAndSalesMilestones", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/LicenseAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_GeneralandadministrativeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[General and administrative]", "verboseLabel": "General and administrative" } } }, "localname": "GeneralandadministrativeMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails1" ], "xbrltype": "domainItemType" }, "drma_IPOsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IPO" } } }, "localname": "IPOsMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "drma_IncreasingSharesAuthorizedForIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increasing shares authorized for issuance" } } }, "localname": "IncreasingSharesAuthorizedForIssuance", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_IncrementalNumberofWarrantsIssuedAtIpo": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incremental number of warrants issued at IPO" } } }, "localname": "IncrementalNumberofWarrantsIssuedAtIpo", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_InitialPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Initial Public Offering [Member]" } } }, "localname": "InitialPublicOfferingMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "domainItemType" }, "drma_IssuanceOfCommonStockAndWarrantsNetIssuanceCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of Common Stock and warrants, net issuance costs" } } }, "localname": "IssuanceOfCommonStockAndWarrantsNetIssuanceCosts", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "drma_IssuanceOfCommonStockAndWarrantsNetIssuanceCostsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of Common Stock and warrants, net issuance costs, amount" } } }, "localname": "IssuanceOfCommonStockAndWarrantsNetIssuanceCostsAmount", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "drma_IssuanceOfCommonStockAndWarrantsNetIssuanceCostsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of Common Stock and warrants, net issuance costs, shares" } } }, "localname": "IssuanceOfCommonStockAndWarrantsNetIssuanceCostsShares", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "drma_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of common stock and warrants, net of issuance costs, amount" } } }, "localname": "IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsAmount", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "drma_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock and warrants, net of issuance costs, shares" } } }, "localname": "IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsShares", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "drma_IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of common stock upon exercise of pre-funded warrants, amount" } } }, "localname": "IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsAmount", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "drma_IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon exercise of pre-funded warrants, shares" } } }, "localname": "IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsShares", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "drma_IssuanceOfRestrictedStockUnitAwardsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of restricted stock unit awards" } } }, "localname": "IssuanceOfRestrictedStockUnitAwardsAmount", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "drma_LicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License Agreement" } } }, "localname": "LicenseAgreementMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "drma_LicenseAgreementSecondAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License Agreement (Second Amendment)" } } }, "localname": "LicenseAgreementSecondAmendmentMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/LicenseAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "drma_LicenseAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[License Agreements]", "verboseLabel": "License Agreements" } } }, "localname": "LicenseAgreementsMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/LicenseAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "drma_LoanAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan and Security Agreement" } } }, "localname": "LoanAndSecurityAgreementMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "drma_LoanAndSecurityAgreementWithSiliconValleyBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan and Security Agreement with Silicon Valley Bank", "verboseLabel": "Loan and Security Agreement with Silicon Valley Bank" } } }, "localname": "LoanAndSecurityAgreementWithSiliconValleyBankMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative", "http://drma.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "drma_MaximumFutureMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Maximum future milestone payments" } } }, "localname": "MaximumFutureMilestonePayments", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/LicenseAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_NetConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net consideration" } } }, "localname": "NetConsideration", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_NetLossAttributableToCommonStockholders": { "auth_ref": [], "calculation": { "http://drma.com/role/StatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Net loss attributable to common stockholders]", "totalLabel": "Net loss attributable to common stockholders", "verboseLabel": "Net loss attributable to common stockholders" } } }, "localname": "NetLossAttributableToCommonStockholders", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfOperationsUnaudited", "http://drma.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "drma_NetLossPerShareOfCommonStockBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net loss per share of common stock, basic and diluted" } } }, "localname": "NetLossPerShareOfCommonStockBasicAndDiluted", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "drma_OfferingPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Offering price" } } }, "localname": "OfferingPrice", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "drma_OfferingPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Offering price]", "verboseLabel": "Offering price" } } }, "localname": "OfferingPricePerShare", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "drma_OptionsExercisedToPurchaseAdditionalWarrantsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Options exercised to purchase additional warrants, Exercise price" } } }, "localname": "OptionsExercisedToPurchaseAdditionalWarrantsExercisePrice", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "drma_PaymentsForItsLongTermDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Payments for its long-term debt" } } }, "localname": "PaymentsForItsLongTermDebt", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_PaymentsMadeToRelatedPartyAfterIpoClosed": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Payments made to related party after IPO closed" } } }, "localname": "PaymentsMadeToRelatedPartyAfterIpoClosed", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/LicenseAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_PercentageOfFullyDilutedCapitalization": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Percentage of fully diluted capitalization" } } }, "localname": "PercentageOfFullyDilutedCapitalization", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/LicenseAgreementsDetailsNarrative" ], "xbrltype": "percentItemType" }, "drma_PercentagesOfInitialPublicPerShareOfferingPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Percentages of initial public per share offering price" } } }, "localname": "PercentagesOfInitialPublicPerShareOfferingPrice", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "percentItemType" }, "drma_PipeCommonStockConversionOfStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PIPE Common Stock, Conversion of Stock, Shares Issued" } } }, "localname": "PipeCommonStockConversionOfStockSharesIssued", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_PreFundedWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Pre funded" } } }, "localname": "PreFundedWarrant", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_PreFundedWarrantOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Pre funded outstanding" } } }, "localname": "PreFundedWarrantOutstanding", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_PreFundedWarrantsToPurchaseCommonShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Pre-funded warrants to purchase common share" } } }, "localname": "PreFundedWarrantsToPurchaseCommonShare", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_PreferredAndCommonStockParValuePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred and common stock par value per share" } } }, "localname": "PreferredAndCommonStockParValuePerShare", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "drma_PreferredStockWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock Warrants Member" } } }, "localname": "PreferredStockWarrantsMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "drma_PreferredUnitInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred unit interest rate" } } }, "localname": "PreferredUnitInterestRate", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "drma_PreferredUnitsSurrender": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Units, surrendered" } } }, "localname": "PreferredUnitsSurrender", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_PrepaidOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Prepaid other" } } }, "localname": "PrepaidOther", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/BalanceSheetDetailsDetails" ], "xbrltype": "monetaryItemType" }, "drma_PrepaidResearchAndDevelopmentCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Prepaid research and development costs" } } }, "localname": "PrepaidResearchAndDevelopmentCosts", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/BalanceSheetDetailsDetails" ], "xbrltype": "monetaryItemType" }, "drma_ProceedsFromIssuanceOfPreferredUnits": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from issuance of preferred units" } } }, "localname": "ProceedsFromIssuanceOfPreferredUnits", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_ProceedsFromIssuancesOfCommonStockUponExercisesOfPreFundedWarrants": { "auth_ref": [], "calculation": { "http://drma.com/role/StatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from issuances of common stock upon exercises of pre-funded warrants" } } }, "localname": "ProceedsFromIssuancesOfCommonStockUponExercisesOfPreFundedWarrants", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "drma_ProceedsFromSeriesAFinancing": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Proceeds from Series A financing" } } }, "localname": "ProceedsFromSeriesAFinancing", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_RedemptionOfSeries1CPreferredAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Redemption of Series 1c preferred shares" } } }, "localname": "RedemptionOfSeries1CPreferredAmount", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "drma_RedemptionOfSeries1CPreferredSharesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Redemption of Series 1c preferred shares, amount" } } }, "localname": "RedemptionOfSeries1CPreferredSharesAmount", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "drma_RedemptionOfSeries1CPreferredSharesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redemption of Series 1c preferred shares, shares" } } }, "localname": "RedemptionOfSeries1CPreferredSharesShares", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "drma_RedemptionOfSeries1CPreferredStock": { "auth_ref": [], "calculation": { "http://drma.com/role/StatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Redemption of Series 1c preferred stock" } } }, "localname": "RedemptionOfSeries1CPreferredStock", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "drma_RemainingBalanceCommittedToFinancingPayableAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Remaining balance committed to financing payable amount" } } }, "localname": "RemainingBalanceCommittedToFinancingPayableAmount", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_ResearchanddevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Research and development]", "verboseLabel": "Research and development" } } }, "localname": "ResearchanddevelopmentMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails1" ], "xbrltype": "domainItemType" }, "drma_RestrictedStockUnitBeginningBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted stock unit, Beginning balance" } } }, "localname": "RestrictedStockUnitBeginningBalance", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails3" ], "xbrltype": "sharesItemType" }, "drma_RestrictedStockUnitGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted stock unit, granted" } } }, "localname": "RestrictedStockUnitGranted", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails3" ], "xbrltype": "sharesItemType" }, "drma_RsusCancelled": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RSUs cancelled" } } }, "localname": "RsusCancelled", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails3" ], "xbrltype": "sharesItemType" }, "drma_RsusSettled": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RSUs settled" } } }, "localname": "RsusSettled", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails3" ], "xbrltype": "sharesItemType" }, "drma_SereiesOneAPreferredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sereies One A Preferred Member" } } }, "localname": "SereiesOneAPreferredMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "drma_Series1DPreferredUnitsIssuedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Series 1d Preferred Units issued, amount" } } }, "localname": "Series1DPreferredUnitsIssuedAmount", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "drma_Series1DPreferredUnitsIssuedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series 1d Preferred Units issued, shares" } } }, "localname": "Series1DPreferredUnitsIssuedShares", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "drma_SeriesOneAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series 1a Preferred Stock" } } }, "localname": "SeriesOneAPreferredStockMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "domainItemType" }, "drma_SeriesOneAPreferredUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series 1a Preferred Units" } } }, "localname": "SeriesOneAPreferredUnitsMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative", "http://drma.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "drma_SeriesOneAWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series One A Warrants Member" } } }, "localname": "SeriesOneAWarrantsMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "drma_SeriesOneBPreferredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series One B Preferred Member" } } }, "localname": "SeriesOneBPreferredMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "drma_SeriesOneBPreferredUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series 1b Preferred Units" } } }, "localname": "SeriesOneBPreferredUnitsMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "drma_SeriesOneCPreferredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series One C Preferred Member" } } }, "localname": "SeriesOneCPreferredMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "drma_SeriesOneCPreferredUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series 1c Preferred Units" } } }, "localname": "SeriesOneCPreferredUnitsMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "drma_SeriesOneDPreferredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series One D Preferred Member" } } }, "localname": "SeriesOneDPreferredMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "drma_SeriesOneDPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series 1d Preferred Stock" } } }, "localname": "SeriesOneDPreferredStockMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative", "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "drma_SeriesOnePreferredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series One Preferred Member" } } }, "localname": "SeriesOnePreferredMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "drma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1F": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of Options Outstanding, Options Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1F", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails2" ], "xbrltype": "sharesItemType" }, "drma_StockAwardsGrantedVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock awards granted, vesting period" } } }, "localname": "StockAwardsGrantedVestingPeriod", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetailsNarrative" ], "xbrltype": "stringItemType" }, "drma_StockBasedCompensationExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "stock-based compensation expense", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "StockBasedCompensationExpense", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetailsNarrative", "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_StockConverted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock converted" } } }, "localname": "StockConverted", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_StockUnitsFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Stock units, fair value" } } }, "localname": "StockUnitsFairValue", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_SubordinatedConvertiblePromissoryNotes": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Subordinated Convertible Promissory Notes]", "verboseLabel": "Subordinated Convertible Promissory Notes" } } }, "localname": "SubordinatedConvertiblePromissoryNotes", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/SubordinatedConvertiblePromissoryNotes" ], "xbrltype": "textBlockItemType" }, "drma_ThresholdsPricePerShareMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Thresholds price per share maximum" } } }, "localname": "ThresholdsPricePerShareMaximum", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "drma_ThresholdsPricePerShareMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Thresholds price per share minimum" } } }, "localname": "ThresholdsPricePerShareMinimum", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "drma_TwoThousandTwentyOneOmnibusEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2021 Omnibus Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandTwentyOneOmnibusEquityIncentivePlanMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetailsNarrative" ], "xbrltype": "domainItemType" }, "drma_UnderwriterIPOWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Underwriter IPO Warrants" } } }, "localname": "UnderwriterIPOWarrantsMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "drma_UnderwritersDiscountsAndOfferingExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Underwriters' discounts and offering expenses" } } }, "localname": "UnderwritersDiscountsAndOfferingExpenses", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_VillaniIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Villani, Inc", "verboseLabel": "Villani, Inc" } } }, "localname": "VillaniIncMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative", "http://drma.com/role/LicenseAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "drma_WarrantOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding" } } }, "localname": "WarrantOutstanding", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_WarrantsExercisableIntoCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants exercisable into common stock" } } }, "localname": "WarrantsExercisableIntoCommonStock", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_WarrantsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise price" } } }, "localname": "WarrantsExercisePrice", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "drma_WarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants exercised" } } }, "localname": "WarrantsExercised", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_WarrantsExercisedDuringPeriodShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants, exercised during period" } } }, "localname": "WarrantsExercisedDuringPeriodShare", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_WarrantsExpireDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants, expire date" } } }, "localname": "WarrantsExpireDate", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "drma_WarrantsFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Warrants, fair value" } } }, "localname": "WarrantsFairValue", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "drma_WarrantsIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants, issued" } } }, "localname": "WarrantsIssued", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/Cover", "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "drma_WarrantsSoldToPurchaseOneShareOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants sold to purchase one share of common stock" } } }, "localname": "WarrantsSoldToPurchaseOneShareOfCommonStock", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_WarrantsSoldToPurchaseOneShareOfCommonStockExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants sold to purchase one share of common stock, Exercise price" } } }, "localname": "WarrantsSoldToPurchaseOneShareOfCommonStockExercisePrice", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "drma_WarrantsSoldToPurchaseShareOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants sold to purchase share of common stock" } } }, "localname": "WarrantsSoldToPurchaseShareOfCommonStock", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_WarrantsSoldToPurchaseShareOfCommonStockExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants sold to purchase share of common stock, Exercise price" } } }, "localname": "WarrantsSoldToPurchaseShareOfCommonStockExercisePrice", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "drma_WarrantsSoldToPurchaseShareOfCommonStockExercisePricePercentageOfPublicOfferingPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants sold to purchase share of common stock, Exercise price Percentage of public offering price" } } }, "localname": "WarrantsSoldToPurchaseShareOfCommonStockExercisePricePercentageOfPublicOfferingPrice", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "percentItemType" }, "drma_WarrantsToPurchaseOneShareOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants to purchase one share of common stock" } } }, "localname": "WarrantsToPurchaseOneShareOfCommonStock", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "drma_WeightedAverageBasicAndDilutedCommonUnitsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted-average basic and diluted common units/shares" } } }, "localname": "WeightedAverageBasicAndDilutedCommonUnitsShares", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/StatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" }, "drma_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Weighted-average basic and diluted common units/shares]", "verboseLabel": "Weighted-average basic and diluted common units/shares" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicsAndDiluted", "nsuri": "http://drma.com/20220930", "presentation": [ "http://drma.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "srt_MaximumMember": { "auth_ref": [ "r158", "r159", "r160", "r161", "r175", "r189", "r216", "r217", "r317", "r318", "r319", "r320", "r321", "r322", "r341", "r376", "r377", "r386", "r387" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://drma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://drma.com/role/EquityIncentivePlanDetailsNarrative", "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r158", "r159", "r160", "r161", "r175", "r189", "r216", "r217", "r317", "r318", "r319", "r320", "r321", "r322", "r341", "r376", "r377", "r386", "r387" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://drma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://drma.com/role/EquityIncentivePlanDetailsNarrative", "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r153", "r158", "r159", "r160", "r161", "r175", "r189", "r214", "r216", "r217", "r249", "r250", "r251", "r317", "r318", "r319", "r320", "r321", "r322", "r341", "r376", "r377", "r386", "r387" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://drma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://drma.com/role/EquityIncentivePlanDetailsNarrative", "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r153", "r158", "r159", "r160", "r161", "r175", "r189", "r214", "r216", "r217", "r249", "r250", "r251", "r317", "r318", "r319", "r320", "r321", "r322", "r341", "r376", "r377", "r386", "r387" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://drma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://drma.com/role/EquityIncentivePlanDetailsNarrative", "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": { "auth_ref": [ "r76", "r402" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.", "label": "Schedule of balance sheet details" } } }, "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://drma.com/role/BalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r127", "r304" ], "lang": { "en-us": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals." } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r25", "r310" ], "calculation": { "http://drma.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedCappingClosurePostClosureAndEnvironmentalCosts": { "auth_ref": [ "r28", "r152" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated costs accrued as of the balance sheet date to comply with regulatory requirements pertaining to the retirement of a waste management facility (such as a landfill or waste treatment facility). Represents the portion that will be paid within one year or the normal operating cycle, if longer.", "label": "Accrued research and development costs" } } }, "localname": "AccruedCappingClosurePostClosureAndEnvironmentalCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheetDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxes": { "auth_ref": [ "r10", "r12", "r269", "r358", "r369" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes.", "label": "Accrued legal fees" } } }, "localname": "AccruedIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheetDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r17", "r310" ], "calculation": { "http://drma.com/role/BalanceSheets": { "order": 7.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r78", "r79", "r80", "r259", "r260", "r261", "r285" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r218", "r263", "r264" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r253" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "[Share-Based Payment Arrangement, Expense]", "terseLabel": "Incremental stock-based compensation expense", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails1", "http://drma.com/role/EquityIncentivePlanDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r50", "r62", "r177", "r296" ], "calculation": { "http://drma.com/role/StatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount costs" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r62", "r177", "r181", "r182", "r297" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Net of debt discount costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Total potentially dilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r8", "r74", "r110", "r118", "r122", "r134", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r276", "r278", "r288", "r308", "r310", "r356", "r368" ], "calculation": { "http://drma.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis": { "auth_ref": [ "r14", "r186", "r203", "r204", "r205" ], "lang": { "en-us": { "role": { "documentation": "Information by title of series or issue of auction market preferred securities.", "label": "Auction Market Preferred Securities, Stock Series [Axis]" } } }, "localname": "AuctionMarketPreferredSecuritiesStockSeriesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain": { "auth_ref": [ "r14", "r186", "r203", "r204", "r205" ], "lang": { "en-us": { "role": { "documentation": "Title of series or issue of auction market preferred securities based on rights (names are typically labeled by day of the week, duration between intervals, or combination of both)." } } }, "localname": "AuctionMarketPreferredSecuritiesStockSeriesTitleDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r221", "r222", "r223", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r244", "r245", "r248", "r249", "r250", "r251", "r252" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails3", "http://drma.com/role/EquityIncentivePlanDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheetDetailsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r280", "r281" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position)." } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheetDetailsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "verboseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r2", "r77", "r109" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "verboseLabel": "Organization and Basis of Presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/OrganizationAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r6", "r64" ], "calculation": { "http://drma.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r57", "r64", "r70" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents]", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r57", "r289" ], "calculation": { "http://drma.com/role/StatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r13", "r14", "r15", "r71", "r74", "r90", "r91", "r92", "r94", "r95", "r99", "r100", "r101", "r134", "r163", "r167", "r168", "r169", "r172", "r173", "r187", "r188", "r191", "r195", "r202", "r288", "r394" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative", "http://drma.com/role/LongtermDebtDetailsNarrative", "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative", "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r209", "r219" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/Cover", "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/Cover", "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Warrant exercise price", "terseLabel": "Exercise price per share", "verboseLabel": "Exercise price per share" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative", "http://drma.com/role/LongtermDebtDetailsNarrative", "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Warrant units to purchase stocks", "verboseLabel": "Warrant units to purchase stocks" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative", "http://drma.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Warrant outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r155", "r156", "r157", "r162", "r385" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Additional shares reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r78", "r79", "r285" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock shares, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock shares, authorized", "verboseLabel": "Common stock, authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheetsParenthetical", "http://drma.com/role/EquityIncentivePlanDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued", "verboseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheetsParenthetical", "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r15", "r202" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock shares, outstanding", "terseLabel": "Common stock outstanding", "verboseLabel": "Common stock outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheetsParenthetical", "http://drma.com/role/EquitySecuritiesDetailsNarrative", "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r15", "r310" ], "calculation": { "http://drma.com/role/BalanceSheets": { "order": 8.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, par value $0.0001, 250,000,000 shares authorized and 12,102,214 shares issued and outstanding as of September 30, 2022; and 90,000,000 shares authorized and 8,328,629 shares issued and outstanding as of December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonUnitIssuanceValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stated value of common units of ownership issued by a limited liability company (LLC).", "label": "Consideration" } } }, "localname": "CommonUnitIssuanceValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonUnitIssued": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "Number of common units issued of limited liability company (LLC).", "label": "Common units issued" } } }, "localname": "CommonUnitIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CompensationAndBenefitsTrust": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of a trust established to hold the stock of an employee compensation and benefits plan as of the balance sheet date.", "label": "Accrued compensation and benefits" } } }, "localname": "CompensationAndBenefitsTrust", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheetDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "401(k) Plan" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r39", "r41", "r42", "r48", "r363", "r375" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Deemed dividend upon amendment to the terms of the Series 1d convertible preferred stock" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r67", "r68", "r69" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of preferred stock to common stock at IPO", "verboseLabel": "Conversion of stock amount" } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative", "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountIssued1": { "auth_ref": [ "r67", "r68", "r69" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cash received from conversion of convertible note issued" } } }, "localname": "ConversionOfStockAmountIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r67", "r68", "r69" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of stock", "verboseLabel": "Preferred stock, Conversion of Stock, Shares Converted" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative", "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r67", "r68", "r69" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Common Stock, Conversion of Stock, Shares Issued" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r9", "r357", "r367", "r384" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes [Member]" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities": { "auth_ref": [ "r203" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of convertible preferred stock that was converted to other securities.", "label": "Convertible promissory notes" } } }, "localname": "ConvertiblePreferredStockConvertedToOtherSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/RelatedPartiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleSubordinatedDebt": { "auth_ref": [ "r11", "r359", "r370" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, the carrying value of convertible subordinated debt, as of the balance sheet date, initially scheduled to be repaid after one year or beyond the normal operating cycle if longer. This form of debt can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder, and places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets.", "label": "Subordinated convertible promissory notes" } } }, "localname": "ConvertibleSubordinatedDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleSubordinatedDebtCurrent": { "auth_ref": [ "r28" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of convertible subordinated debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. This form of debt can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder, and places a lender in a lien position behind debt having a higher priority of repayment upon liquidation of the entity's assets.", "label": "[Convertible Subordinated Debt, Current]", "verboseLabel": "Subordinated convertible promissory notes" } } }, "localname": "ConvertibleSubordinatedDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r67", "r69" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Principal Amount", "verboseLabel": "Subordinated convertible promissory notes" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative", "http://drma.com/role/RelatedPartiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r67", "r69" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Subordinated convertible promissory notes converted into shares units" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LongTerm Debt" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r11", "r179", "r359", "r367" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Carrying value" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r174", "r180" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Conversion price per share" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentDecreaseForgiveness": { "auth_ref": [ "r73" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.", "label": "Outstanding loan forgiven" } } }, "localname": "DebtInstrumentDecreaseForgiveness", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/LicenseAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFeeAmount": { "auth_ref": [ "r31" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.", "label": "Non-refundable amendment fee" } } }, "localname": "DebtInstrumentFeeAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "auth_ref": [ "r73" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.", "label": "Debt Conversion, Converted Instrument, Accrued Interest" } } }, "localname": "DebtInstrumentIncreaseAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r30", "r175", "r287" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r32" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "Final Principal Payment" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Financing Costs" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r176", "r297" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "[Debt Issuance Costs, Net]", "verboseLabel": "Deferred Financing Costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredOfferingCosts": { "auth_ref": [ "r148" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Deferred offering costs", "verboseLabel": "Deferred offering costs" } } }, "localname": "DeferredOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheetDetailsDetails", "http://drma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositLiabilitiesAccruedInterest": { "auth_ref": [ "r361" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued but unpaid interest on deposit liabilities.", "label": "Accrued interest" } } }, "localname": "DepositLiabilitiesAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DescriptionOfEffectOnPreviouslyReportedSegmentInformationForChangeInCompositionOfReportableSegments": { "auth_ref": [ "r124", "r125" ], "lang": { "en-us": { "role": { "documentation": "Disclosure about a restatement of previous periods' segment information resulting from a change in the composition of the entity's reportable segments.", "label": "License Agreements" } } }, "localname": "DescriptionOfEffectOnPreviouslyReportedSegmentInformationForChangeInCompositionOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r220", "r221", "r254", "r255", "r257", "r265" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "verboseLabel": "Equity Incentive Plan" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Incentive Plan" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DividendsPreferredStock": { "auth_ref": [ "r206", "r366" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "DividendsPreferredStock" } } }, "localname": "DividendsPreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/RelatedPartiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPreferredStockStock": { "auth_ref": [ "r206", "r366" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.", "label": "[Dividends, Preferred Stock, Stock]", "verboseLabel": "Deemed dividend" } } }, "localname": "DividendsPreferredStockStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r96", "r97" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net Loss Per Common Unit/Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r256" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Unrecognized stock based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted-Average Recognized Remaining Contractual Term (in Years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Securities" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r44", "r45", "r46", "r78", "r79", "r80", "r82", "r87", "r89", "r98", "r135", "r202", "r206", "r259", "r260", "r261", "r274", "r275", "r285", "r290", "r291", "r292", "r293", "r294", "r295", "r298", "r378", "r379", "r380" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ExtraordinaryAndUnusualItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet Details" } } }, "localname": "ExtraordinaryAndUnusualItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r62", "r184" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Estimated fair value of warrant units" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r129", "r130", "r131", "r132", "r133", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r178", "r200", "r283", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r394", "r395", "r396", "r397", "r398", "r399", "r400" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails", "http://drma.com/role/EquityIncentivePlanDetails2", "http://drma.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r49" ], "calculation": { "http://drma.com/role/StatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "[General and Administrative Expense]", "verboseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r149", "r150" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Patent Costs" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statements of Operations (unaudited)" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r151", "r154" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r43", "r267", "r268", "r270", "r271", "r272", "r273" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r59", "r66" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Cash paid for taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r61" ], "calculation": { "http://drma.com/role/StatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "[Increase (Decrease) in Accounts Payable]", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r61" ], "calculation": { "http://drma.com/role/StatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "[Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities]", "verboseLabel": "Accrued and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInNotesPayableCurrent": { "auth_ref": [ "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in current portion (due within one year or one business cycle) of obligations evidenced by formal promissory notes.", "label": "Increase convertible promissory notes" } } }, "localname": "IncreaseDecreaseInNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase/(decrease) in cash resulting from changes in:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r61" ], "calculation": { "http://drma.com/role/StatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "[Increase (Decrease) in Prepaid Expense]", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InsuranceDisclosureTextBlock": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.", "label": "Insurance Disclosure [Text Block]", "verboseLabel": "License Agreements" } } }, "localname": "InsuranceDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/LicenseAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestAndOtherIncomeTextBlock": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for interest and other income.", "label": "Interest Income" } } }, "localname": "InterestAndOtherIncomeTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpenseSubordinatedNotesAndDebentures": { "auth_ref": [ "r365" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest expense incurred during the reporting period on subordinated notes and debentures. Includes amortization of expenses incurred in the issuance of subordinated notes and debentures.", "label": "Subordinated convertible promissory notes interest" } } }, "localname": "InterestExpenseSubordinatedNotesAndDebentures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r364" ], "calculation": { "http://drma.com/role/StatementsOfOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest (income) expense, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r55", "r58", "r66" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r361", "r373" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest payable" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivable": { "auth_ref": [ "r16" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.", "label": "Interest receivable" } } }, "localname": "InterestReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheetDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r27", "r74", "r119", "r134", "r163", "r164", "r165", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r277", "r278", "r279", "r288", "r308", "r309" ], "calculation": { "http://drma.com/role/BalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities:" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r21", "r74", "r134", "r288", "r310", "r360", "r372" ], "calculation": { "http://drma.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "[Liabilities and Equity]", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Stockholders' Equity:" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.", "label": "Bearing interest prime rate (percentage)" } } }, "localname": "LongTermDebtPercentageBearingFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-Term Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/LongtermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations": { "auth_ref": [ "r57" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in cash associated with the entity's discontinued operations.", "label": "Net Cash Used In Operation" } } }, "localname": "NetCashProvidedByUsedInDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r57" ], "calculation": { "http://drma.com/role/StatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "[Net Cash Provided by (Used in) Financing Activities]", "totalLabel": "Net cash provided by financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r57", "r60", "r63" ], "calculation": { "http://drma.com/role/StatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Net cash used in operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r38", "r40", "r46", "r47", "r63", "r74", "r81", "r83", "r84", "r85", "r86", "r88", "r89", "r93", "r110", "r117", "r120", "r121", "r123", "r134", "r163", "r164", "r165", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r286", "r288", "r362", "r374" ], "calculation": { "http://drma.com/role/StatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://drma.com/role/StatementsOfOperationsUnaudited": { "order": 7.0, "parentTag": "drma_NetLossAttributableToCommonStockholders", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "negatedLabel": "Net loss", "terseLabel": "Net Loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited", "http://drma.com/role/StatementsOfOperationsUnaudited", "http://drma.com/role/StatementsOfStockholdersEquityUnaudited", "http://drma.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r11", "r359", "r370" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Notes Payable [Member]" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r24", "r75", "r303" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Notes payable related parties" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesNoncurrent": { "auth_ref": [ "r33", "r75", "r302" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).", "label": "Notes payable non related parties" } } }, "localname": "NotesPayableRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingCostsAndExpenses": { "auth_ref": [], "calculation": { "http://drma.com/role/StatementsOfOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.", "label": "[Operating Costs and Expenses]", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingCostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingCostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingCostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r110", "r117", "r120", "r121", "r123" ], "calculation": { "http://drma.com/role/StatementsOfOperationsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "[Operating Income (Loss)]", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OptionIndexedToIssuersEquityStrikePrice1": { "auth_ref": [ "r185", "r282" ], "lang": { "en-us": { "role": { "documentation": "Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.", "label": "Option exercise price" } } }, "localname": "OptionIndexedToIssuersEquityStrikePrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://drma.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Accrued and other current liabilities", "verboseLabel": "Accrued other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheetDetailsDetails", "http://drma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesNoncurrent": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.", "label": "Total accrued and other current liabilities" } } }, "localname": "OtherAccruedLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheetDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income and expenses:" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subordinated Convertible Promissory Notes" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentForManagementFee": { "auth_ref": [ "r56", "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount paid to managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).", "label": "Final Payment" } } }, "localname": "PaymentForManagementFee", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDerivativeIssuanceCosts": { "auth_ref": [ "r54" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of a derivative security.", "label": "Issuance costs" } } }, "localname": "PaymentsOfDerivativeIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r54" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Net of issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r221", "r222", "r223", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r244", "r245", "r248", "r249", "r250", "r251", "r252" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetailsNarrative", "http://drma.com/role/EquitySecuritiesDetailsNarrative", "http://drma.com/role/LicenseAgreementsDetailsNarrative", "http://drma.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r221", "r222", "r223", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r244", "r245", "r248", "r249", "r250", "r251", "r252" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetailsNarrative", "http://drma.com/role/EquitySecuritiesDetailsNarrative", "http://drma.com/role/LicenseAgreementsDetailsNarrative", "http://drma.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PostemploymentBenefitsDisclosureTextBlock": { "auth_ref": [ "r212", "r213" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for postemployment benefits, which may include supplemental unemployment benefits, obligations recognized for all types of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement. Disclosure may also include discussion that an obligation for postemployment benefits is not accrued in accordance with regulation only because the amount cannot be reasonably estimated.", "label": "Postemployment Benefits Disclosure [Text Block]", "verboseLabel": "401(k) Plan" } } }, "localname": "PostemploymentBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/KPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock Member" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredUnitsIssued": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "The number of preferred units issued.", "label": "Preferred units, issued", "verboseLabel": "Preferred units, issued" } } }, "localname": "PreferredUnitsIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative", "http://drma.com/role/LicenseAgreementsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.", "label": "Prepaid external development costs" } } }, "localname": "PrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheetDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r23" ], "calculation": { "http://drma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets", "verboseLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheetDetailsDetails", "http://drma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r22", "r146", "r147" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Total prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheetDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r5", "r145", "r147" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheetDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromBankDebt": { "auth_ref": [ "r52" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from bank borrowing during the year.", "label": "Proceeds from borrowing" } } }, "localname": "ProceedsFromBankDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "auth_ref": [ "r52" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.", "label": "Net issuance cost" } } }, "localname": "ProceedsFromDebtNetOfIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r51" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from issuance initial public offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r51" ], "calculation": { "http://drma.com/role/StatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from issuance of common stock and warrants, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r51" ], "calculation": { "http://drma.com/role/StatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds from issuance of Series 1d preferred units" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSubordinatedLongTermDebt": { "auth_ref": [ "r52" ], "calculation": { "http://drma.com/role/StatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing where a lender is placed in a lien position behind debt having a higher priority of repayment (senior) in liquidation of the entity's assets or underlying collateral.", "label": "Net proceeds from issuance of convertible subordinated promissory notes" } } }, "localname": "ProceedsFromIssuanceOfSubordinatedLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r51" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from issuance of warrant" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r51" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Gross Proceeds from warrants purchase of common stock" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfNotesPayable": { "auth_ref": [], "calculation": { "http://drma.com/role/StatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.", "label": "Payments on debt" } } }, "localname": "ProceedsFromRepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subordinated Convertible Promissory Notes (Details Narrative)" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r215", "r301", "r302" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r215", "r301", "r302", "r305" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative", "http://drma.com/role/LicenseAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative", "http://drma.com/role/LicenseAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Parties" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r215", "r301", "r305", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r299", "r300", "r302", "r306", "r307" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "verboseLabel": "Related Parties" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/RelatedParties" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r53" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Long term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r266", "r342", "r388" ], "calculation": { "http://drma.com/role/StatementsOfOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "[Research and Development Expense]", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "RSU's outstanding [Member]", "verboseLabel": "RSU's outstanding [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails3", "http://drma.com/role/EquityIncentivePlanDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License Agreements (Details Narrative)" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r18", "r206", "r310", "r371", "r381", "r382" ], "calculation": { "http://drma.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r78", "r79", "r80", "r82", "r87", "r89", "r135", "r259", "r260", "r261", "r274", "r275", "r285", "r378", "r380" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Basis of Presentation (Details Narrative)" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of stock" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of potentially diluted basic earnings" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in common stock outstanding.", "label": "Schedule of stock option activity" } } }, "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of earnings per share, basic and diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r225", "r240", "r243" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of stock-based compensation expense" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Weighted-average assumptions used for the stock option grants" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of restricted stock unit" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r111", "r112", "r113", "r114", "r115", "r116", "r126" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentsGeographicalAreasAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details)" } } }, "localname": "SegmentsGeographicalAreasAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SeriesAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A classification of auction market preferred securities that may have different rights to other classifications of auction market preferred securities, for example Series B.", "label": "Series A" } } }, "localname": "SeriesAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r61" ], "calculation": { "http://drma.com/role/StatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "[Share-Based Payment Arrangement, Noncash Expense]", "terseLabel": "Stock-based compensation expense", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetailsNarrative", "http://drma.com/role/EquitySecuritiesDetailsNarrative", "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Stock compensation for services" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Number of Options Outstanding, Options exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails2" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Weighted-Average Exercise Price, Options exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails2" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Number of Options Outstanding, Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails2" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number]", "periodEndLabel": "Number of Options Outstanding, Ending balance", "periodStartLabel": "Number of Options Outstanding, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails2" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price]", "periodEndLabel": "Weighted-Average Exercise Price, Ending balance", "periodStartLabel": "Weighted-Average Exercise Price, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails2" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Description of terms of award under share-based payment arrangement.", "label": "Expected life in years" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r221", "r222", "r223", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r244", "r245", "r248", "r249", "r250", "r251", "r252" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails3", "http://drma.com/role/EquityIncentivePlanDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted-Average Exercise Price, Options exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails2" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted-Average Exercise Price, Options cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails2" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted-Average Exercise Price, Options granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails2" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r224", "r246", "r247", "r248", "r249", "r252", "r262", "r265" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Stock awards granted, exercisable period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r258" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Unrecognized stock based compensation expenses" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted-Average Remaining Contractual Term (in Years), Options exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails2" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted-Average Remaining Contractual Term (in Years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails2" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative", "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative", "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative", "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative", "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r13", "r14", "r15", "r71", "r74", "r90", "r91", "r92", "r94", "r95", "r99", "r100", "r101", "r134", "r163", "r167", "r168", "r169", "r172", "r173", "r187", "r188", "r191", "r195", "r202", "r288", "r394" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative", "http://drma.com/role/LongtermDebtDetailsNarrative", "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative", "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r36", "r44", "r45", "r46", "r78", "r79", "r80", "r82", "r87", "r89", "r98", "r135", "r202", "r206", "r259", "r260", "r261", "r274", "r275", "r285", "r290", "r291", "r292", "r293", "r294", "r295", "r298", "r378", "r379", "r380" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheetDetailsDetails", "http://drma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://drma.com/role/EquityIncentivePlanDetails", "http://drma.com/role/EquityIncentivePlanDetails1", "http://drma.com/role/EquityIncentivePlanDetails2", "http://drma.com/role/EquityIncentivePlanDetails3", "http://drma.com/role/EquityIncentivePlanDetailsNarrative", "http://drma.com/role/EquitySecuritiesDetailsNarrative", "http://drma.com/role/LicenseAgreementsDetailsNarrative", "http://drma.com/role/LongtermDebtDetailsNarrative", "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative", "http://drma.com/role/StatementsOfStockholdersEquityUnaudited", "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative", "http://drma.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statements of Cash Flows (unaudited)" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheets" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statements of Stockholder's Equity (Unaudited)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r78", "r79", "r80", "r98", "r343" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheetDetailsDetails", "http://drma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://drma.com/role/EquityIncentivePlanDetails", "http://drma.com/role/EquityIncentivePlanDetails1", "http://drma.com/role/EquityIncentivePlanDetails2", "http://drma.com/role/EquityIncentivePlanDetails3", "http://drma.com/role/EquityIncentivePlanDetailsNarrative", "http://drma.com/role/EquitySecuritiesDetailsNarrative", "http://drma.com/role/LicenseAgreementsDetailsNarrative", "http://drma.com/role/LongtermDebtDetailsNarrative", "http://drma.com/role/OrganizationAndBasisOfPresentationDetailsNarrative", "http://drma.com/role/StatementsOfStockholdersEquityUnaudited", "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative", "http://drma.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r67", "r68", "r69" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Proceeds from stock issued" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/LicenseAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Stock Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails", "http://drma.com/role/EquityIncentivePlanDetails2", "http://drma.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r15", "r19", "r20", "r74", "r128", "r134", "r288", "r310" ], "calculation": { "http://drma.com/role/BalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "[Stockholders' Equity Attributable to Parent]", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheets", "http://drma.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r72", "r188", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r201", "r206", "r210", "r284" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Equity Securities" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Description of reverse split" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquitySecuritiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubordinatedBorrowingInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stated interest rate of the subordinated debt.", "label": "Bear interest rate" } } }, "localname": "SubordinatedBorrowingInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SubordinatedConvertiblePromissoryNotesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "verboseLabel": "Balance Sheet Details" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/BalanceSheetDetails" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosures:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/StatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r129", "r130", "r131", "r132", "r133", "r178", "r200", "r283", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r394", "r395", "r396", "r397", "r398", "r399", "r400" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/EquityIncentivePlanDetails", "http://drma.com/role/EquityIncentivePlanDetails2", "http://drma.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r102", "r103", "r104", "r105", "r106", "r107", "r108" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://drma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r109": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "35", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8984-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.A)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r157": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r162": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r183": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21564-112644" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.F)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r211": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "https://asc.fasb.org/topic&trid=49130413" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410195&loc=d3e80090-111668" }, "r213": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "https://asc.fasb.org/topic&trid=2197446" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r265": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r307": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.23)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.8)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r37": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "https://asc.fasb.org/topic&trid=2122208" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r383": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "944", "URI": "https://asc.fasb.org/topic&trid=2303980" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r389": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r390": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r391": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r392": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r393": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r394": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r395": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r396": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r397": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r398": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r399": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r400": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r401": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r402": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "12", "Subsection": "04" }, "r403": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r77": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" } }, "version": "2.1" } ZIP 55 0001654954-22-015035-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-22-015035-xbrl.zip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�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